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toxins. In vitro studies in polarized cell lines showed that upon transfection rat Oatp4c1 
localizes at the apical membrane. The objectives of this project were to further validate 
the subcellular localization of Oatp4c1/OATP4C1 in rat and human tissues as well as 
their localization and function in polarized cells. 
Using several complementary biochemical, molecular and proteomic methods as 
well as antibodies amenable to immunohistochemistry, immunofluorescence, and 
immunoblotting, we investigated the expression pattern of Oatp4c1 in epithelial cell lines 
and in the rat kidney and mammary gland (MG). Collectively, these data demonstrated 
that rat Oatp4c1 localized at the apical cell surface of polarized epithelium and primarily 
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Drug uptake studies in Oatp4c1-expressing cells demonstrated that Oatp4c1-
mediated estrone-3-sulfate (E3S) uptake was ATP-independent and pH-dependent. The 
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maximum transport rate (Vmax). In addition, E3S transport inhibition by various substrates 
suggests that Oatp4c1 possesses multiple substrate binding sites.   
The apical localization of Oatp4c1 in the rat kidney and MG is a novel finding and 
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secretion, of its substrates. In addition, the upregulation of Oatp4c1 expression during 
lactation indicates that it is involved in reuptake of xenobiotic from the milk, resulting in 
their reduced exposure to the suckling infants, or that it functions as a scavenger 
system. Further, studies to identify physiological substrates are needed to better 
understand the significance of Oatp4c1 function in renal and mammary epithelium. 
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CHAPTER 1 : BACKGROUND 
A.  Drug transporters in lactating mammary epithelium 
Breast milk offers the most complete nutrition for infant growth and 
development, and breastfeeding is widely advocated because of numerous benefits 
for infants and mothers. For infants, breastfeeding enhances cognitive development 
and immune system function, thus decreasing the risk of contracting infectious 
diseases. For mothers, breastfeeding promotes postpartum recovery, and decreases 
the risk of osteoporosis and incidences of both breast cancer and ovarian cancer (1, 
2). However, maternal medications may pose exposure risks to nursing infants. The 
limited information regarding drug transfer into the milk makes patients and 
physicians hesitate when deciding between maternal therapeutic benefit and infant 
drug exposure risk. A better understanding of the mechanism of drug transfer into 
the milk will facilitate these therapeutic decisions regarding drug use during lactation.  
The mammary gland is the organ that produces milk. It is comprised of 
epithelium and stroma (mammary fat pad), which is connective tissue. The 
epithelium consists of ducts and milk production unit, alveoli. Mammary epithelial 
cells are luminal secretory cells, which undergo extensive proliferation and 
differentiation during pregnancy and lactation to produce breast milk and secrete it 
into a central lumen, which opens to the body surface through the nipple. The luminal 
secretory cells form the barrier between the breast milk and the maternal circulation 
with an apical surface facing the lumen (milk) and a basolateral surface facing the 
blood. They are surrounded by basal myoepithelial cells, which are contractile 
following oxytocin stimuli, and subsequently eject the milk (3, 4).  
During lactation, the mammary gland is responsible for delivering essential 
nutrients, as well as xenobiotics, to suckling infants via breast milk. Many substances 
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enter into breast milk by passive diffusion, and their exposure risks can therefore be 
predicted using mathematical models incorporating drug protein binding, ionization, 
and fat partitioning (5, 6). Nevertheless, some water soluble substances need 
transporters to efficiently cross the lactating mammary epithelial cells (LMEC). 
Several adenosine triphosphate (ATP)-binding cassette (ABC) transporters and 
solute carrier (SLC) have been reported to be expressed on the mammary 
epithelium. However, to date, only ABCG2 has been demonstrated to be important 
for drug transfer into the milk. 
 
1. ATP-binding cassette (ABC) transporter superfamily 
The ABC transporter superfamily consists of 7 subfamilies categorized A - 
G, based on membrane topology and sequence homology. ABC transporters 
consist of a pair of cytoplasmic ATP-binding domains, also known as nucleotide 
binding domains (NBD), and two sets of transmembrane domains (TMD). The 
NBD contain three conserved sequences: Walker A and B motifs and a signature 
C motif. Walker A and B motifs can be found in all ATP-binding proteins, but the 
C motif is specific to ABC transporters. ABC transporters are organized as either 
full transporters containing two NBD and TMD or half transporters containing one 
of each domain. Half transporters assemble as either a homodimer or a 
heterodimer to be functional. ABC transporters are called primary active efflux 
transporters because they utilize energy derived from ATP hydrolysis to 
unidirectionally efflux a wide range of molecules against their concentration 
gradient (7).  
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Several ABC transporters have been identified in mammary gland. The 
prototypical ABC transporter is ABCB1, which is also known as multidrug 
resistance protein 1 (MDR1) or P-glycoprotein (P-gp). P-gp is a full length 
transporter with 12 TMD with cytoplasmic N- and C- terminals. P-gp was 
identified in human mammary gland by immunohistochemistry (8, 9), and mRNA 
and protein expression appears to be down-regulated during lactation in humans 
and mice (10, 11).  
The ABCC family encodes multidrug resistance-associated proteins 
(MRPs). Larger MRPs (1, 2, 3, 6 and 7) contain 17 TMD with extracellular N-
terminal and intracellular C-terminal. Smaller MRPs (4 and 5) consist of 12 TMD 
with intracellular N- and C-terminals (12). ABCC1, ABCC2, and ABCC5 mRNA 
were detected in both LMEC isolated from human breast milk and non-lactating 
mammary epithelial cells (MEC) isolated from reduction mammoplasty 
specimens, while ABCC3 and ABCC4 were not detected in either tissues.  
ABCC1 expression is lower in LMEC relative to MEC at mRNA and protein levels 
in humans and mice, respectively (10, 11). During lactation, mRNA expression of 
ABCC2 is not changed, whereas ABCC5 is increased 1.7-fold in LMEC as 
compared to MEC (11). 
ABCG2 (Human: ABCG2; rodent: Abcg2), also known as breast cancer 
resistance protein (BCRP), is a half-transporter containing only 6 TMD, and 
forms a homodimer to acquire transport activity. ABCG2/Abcg2 localizes at the 
apical membrane in mouse, rat, cow, and human lactating mammary tissues. Its 
expression increases during mammary gland development and achieves highest 
levels during lactation (10, 13). Several studies using the Abcg2 knockout mouse 
model have demonstrated that Abcg2 plays an important role in xenobiotics as 
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well as riboflavin (vitamin B2) transfer into the milk (Table 1-1) (14-17). It is 
interesting to note that milk secretion of riboflavin in Abcg2 knockout mice is 
reduced 60-fold compared to wild-type mice. This suggests that Abcg2 is 
involved in nutrient transfer from mother to suckling infant via breast milk (14). In 
addition, drugs such as nitrofurantoin, cimetidine, acyclovir, and ciprofloxacin, for 
which milk to plasma ratio cannot be explained by passive diffusion, are shown to 
be ABCG2/Abcg2 substrates (16-19). This suggests that ABCG2/Abcg2 may be 
a major factor in facilitating drug transfer into the milk.  
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Table 1-1: Milk to plasma AUC ratios for certain drugs in wild-type and 
Abcg2 knockout (Abcg2-/-) mice. 
Wild-type Abcg2-/- Ratio Reference 
Riboflavin 25.0 0.37 67.6 (14) 
Nitrofurantoin 45.7 0.6 76.2 (15) 
PhIP 12.8 0.5 28.1 (16) 
Topotecan 6.7 0.7 10.1 
Cimetidine 13.7 2.3 6.0 
Aflatoxin B1 0.7 0.2 3.8 
IQ 0.9 0.3 3.4 
Acyclovir 1.3 0.4 3.3 
Trp-P-1 1.1 0.4 2.6 
Ciprofloxacin 4.44 2.19 2 (17) 
 
 
2. Solute carrier (SLC) superfamily 
The SLC family consists of 52 subfamilies, with over 410 family members 
(20, 21). SLC family members have varied biochemical properties, including G-
protein coupling receptors, voltage gated ion channels, tyrosine kinase receptors, 
and various transporters for small molecules or organic anions/cations. Among 
SLC family members, SLC15, 21 and 22 families are relevant for xenobiotics 
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transport in the mammary gland. Many of these transporters transfer their 
substrates bidirectionally by facilitated diffusion down a concentration gradient or 
by secondary active transport coupled with endogenous ions to exchange or 
cotransport across cell membranes, but are typically considered as uptake 
transporters.  
The peptide transporters (SLC15) contain 12 TMD, a large extracellular 
loop between TMD 9 and 10, and intracellular N- and C-terminals. Both 
SLC15A1 (PEPT1) and SLC15A2 (PEPT2) transporters have similar substrate 
selectivity, but PEPT1 is a low-affinity, high-capacity transporter, while PEPT2 is 
a high-affinity, low-capacity carrier (22). Both PEPT1 and PEPT2 are expressed 
in LMEC by RT-PCR analysis. During lactation, mRNA expression of SLC15A1 is 
downregulated, while SLC15A2 increased 28-fold in the LMEC as compared to 
the MEC (11). In situ hybridization analysis showed that Slc15a2 mRNA localize 
at the apical side of rat ductal epithelium (23). The apical localization suggests 
PEPT2/Pept2 may function as a scavenger system to transport the product of 
milk protein hydrolysis back into the mammary epithelium driven by an inward-
directed proton gradient from breast milk (pH 6.8-7.2 (24)). It may also reuptake 
some peptide-like drugs such as cephalosporins back into the mammary 
epithelium, thus reducing the burden of the milk. (23). 
Organic anion or cation transport is mediated mostly by solute carrier 
organic anion transporter family (SLCO) (previously SLC21) and SLC22 families. 
SLCO family encodes for organic anion transporting polypeptides (rodents: 
Oatps, human: OATPs). They contain 12 TMD with cytoplasmic N- and C-
terminals and a large extracellular loop between TMD 9 and 10 (25). SLC22 
family includes organic cation transporters (OCT, SLC22A1-3), zwitterion/cation 
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transporters (OCTN, SLC22A4-5), and organic anion transporters (OAT, 
SLC22A6-20).  They all consist of 12 TMD with cytoplasmic N- and C-terminals, 
a large extracellular loop between TMD 1 and 2, and a large intracellular loop 
between TMD 6 and 7 (26). For organic anion transport, OATs  transport 
relatively small organic anions (generally <400 Da) such as PAH, probenecid and 
fluorescein, while OATPs transport comparably bulky compounds (generally > 
500 Da) such as conjugated steroids, bile acids, thyroid hormone, eicosanoids, 
peptides, cardiac glycosides (digoxin, ouabain), and numerous drugs (27). 
OATPs currently comprise six families (OATP1-6), containing 11 human 
isoforms and 14 rat isoforms. They transport a wide range of amphipathic 
compounds generally by a bidirectional, sodium-independent, pH-dependent, 
electroneutral mechanism (28). SLCO1A2 (OATP1A2, previously: OATP-A), 
SLCO2B1 (OATP2B1, previously: OATP-B), SLCO3A1 (OATP3A1, previously: 
OATP-D), and SLCO4A1 (OATP4A1, previously: OATP-E) mRNA were detected 
in both LMEC and MEC by RT-PCR or Northern blot analysis (11, 29). During 
lactation, mRNA expression of both SLCO1A2 and SLCO2B1 increases about 
1.5-fold in LMEC relative to MEC, whereas SLCO3A1 and SLCO4A1 are 
downregulated. Immunohistochemical analysis showed that OATP2B1 localizes 
in the contractile myoepithelial cells rather than the luminal secretory cells (29). 
Interestingly, microarray analysis has shown that SLCO4C1 (OATP4C1) mRNA 
expression increases 70-fold in LMEC relative to MEC (30). This suggests a 
potential role of OATP4C1 in drug transfer into breast milk. The characterization 
of OATP4C1 is discussed in greater detail in the section D. 
SLC22A1 (OCT1) and SLC22A3 (OCT3), but not SLC22A2 (OCT2), mRNA 
were detected in both LMEC and MEC by RT-PCR analysis (11, 31). During 
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lactation, mRNA expression of SLC22A1 increases 7.8-fold in LMEC as 
compared to MEC, whereas SLC22A3 is downregulated. OCTN1 (SLC22A4) and 
OCTN2 (SLC22A5) were both detected in human mammary tissue by Western 
blotting, and OCTN2 was detected in the ductal-lobular-alveolar structures, as 
demonstrated by immunohistochemical analysis (32). During lactation, mRNA 
expression of SLC22A4 increases about 6-fold in LMEC relative to MEC, 
whereas SLC22A5 is downregulated. SLC22A6 - 8 (OAT1 - 3) were not detected 
in lactating or non-lactating human and rat mammary tissue (11, 29, 31).   
 
B.  Renal physiology 
The kidney plays a critical role in maintaining homeostasis in body fluid 
composition, conserving essential nutrients, and eliminating natural byproducts, 
toxins, drugs and drug metabolites from the body. A simple diagram of the structure 
of the kidney is shown in Figure 1-1. Each kidney is covered by an inelastic capsule, 
which confines the volume of the kidney despite changes in blood pressure. Each 
kidney comprises two regions: a dark brown outer region named the cortex, and a 
pale inner region, which is divided into the medulla and the renal pelvis. The medulla 
consists of 7 to 18 large conical masses (usually 7 in humans) known as the renal 
pyramids. The broad base of each pyramid faces the cortex and their apex, papilla, 
is at renal pelvis. The renal pelvis contains the major renal blood vessels and ureter 
origin.  
Each human kidney contains about 1.25 million functional units, which are 
called nephrons. Each nephron is composed of a renal corpuscle attached to a long 
thin convoluted tube and its associated blood supply. The renal corpuscle consists of 
Bowman’s capsule and glomerulus which is a capillary tuft that receives the blood 
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supply from an afferent arteriole of the renal circulation. The proximal tubule arises 
directly from Bowman’s capsule and connects with the descending loop of Henle. 
The thin descending limb turns and ascends towards the cortex, and connects to the 
thick segment. The terminal segment of the thick ascending limb of the loop of Henle 
and the initial part of the distal tubule contact the afferent arteriole close to the 
glomerulus and form the juxtaglomerular apparatus, which is responsible for 
regulation of sodium balance. The distal tubules of a number of nephrons merge via 
connecting tubules to form collecting ducts and pass through the cortex and medulla 
to the renal pelvis. 
These structures are comprised of epithelial cells, which are rich in 
mitochondria suggesting a major role in active transport. These cells are joined via 
tight junctions near the apical surface, which is densely covered by microvilli forming 
a brush border. The brush border (apical) membrane faces the urine, and the 
basolateral membrane faces the blood. The renal excretory systems consist of three 
major processes: glomerular filtration, tubular secretion, and tubular reabsorption. 
The sum of the three processes for a compound undergoing in the nephrons 
determines its net renal excretion rate. The glomerular blood pressure provides the 
driving force to filter water and solute out from the blood to Bowman’s capsule. About 
20% of the renal blood flow undergoes filtration at the glomerulus and passes along 
to the proximal tubule. Low molecular weight substances which are not bound to 
plasma protein (e.g., albumin) are more likely to be filtered. The filtered substances, 
including glucose, amino acids, sodium, chloride, bicarbonate and exogenous 
substances (e.g., β-lactam antibiotics), may be reabsorbed from the glomerular 
filtrate to the blood. The reabsorption is accompanied by an osmotic equivalent of 
water so that about two-thirds of the filtered fluid has been reabsorbed by the end of 
the proximal tubule. In addition to reabsorbing solutes, the proximal tubule actively 
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secretes some organic anions and cations into the lumen. The homeostasis of 
endogenous and exogenous substances is achieved by tubular secretion and 
reabsorption, which are mediated by multiple transporters localized at both sides of 
the plasma membranes, mainly in the proximal tubular cells. Tubular secretion and 
reabsorption can occur as a facilitated transport to transfer substances down a 
concentration gradient or as an active transport requiring energy to move substances 
against a concentration gradient (33, 34). 
 
Figure 1-1: Cross-sectional view of the kidney (34). 
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C.  Drug transporters in the kidney 
The kidney is responsible for homeostasis of endogenous and exogenous 
substances through tubular secretion and reabsorption. Many of the urinary-
eliminated drugs and metabolites are water soluble and cannot easily cross the lipid 
bilayer of cell membranes. Transporters are needed for selective and efficient 
transport in renal tubular cells, including the ABC and SLC transporters (Figure 1-2). 
Several studies have demonstrated that overlapping substrate specificity among 
uptake and efflux transporters is likely to accelerate the translocation of endogenous 
and exogenous substances across epithelial or endothelial barriers, and this process 
is often called vectorial transport (35, 36). Thus, it is important to obtain detailed 
knowledge regarding transporters expressed in the kidney and their substrates to 
better understand renal tubular secretion and reabsorption of drugs and/or their 
metabolites. In the long term, such information will be important in predicting renal 
drug excretion and transporter-mediated drug-drug interactions. The detailed 
information of ABC transporter superfamily and SLC superfamily expressed in the 
kidney is described below.  
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Figure 1-2: ABC and SLC transporters in proximal tubular cells (adapted from 
literature (37-39)). 
 
1. ABC transporters  
Among ABC transporters, ABCB1, ABCC1-6 and ABCG2 are relevant for 
xenobiotic transport in the kidney. Because of unidirectional transport, function of 
ABC transporters in the kidney is determined by their subcellular localization. The 
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apical transporters are responsible for renal tubular secretion, while the 
basolateral transporters are important in renal tubular reabsorption. 
ABCB1 is expressed at the apical membrane in proximal tubules (40). It 
plays an important role in tubular secretion of digoxin, and may be responsible 
for clinically important drug-drug interactions, such as digoxin-quinidine or 
digoxin-verapamil (41).  
ABCC1 localizes at the basolateral membranes of the limb of Henle,  distal 
tubules and collecting ducts, but not proximal tubules in mouse kidney (42). 
ABCC1 along with an apical uptake transporter may facilitate the tubular 
reabsorption of substances from fluids in the distal tubules. ABCC1 substrates 
include a variety of physiological substances such as glutathione, glucuronide 
and sulfate conjugates as well as xenobiotics, such as methotrexate (MTX), 
doxorubicin, topotecan and vinblastine (12).  
ABCC2 is expressed apically in proximal tubules (43, 44) and plays an 
important role in tubular secretion of its substrates. ABCC2 shares considerable 
substrate specificity with ABCC1, but has a distinct function in the body because 
of different subcellular localization (12). In a patient with a heterozygous ABCC2 
mutation, nephrotoxicity was reported due to reduced MTX elimination (45).  
ABCC3 localizes at the basolateral membranes in rat distal tubules, thick 
ascending loop of Henle, and in human proximal tubules (46, 47). ABCC3 may 
be involved in tubular reabsorption of its substrates, which are similar to ABCC1 
(12).  
ABCC4 localizes at the apical membrane of renal proximal tubules (48, 49). 
Studies in Abcc4 knockout mice revealed the importance of this protein in the 
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tubular secretion of various drugs, such as antivirals (adefovir, tenofovir), 
diuretics (hydrochlorothiazide, furosemide) and cephalosporin antibiotics (50). 
ABCC4 may also facilitate the tubular secretion of other substrates, such as 
cyclic nucleotides, MTX, topotecan, prostaglandins, urate, para-aminohippurate 
(PAH) and several anionic conjugates (50).  
ABCC5 is expressed in the kidney (51, 52), but the localization in the 
kidney has not been determined yet. Nevertheless, ABCC5 polarizes to 
basolateral membrane when stably transfected in MDCKII cells, and mediates 
the transport of nucleotide analogues, such as adefovir, mercaptopurine, 
thioguanine, cyclic adenosine monophosphate (cAMP) and cyclic guanosine 
monophosphate (cGMP) (53, 54). The role of ABCC5 in the kidney remains to be 
investigated.  
ABCC6 is highly expressed in kidney and liver and is localized at the 
basolateral membrane in the proximal tubules (55, 56). It has a limited substrate 
specificity, which includes the endothelin receptor antagonist BQ123 (cyclo [Trp-
Asp-Pro-Val-Leu]), S-(dinitrophenyl)-glutathione and leukotriene C4. Its role in 
renal elimination of its substrates remains to be clarified.  
ABCG2 is expressed at the apical membrane in proximal tubules (57, 58). 
The apical localization suggests its role in facilitating the elimination of its 
substrates into the urine. ABCG2 transports a wide range of substrates, including 
uncharged or amphiphilic compounds, particularly anticancer drugs, such as 
topotecan, MTX, doxorubicin (12). 
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2. SLC transporters  
Among SLC family members, SLC15, 17, 21 and 22 families are relevant 
for xenobiotics transport in the kidney. These transporters are typically 
considered as uptake transporters. Therefore, the apical SLC transporters are 
mostly responsible for renal tubular reabsorption, while the basolateral SLC 
transporters are important in renal tubular secretion. 
Pept1 and Pept2 localize at the apical membrane in the S1 segments and 
S2/S3 segments in the rat proximal tubules, respectively (59). They are proton 
oligopeptide cotransporters and mediate the renal reabsorption of small anionic 
peptides and various peptide-like drugs, such as the β-lactam antibiotic  
cephalosporin (22).  
Sodium-dependent phosphate cotransporter 1 (NPT1) (SLC17A1) belongs 
to type I phosphate/vesicular glutamate transporters (SLC17) containing at least 
6 (perhaps 8) TMD (60). It localizes at the apical membrane in all segments of 
rabbit renal proximal tubules (61), and handles the tubular secretion of urate, 
PAH and various anionic drugs (62).  
Among OATPs, only Oatp1a1, Oatp1a3v1, Oatp1a3v2, Oatp1a5, Oatp2a1, 
OATP1A2 and Oatp4c1/OATP4C1 have been detected in rodents/human kidney. 
Oatp1a1 (previously: Oatp1, Oatp) is expressed at the apical membrane of the 
proximal tubule S3 segment in the outer medulla (63). Oatp1a1 has broad 
substrate specificity, including anionic, cationic, and neutral compounds. It is 
expressed predominantly in males and its expression has been related to the 
longer half-life of perfluorocarboxylates (PFO) as compared to female rats, which 
indicates an important role in renal reabsorption of PFO (64). The transport 
mechanisms of Oatp1a1 have been proposed as solute/HCO3- exchange and 
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solute/GSH exchange (65, 66). OATP1A2 (previously: OATP-A) localizes at the 
apical membrane in human distal tubules (67) and probably participates in the 
saturable reabsorption of MTX (68). Oatp1a3v1 (previously: OAT-K1) and 
Oatp1a3v2 (previously: OAT-K2) are expressed exclusively in the kidney (69). 
Oatp1a3v1 was detected in the brush-border membranes isolated from rat kidney 
by Western blotting. In addition, both Oatp1a3v1 and Oatp1a3v2 showed a 
functionally apical uptake or efflux in cell systems (70-72), which suggests that 
they function as bidirectional organic anion transporters at the apical membrane. 
Oatp1a3v1 and Oatp1a3v2 have also been implicated as the major exceretory 
route of MTX and may be responsible for the folinic acid rescue for high-dose 
MTX treatment of acute lymphocytic leukemia by exchanging extracellular folinic 
acid for intracellular MTX (73, 74). Oatp1a5 (previously: Oatp3) mRNA is highly 
expressed in rat kidney (75), but its localization has not been determined yet. 
Endogenous or exogenous substances (e.g., thyroid hormones, E3S, 
fexofenadine, digoxin) have been reported to interact with rat Oatp1a5 (76, 77), 
but the role of Oatp1a5 in renal drug elimination remains to be clarified. Oatp2a1 
(previously: PGT) localizes at the apical surface of rat collecting ducts, 
glomerular endothelial and mesangial cells and is responsible for renal 
reabsorption of prostanoids (78). OATP4C1/Oatp4c1 (previously: OATP-H) was 
reported to be expressed at the basolateral membrane of the proximal tubules 
(79). The expression and functional characterization of OATP4C1 is discussed in 
greater detail in section D. 
Oct1, Oct2 and Oct3 all localize at basolateral membrane of rat proximal 
tubules (80-82). Oct1 is mainly expressed in S1/S2 segments of rat proximal 
tubules. Oct2 is predominantly expressed in S2/S3 segments of rat proximal 
tubules, and in all segments of human proximal tubules. OCTs are facilitative and 
 17 
 
bidirectional diffusion transporters mediating electrogenic and Na+-independent 
flux of small organic cations with a molecular weight up to about 400-500 Da 
(83). The transport direction is determined by concentration gradients and the 
electrical potential across the membrane. OCT1, OCT2 and OCT3 have a broad 
overlap of substrate and inhibitor specificities. OCTs mediate the renal excretion 
of neurotransmitters dopamine, epinephrine, and many organic cation drugs such 
as desipramine, metformin, cimetidine and cisplatin. OCTs also mediate the renal 
reabsorption of choline (26).  
OCTN1 and OCTN2 are strongly expressed at the apical membranes of 
proximal tubules (84, 85). OCTN1 is a bidirectional proton/organic cation 
antiporter (86, 87), whereas OCTN2 may function as a unidirectional sodium/L-
carnitine cotransporter or a bidirectional sodium-independent organic cation 
transporter (88, 89). OCTN1 and OCTN2 mediate the renal secretion of organic 
cations, such as verapamil, choline, whereas OCTN2 can also mediate the 
reabsorption of L-carnitine following exchange with cationic compounds (26).    
OATs are organic anion/dicarboxylate (favorably α-ketoglutarate) 
exchangers. OAT1 s predominantly expressed in the kidney (90). It localizes at 
the basolateral membrane in S2 segment of rat proximal tubules and all 
segments of human proximal tubules (82, 91). OAT2 is highly expressed in the 
liver and to a lesser extent in the kidney (90). Its localization in the kidney is 
controversial. It was detected at the basolateral membrane of human proximal 
tubules (92), but it has also been reported at the apical surface of rat medullary 
thick ascending limb of Henle’s loop and the collecting ducts (91) or proximal 
tubule S3 segments (93). Therefore, the role of OAT2 in kidney is still unclear. 
OAT3 is exclusively expressed in the kidney and its mRNA expression is 
considerably higher than OAT1 in human kidney (82). OAT3 is expressed at the 
 18 
 
basolateral membrane in all segments of rat or human proximal tubules (82, 91, 
94). OAT1 and OAT3 mediate the first step of renal tubular excretion of their 
substrates. They have wide overlapping substrate specificities, including 
endogenous substrates such as PAH, cyclic nucleotides, prostaglandins, urate, 
uremic toxins, as well as anionic drugs, such as β-lactam antibiotics, non-
steroidal anti-inflammatory drugs (NSAIDs), antiviral drugs, antidiabetic and 
anticancer drugs. In addition, OAT1 has a larger contribution to low-molecular 
weight drugs, whereas OAT3 transports more bulky amphipathic anions, such as 
hepatic hydroxymethylglutaryl –Coenzyme A (HMG-CoA) reductase inhibitors 
(statins), and even some cationic drugs, including H2 receptor antagonists (95). 
OAT4 is highly expressed in the kidney and to a lesser extent in the placenta. It 
localizes at the apical membrane of the proximal tubules (96, 97), and is involved 
in renal reabsorption of organic anions, such as E3S, MTX and PAH, driven by 
an outwardly directed dicarboxylate gradient (84, 98). Urate transporter 1 
(URAT1 is mainly expressed in the kidney, and is localized at the apical 
membrane of proximal tubules (99, 100). OAT4 and URAT1 are urate anion 
exchangers that play a key role in urate homeostasis via a renal reabsorption 
mechanism. OAT10 is predominantly expressed in human kidney, and was 
exclusively detected in the brush-border membrane isolated from the rat kidney. 
It is responsible for renal reabsorption of nicotinate and urate (101). Oat5 
expression is restricted to the kidney, and is localized at the apical membrane in 
the S2/S3 segment of mouse and rat proximal tubules. It may be involved in 
renal reabsorption of E3S (102, 103). 
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D.  OATP4C1 (Human: OATP4C1; rodent: Oatp4c1) 
OATP4C1 (SLCO4C1) was first isolated from human kidney in 2004 (79). It 
was initially called OATP-H and renamed as OATP4C1 according to the HUGO 
Gene Nomenclature Committee (28). It is located on chromosome 5q21, and is 
about 62 kb long including 13 exons and 12 introns. It consists of 724 amino acids, 
and the predicted molecular weight is 79 kDa. OATP4C1 was predicted to contain 12 
TMD with intracellular N- and C-terminals, by hydrophobicity analysis. There are four 
putative N-glycosylation sites in the predicted extracellular loop and five potential 
phosphorylation sites in the intracellular portions. Interestingly, the intracellular loop 
between TMD 6 and 7 of human OATP4C1 and rat Oatp4c1 contain two and one, 
respectively, potential ATP binding sites characteristic of the Walker A motif found in 
ABC transporters but not in other OATP family proteins. The overall homology 
between human and rat Oatp4c1 is 80.4% at the amino acid level.  
Microarray expression studies show that human SLCO4C1 mRNA is highly  
expressed in the kidney, neutrophils, liver, moderately in mammary gland, and 
slightly in lung, skin, peripheral leukocytes and mononuclear cells (104). Rat Slco4c1 
is detected mainly in the kidney and lung, and slightly in the brain by Northern 
analysis (79), while mouse Slco4c1 is detected in the kidney and lung by bDNA 
assay (105). There is no gender difference of Slco4c1 expression in the rat kidney, 
but higher Slco4c1 expression was observed in male mouse kidney as compared to 
females (79, 105). In addition, Slco4c1 expression in kidney increases with age in 
mice(105). RT-PCR from microdissected rat nephron segments showed that rat 
Slco4c1 is detected mainly in the proximal convoluted tubule, proximal straight 
tubule, and slightly in the glomerulus, cortical thick ascending limb and cortical 
collecting duct. Immunohistochemical analyses has shown that Oatp4c1 localizes at 
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the basolateral membrane in the rat proximal tubules (79) as well as human 
OATP4C1 in the transgenic rat harboring human SLCO4C1 (106). In the 5/6 
nephrectomized renal failure model, Slco4c1 expression was significantly decreased 
by Northern blot analysis. This may be related to the changes of pharmacokinetics of 
its substrates in renal failure. Interestingly, microarray analysis showed that 
SLCO4C1 is highly expressed in lung tumors and its mRNA expression is 18-fold 
higher than that in the normal human lung (104). This suggests a potential vital role 
of OATP4C1 in lung cancer. SLCO4C1 was also detected in several cancer cell 
lines, including renal carcinoma cells (ACHN, SN12C), ovarian cancer cells 
(OVCAR-8, OVCAR-3), leukemia cells (HL-60, RPMI-8226, CCRF-CEM), lung 
cancer cells (H322M, H23, HOP-62, H460), glioblastoma (SF-539) and breast cancer 
cells (BT-549) (107).  
A promoter analysis showed that SLCO4C1 promoter region has xenobiotic-
responsive element (XRE) motifs, which are generally recognized by aryl 
hydrocarbon receptors (AhR) and AhR nuclear translocator heterodimer (108). The 
promoter activities are enhanced by nuclear AhR inducers, 3-methylcholanthrene 
and HMG-CoA reductase inhibitors (pravastatin, fluvastatin, simvastatin, lovastatin, 
cerivastatin, itavastatin, mevastatin, atorvastatin, rosuvastatin and pitavastatin). 
Following pravastatin treatment in ACHN cells, SLCO4C1 mRNA expression is 
upregulated 1.73-fold, and uptake of an OATP4C1 substrate, triiodothyronine (T3), is 
increased 1.4-fold (106).  
The reported substrates of OATP4C1 include cardiac glycosides [digoxin (Km 
7.8 μM) and ouabain (Km 0.38 μM)], thyroid hormones [T3 (Km 5.9 μM) and 
thyroxine (T4)], cAMP, MTX (79), sitagliptin (109), and E3S (110). The transport 
direction appears to be unidirectional uptake from outside to inside (79), but the 
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driving force has not been elucidated. Sodium, chloride, and pH did not affect 
OATP4C1-mediated uptake, while ATP depletion partially inhibits T3 uptake to 40% 
(79). However, Leuthold et al. demonstrated that OATP4C1-mediated E3S or T4 
uptake is significantly higher at extracellular pH 6.5 than pH 8.0 (111). In addition, 
OATP4C1 has been suggested to possess multiple substrate recognition sites, 
because digoxin does not inhibit OATP4C1-mediated T3 (79) or E3S (110) uptake 
and vice versa, while E3S and T3 have mutual inhibition.   
Furthermore, the physiological role of OATP4C1, reportedly a basolateral 
uptake transporter, has been postulated to couple with P-glycoprotein, an apical 
efflux transporter, to facilitate the renal clearance of common substrates, such as 
digoxin (79) and uremic toxins (106). In studies with transgenic rats harboring human 
SLCO4C1, the hypertension and renal inflammation were ameliorated in renal failure 
models. The decreased plasma concentrations of uremic toxins (guanidino 
succinate, asymmetric dimethylarginine, and trans-aconitate) suggest that OATP4C1 
may facilitate the excretion of uremic toxins in renal failure models and, by extension, 
in patients with chronic kidney disease. The enhancement of the uremic toxins 
excretion and the amelioration of end-organ damage were also observed by 
pravastatin-induced Slco4c1 up-regulation in rat renal failure models (106). However, 
direct evidence that these toxins are OATP4C1 substrates is lacking.  
 
E.  Summary 
The well documented benefits of breastfeeding and the limited data regarding 
drug transfer into breast milk, make it difficult for patients and their doctors to weigh 
the benefits and risks between maternal treatment and infant drug exposure. For 
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most of the drugs that have been studied, the exposure risks can be predicted by 
passive diffusion using mathematical models that incorporate easily measured 
parameters such as drug protein binding, ionization, and fat partitioning. However, 
several reports showed that certain drugs accumulate in breast milk at substantially 
higher levels than predicted by passive diffusion and in particular, drugs that are 
substrates for xenobiotic transporters. A comprehensive microarray analysis was 
performed to measure the expression of 55 xenobiotic transporter genes in LMEC 
isolated from human breast milk and MEC isolated from reduction mammoplasty 
specimens and to identify the genes that are upregulated during lactation (30). In 
accord with a previous study (10), ABCG2 expression was upregulated during 
lactation by 164-fold in LMEC relative to MEC. A novel finding showed a 70-fold 
increase of SLCO4C1 expression in LMEC as compared to MEC, suggesting a 
potential role in drug transfer into the milk. 
Human OATP4C1 and rat Oatp4c1 have been demonstrated to localize at the 
basolateral membrane in the kidney (79, 106). Therefore, we hypothesized that 
OATP4C1/Oatp4c1 localizes at the basolateral membrane in the mammary gland 
and couples with ABCG2/Abcg2, an apical efflux transporter, to facilitate the transfer 
of common substrates into breast milk. To study the role of Oatp4c1 in drug 
disposition, we sought to generate stably transfected cell lines expressing rat 
Oatp4c1. Initial attempts to generate Oatp4c1-expressing MDCKII cells produced 
unexpected results as the transporter localized at the apical rather than the 
basolateral membranes.  
This dissertation work aims to validate the subcellular localization of 
OATP4C1/Oatp4c1 in the in vitro models and in human/rat tissues and to explore 
their transport characteristics. We used a comprehensive approach, including 
multiple antibodies amenable to immunohistochemistry, immunofluorescence, and 
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immunoblotting to probe the expression of Oatp4c1 in intact tissues and cells as well 
as biochemically separated and enriched apical and basolateral membranes isolated 
from polarized cells and rat renal proximal tubules. Furthermore, proteomic analysis 
was used to qualitatively validate the specificity of these antibodies. Functional 
activity of Oatp4c1 in MDCKII-Oatp4c1 was probed with E3S and MTX. The 
expression and subcellular localization of human OATP4C1 in the in vitro model, 
human kidney, lung tumor specimens and cancer cells were also examined. 
Functional activity of OATP4C1 in MDCKII-OATP4C1 and Sf9-OATP4C1 was 
probed with ouabain and E3S.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Kuei-Ling Kuo 2012 
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CHAPTER 2 : PLAN OF WORK 
Hypothesis 1: Oatp4c1 is upregulated in mammary gland during lactation. It functions 
as a basolateral uptake transporter, and couples with apically-expressed efflux 
transporter Abcg2 to facilitate the transfer of common substrates into the milk. 
Specific Aim 1a: To develop and validate rat Oatp4c1 antibodies amenable for 
immunoblotting, immunohistochemistry and immunofluorescence. 
Specific Aim 1b: To create and validate a stably transfected rat Oatp4c1-
expressing cell line with appropriate characteristics for uptake studies. 
Specific Aim 1c: To determine the expression and subcellular localization of 
Oatp4c1 in rat tissues (liver, kidney, lactating and non-lactating mammary gland). 
To explore the xenobiotic transporters responsible for drug transport into the milk, 
a microarray study was performed by Dr. Philip Empey and showed a 70-fold increase of 
SLCO4C1 mRNA expression in human lactating mammary epithelial cells relative to 
non-lactating mammary epithelial cells (30). The upregulation of SLCO4C1 expression 
during lactation suggested a potential role of OATP4C1 in drug transfer into the milk. To 
determine the subcellular localization of Oatp4c1 in mammary epithelium, rat Oatp4c1 
antibodies will be developed in Specific Aim 1a. The antibody specificities will be 
validated using a stably transfected rat Oatp4c1-expressing cell line established in 
Specific Aim 1b by Western blotting, immunohistochemistry and immunofluorescence. 
To investigate the role of Oatp4c1 in drug disposition, a single clone with the highest 
Oatp4c1 expression will be obtained and will be used in Specific Aim 3a and 3b. Specific 
Aim 1c will investigate the expression and subcellular localization of Oatp4c1 in rat liver, 
kidney, lactating and non-lactating mammary gland by Western blotting and 
immunochemical analysis.   
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Hypothesis 2: Oatp4c1 localizes at the apical membrane in the rat kidney cortex. 
Specific Aim 2a: To verify the apical localization of Oatp4c1 in the rat kidney cortex 
by proteomic analysis in the isolated brush-border membrane (BBM) and 
basolateral membrane (BLM). 
Specific Aim 2b: To determine the precise expression pattern of Oatp4c1 at the 
organ and nephron level. 
A previous study reported that Oatp4c1 localizes to the basolateral membrane in 
the rat kidney cortex (79). However, results from Specific Aim 1c showed that Oatp4c1 
localizes at the apical membrane of polarized epithelial cells grown in vitro. In Specific 
Aim 2a we will isolate BBM and BLM from rat kidney cortex to elucidate these 
contradictory results. The proteins in BBM and BLM preparations will be analyzed by 
Western blotting and LC-MS/MS to validate the localization of Oatp4c1 in rat kidney. 
Specific Aim 2b will determine the precise location of Oatp4c1 at the organ and nephron 
level by double immunofluorescence with proximal tubule marker or distal tubule marker. 
Double immunofluorescence staining will also be used to access the location of Oatp4c1 
relative to major apical efflux transporters in the rat kidney. 
 
Hypothesis 3: Oatp4c1 functions as an uptake transporter involved in renal tubular 
reabsorption. The in vitro cell systems can be used to identify potential substrates and 
explore the physiological role of Oatp4c1. 
Specific Aim 3a: To investigate Oatp4c1 transport characteristics and driving force. 
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Specific Aim 3b: To identify potential Oatp4c1 substrates. 
The kidney is responsible for homeostasis of endogenous and exogenous 
substances through tubular secretion and reabsorption, which in part is mediated by 
various membrane transporters, including those in the SLC superfamily. The results from 
Specific Aim 1c showed that Oatp4c1 localizes at the apical membrane in rat kidney 
inner cortex, suggesting a potential role in renal reabsorption of its substrates. To have a 
better understanding of the physiological role of Oatp4c1, its substrates and transport 
characteristics will be explored. In Specific Aim 3a we will verify E3S, a human 
OATP4C1 substrate (110, 111), as a rat Oatp4c1 substrate and will investigate the 
transport kinetic and driving force of Oatp4c1-mediated E3S transport using the 
Oatp4c1-expressing cells developed in Specific Aim 1a. In Specific Aim 3b we will 
determine the interaction of Oatp4c1 with potential physiological substrates by studying 
their capacity to inhibit transport of E3S.  
  
Hypothesis 4: OATP4C1 is localized at the apical membrane in the in vitro cell systems 
and human kidney, and is highly expressed in lung cancer. The in vitro cell systems can 
be used to study the role of OATP4C1 in drug disposition. 
Specific Aim 4a: To develop and validate human OATP4C1 antibodies amenable 
for immunoblotting, immunohistochemistry and immunofluorescence. 
Specific Aim 4b: To create and validate human OATP4C1-expressing cells with 
appropriate characteristics for functional studies. 
Specific Aim 4c: To determine the expression and subcellular localization of 
OATP4C1 in the human kidney. 
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Specific Aim 4d: To determine the expression of OATP4C1 in cancer cells. 
The subcellular localization of membrane transporters determines their 
physiological function. The novel finding of the apical localization of rat Oatp4c1 in this 
project suggests its physiological role is tubular reabsorption not tubular secretion. To 
validate the subcellular localization of OATP4C1 in human kidney, human OATP4C1 
antibodies will be developed in Specific 4a. The antibody specificities will be validated in 
a stably transfected OATP4C1-expressing cell line established in Specific Aim 4b by 
Western blotting, immunohistochemistry and immunofluorescence. The functional 
activity of OATP4C1 in the transfected cell line will also be validated using ouabain and 
E3S as substrates in uptake studies. OATP4C1 will also be overexpressed in insect cells 
for substrate screening and its functional activity will be probed with ouabain and E3S. In 
Specific Aim 4c we will determine the subcellular localization of OATP4C1 in human 
kidney. In Specific Aim 4d we will examine SLCO4C1/OATP4C1 expression in several 
cancer cell lines, lung tumor and adjacent normal lung tissue sections.  
 
 
 
 
 
 
 
Copyright © Kuei-Ling Kuo 2012 
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CHAPTER 3 : MATERIALS AND METHODS 
A.  Materials 
Madin-Darby canine kidney II (MDCKII) cells were purchased from European 
Collection of Cell Cultures (Salisbury, UK). LLC-PK1 cells (porcine kidney proximal 
tubule epithelial cells) were purchased from American Type Culture Collection 
(ATCC, Manassas, VA).  
Transwells #3414, and snapwells #3407 were obtained from Corning Costar 
(Cambridge, MA).  All cell culture media were purchased from Mediatech (Manassas, 
VA). Fetal bovine serum was from Atlanta Biologicals (Lawrenceville, GA). Penicillin-
streptomycin, blasticidin, geneticin were obtained from Invitrogen (Carlsbad, CA).       
RNeasy Kit, Qiashredder columns, RNase-free DNase set, and QIAprep Spin 
Miniprep Kit were obtained from Qiagen (Valencia, CA).  ThermoScriptTM RT-PCR 
kit, LR ClonaseTM II Enzyme Mix, Tag-On-DemandTM Suppressor System and 
ethidium bromide were purchased from Invitrogen. RecoverALLTM Total nucleic acid 
isolation kit was from Invitrogen Ambion. XL1-Blue Supercompetent cell was from 
Stratagene (Santa Clara, CA). ZymocleanTM Gel DNA Recovery kit was from Zymo 
Research (Irvine, CA). Phusion High-Fidelity PCR kit, restriction enzymes (KpnI, 
SspI, EcoRV, SalI), and PNGase F were purchased from New England Biolabs 
(Ipswich, MA). The SYBR® Green PCR Core Reagents kit was obtained from 
Applied Biosystems (Foster City, CA). All primers were purchased from Integrated 
DNA Technologies (Coralville, IA). Fluorescein calibration dye was obtained from 
Bio-Rad (Hercules, CA). Sea-Kem LE agarose was from Cambrex (Rockland, ME). 
FuGENE 6 transfection reagent and Complete Mini EDTA-free protease inhibitor 
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tablets were obtained from Roche Diagnostics (Indianapolis, IN). Sodium butyrate 
was from Sigma-Aldrich (St. Louis, MO). 
LDS sample buffer, Magic MarkTM XP protein ladder, Prolong Gold antifade 
reagent containing DAPI were purchased from Invitrogen. Polyvinylidene difluoride 
membrane was from Millipore (Billerica, MA). HistoGelTM was obtained from Thermo 
Scientific Richard-Allan Scientific (Kalamazoo, MI). Sulfo-NHS-SS-Biotin, streptavidin 
agarose beads, BCA Protein Assay kit and Supersignal West Pico chemiluminescent 
kit were obtained from Thermo Scientific Pierce (Rockford, IL). Avidin/biotin blocking 
kit, normal goat serum, NovaRED kit, hematoxylin, and Vecta Mount were purchased 
from Vector Laboratories (Burlingame, CA). Streptavidin-HRP reagent was from 
Dakota (Carpinteria, CA).  
Rat monoclonal antibody against E-cadherin (DECMA-1), mouse monoclonal 
antibodies against calbindin-D28k (CB-955) and aquaporin 1 (1/22) were obtained 
from Abcam (Cambridge, MA). Mouse monoclonal antibody against Zo-1 (zo1-1A12), 
Alexa Fluor® 488 goat anti-mouse IgG (H+L) and Alexa Fluor® 568 goat anti-rabbit 
IgG (H+L), Alexa Fluor® 488 goat anti-rabbit IgG (H+L), and Alexa Fluor® 568 goat 
anti-rat IgG (H+L) were from Invitrogen. Mouse monoclonal antibody against β-actin 
(AC-15) was from Sigma-Aldrich. Mouse monoclonal antibody against P-gp (C219) 
was from Signet (Dedham, MA). Mouse monoclonal antibody against human BCRP 
(BXP-21), rat monoclonal antibody against rat Abcg2 (BXP-53) and Mrp4 (M4I-10) 
were from Kamiya (Seattle, WA). Rabbit polyclonal antibody against Na+/K+-ATPase 
(#3010) was obtained from Cell Signaling (Danvers, MA). HRP-conjugated goat anti-
mouse IgG (H+L), HRP-conjugated goat anti-rabbit IgG (H+L), HRP-conjugated goat 
anti-rat IgG (H+L) were purchased from Thermo Scientific Pierce (Rockford, IL). 
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[3H]-E3S (45.6 Ci/mmol) was purchased from Perkin Elmer (Waltham, MA) and 
[3H]-MTX (40 Ci/mmol) from American Radiolabeled Chemicals (St. Louis, MO). Bio-
safe® II scintillation cocktail was obtained from Research Products International 
(Mount Prospect, IL). GF120918 was a gift from GlaxoSmithKline (Research Triangle 
Park, NC). Hoechst 33342 was obtained from Invitrogen. OE67 membrane filters 
were from Millipore Corporation (Bedford, MA). RC55 membrane filters were from 
Schleicher and Schuell (Keene, NJ). 
 
B.  Creation and validation of a rat Oatp4c1-expressing cell line 
1. Development of rat Oatp4c1 antibody 
Rabbit polyclonal antibodies against rat Oatp4c1 were generated using an 
extracellular loop [SPDFEARAGKC (PA1556) (79)], two amino-terminus 
[KGVENPAFVPSSPDTPRR (PA1254); QPRESEDPQKSTEPS (F3608)], and two 
carboxyl-terminus [STITVEEDLNKIENEG (PA1343); TVEEDLNKIENEG 
(PA1562)] sequence peptides (Figure 3-1). The antigen sequence specificities 
were confirmed with NCBI’s BLAST. The antigen preparation, immunization and 
serum collection were performed by Open Biosytems (Rockford, IL). The rabbits 
were immunized with 0.5 mg of antigen on Day 1 and boosted with 0.25 mg of 
antigen on Days 14, 28 and 42. The terminal sera were collected on Day 90. The 
antibody specificities were validated by Western blotting, immunohistochemical 
analysis and immunofluorescence as described in Section B-8, Section B-9 and 
Section B-10. PA1343 was affinity-purified. 
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Figure 3-1: Rat Oatp4c1 antibody antigen peptide sequence and location. 
 
2. Construction of plasmid vector 
Total RNA was isolated from a frozen kidney of a Sprague-Dawley rat using 
RNeasy Kit as directed by the manufacture with sample disruption using 
Qiashredder and on-column DNA digestion. Total RNA concentration was 
determined by the measurement of optical density at 260 nm with a UV-Vis 
Spectrophotometer (ND-1000, NanoDrop, Wilmington, DE). Total RNA quality 
was verified by an OD260/OD280 absorption ratio greater than 2.0.  Reverse-
transcription of 1 μg RNA to cDNA was performed with reverse ThermoScriptTM 
RT-PCR kit with oligo (dT)20 primers using Peltier Thermal Cycler (Waltham, MA). 
Rat Slco4c1 cDNA was amplified using Phusion High-Fidelity PCR kit with 
forward (5’-CACCATGCAGGGTTCCAAGGGAG-3’) and reverse (5’-
CTATCCTTCGTTCTCTATTTTGTTG-3’) primers. The amplification protocol 
included an initial denaturation (98 ºC for 1 min) followed by 40 cycles of a 
denaturation step (98 ºC for 10 sec), an annealing step (64°C for 30 sec) and an 
extension step (72 ºC for 35 sec), and a final extension step (72 ºC for 10 min).  
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To confirm the amplified fragment was of appropriate size, amplification products 
were separated by 0.8% agarose gel electrophoresis in 1 x TBE running buffer 
(89 mM Tris-Borate, 2 mM EDTA, pH 8.0) for 1 hr at 80 V. The gel was visualized 
by staining with 0.5 µg/ml ethidium bromide, and imaged on an Image Station 
2000 MM (Eastman Kodak, New Haven, CT). The single band at appropriate size 
was cut from the gel on a UV lamp transilluminator (Fisher Scientific, Pittsburgh, 
PA) and purified using ZymocleanTM Gel DNA Recovery kit following the 
manufacture’s protocol. The subsequent sequence (Slco4c1) was cloned into the 
vector pENTR using pENTR Directional TOPO Cloning kit and the construct was 
transformed into competent One Shot TOP10 E. coli. The competent cells were 
grown in an agar plate with 50 µg/ml kanamycin. The plasmid DNA was isolated 
from positive transformants using QIAprep Spin Miniprep Kit according to the 
manufacturer’s protocol. The plasmid construct (500 ng) was validated by 
EcoRV, SalI or KpnI restriction enzyme digestion for 2 hr at 37°C and 0.8% 
agarose gel electrophoresis. The sequence was confirmed (Davis sequencing, 
Davis, CA) to share 100% identity with rat Slco4c1 sequence (GeneBank 
accession number NM_001002024). The plasmid DNA (150 ng, pENTR/Slco4c1) 
was then subcloned into the multiple cloning site of the mammalian expression 
vector pcDNA6.2/GFP-DEST using Gateway® LR Clonase® II enzyme mix as 
directed by the manufacturer’s protocol. The construct was transformed into XL1-
Blue Supercompetent cells and the competent cells were grown in an agar plate 
with 100 µg/ml carbenicillin. The plasmid DNA (pcDNA6.2/GFP-DEST/Slco4c1, 
Figure 3-2) from positive transformants was validated by EcoRV, SspI and KpnI 
restriction enzyme digestion for 2 hr at 37°C and 0.8% agarose gel 
electrophoresis.  
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Figure 3-2: pcDNA6.2/GFP-DEST/ Slco4c1 plasmid construct. 
 
3. Cell culture and transfection  
MDCKII cells were cultured in minimum essential medium (MEM) 
supplemented with 5% fetal bovine serum, 100 U/ml penicillin, and 100 µg/ml 
streptomycin at 37°C in a humidified incubator with 5% CO2. LLC-PK1 cells were 
cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 
10% fetal bovine serum, 100 U/ml penicillin, and 100 µg/ml streptomycin. The 
pcDNA6.2/GFP-DEST/Slco4c1 and pcDNA6.2/GFP-DEST (vector) were 
transfected into MDCKII and LLC-PK1 cells at 50% confluence with the lipid-
based FuGENE 6 transfection reagent at a 3:1 ratio as directed by 
manufacturer’s protocol. The transfected cells were selected with 5 µg/ml of 
blasticidin. Success of transfection was evaluated by Western blot analysis of cell 
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lysates and immunohistochemical analysis of paraformaldehyde-fixed paraffin-
embedded cell pellet sections for rat Oatp4c1 following procedures described in 
Section B-8 Western blot and Section B-9 Immunohistochemistry. The 
subcellular localization in pooled cells was examined by confocal microscopy and 
surface protein biotinylation assay as described in Section B-10 
Immunofluorescence microscopy and Section B-11 Surface protein biotinylation 
assay.  
 
4. Single clone selection by fluorescence-activated cell sorting (FACS) with 
transiently expressed C-terminal-tagged green fluorescent protein (GFP)  
MDCKII-Oatp4c1 (1 x 106 cells/well) were grown in a 6-well plate and 
allowed to become 90% confluent overnight. Cells were treated with Tag-On-
DemandTM Suppressor System for 6 hr at 37°C, and then replaced with fresh 
growth medium. After 48 hr, cells were trypsinized, pelleted by centrifugation at 
300 g for 5 min, resuspended in growth medium and filtered with a 35 µm cell 
strainer to remove cell clumps and debris. FACS analyses were performed at UK 
Flow Cytometry Core Facility. Cells were sorted into individual wells in 96-well 
plates with excitation at 478 nm and emission at 507 nm using FACSCalibur 
cytofluorimeter (BD Biosciences, San Jose, CA) and MoFloTM High-Performance 
Cell Sorter (DakoCytomation, Fort Collins, CO). Cells in 96-well plates were 
immediately transferred to the incubator. Cell medium was replaced every three 
days. Upon confluence, cells were transferred to 24-well plate, 12-well plate, 6-
well plate, T-25 and T-75 serially. Oatp4c1 expression was evaluated by 
immunofluorescence staining as described in Section B-10 Immunofluorescence 
microscopy. 
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5. Single clone selection by immunofluorescence labeling and FACS 
The immunofluorescence labeling of viable cells was according to 
procedures described by Cunningham with some modifications (112). MDCKII-
Oatp4c1 cells (1 × 106 cells) were trypsinized, pelleted by centrifugation at 300 g 
for 5 min, resuspended in 10% BSA/PBS containing 110 µg/ml PA1343 (for rat 
Oatp4c1) and incubated for 1 hr at room temperature. Cells were washed with 
PBS and centrifuged twice. Cell pellets were labeled with 4 µg/ml Alexa Fluor 
488 goat anti-rabbit IgG in 10% BSA/PBS for 30 min at 4°C. Following two 
washes with PBS and centrifugation, cells were resuspended in growth medium. 
At UK Flow Cytometry Core Facility, cells were sorted into individual wells in 96-
well plates with excitation at 495 nm and emission at 519 nm. Cells in 96-well 
plates were immediately transferred to the incubator. Cell medium was replaced 
every three days. Upon confluence, cells were transferred to 24-well plates, 12-
well plates, 6-well plates, T-25 and T-75 flasks serially. Oatp4c1 expression was 
evaluated by immunofluorescence staining as described in Section B-10 
Immunofluorescence microscopy. 
 
6. Single clone selection by serial dilution 
MDCKII-Oatp4c1 cells were plated in 96-well plates as shown in Figure 
3-3. Cells were trypsinized, centrifuged, resuspended in growth medium. Cell 
suspension (5 x 103 cells/ml; 200 μl) was added in A1 and growth medium (100 
μl) was added to all the other wells. Cell suspension (100 μl) was transferred 
from A1 to B1 and mixed by gently pipetting and repeated down the entire 
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column. Cell suspension (100 μl) from H1 was discarded to have the same 
volume as the wells above it. Growth medium (100 μl) was added to the first 
column to achieve final volume of 200 μl. Cell suspension (100 μl) was 
transferred from the first column to the second column and mixed by gently 
pipetting and repeated across entire plate. Cell suspension (100 μl) from each 
well in the last column was discarded. The final volume was brought to 200 μl by 
adding 100 μl of growth medium. Cell medium was replaced every three days. 
Upon confluence, cells were transferred to 24-well plates, 12-well plates, 6-well 
plates, T-25 and T-75 flasks serially. Oatp4c1 expression was evaluated by 
immunofluorescence staining as described in Section B-10 Immunofluorescence 
microscopy. 
 
 
Figure 3-3: Plate setup for serial dilution. 
 
 37 
 
7. Regulation of Oatp4c1 expression by sodium butyrate, blasticidin, simvastatin, 
glycerol, and MG132 
MDCKII-Oatp4c1 cells were grown in 6-well plates (5 x 105 cells/well) or 
Lab-TekTM 8-well chamber slides (1.4 x 104 cells/well, Thermo Scientific Nunc, 
Rochester, NY) allowed to become 50% confluent overnight, and then incubated 
with  0.1 - 5 mM of sodium butyrate for 24 hr. Cells grown in 6-well plates were 
washed with ice-cold PBS, scraped with cell scrapers and centrifuged at 300 g 
for 5 min. Cell lysates were prepared and subjected to Western blot to evaluate 
Oatp4c1 expression as described in Section B-8 Western blot. Total RNA was 
isolated from cell pellets and subjected to qRT-PCR analysis to assess Slco4c1 
mRNA expression as described in Section C-1 Quantitative real time polymerase 
chain reaction (qRT-PCR). Cells grown in chamber slides were stained for 
immunofluorescence analysis to evaluate Oatp4c1 expression as described in 
Section B-10 Immunofluorescence microscopy.  
Cells were also grown in 10 and 30 μg/ml of blasticidin for two passages or 
treated with 10 and 20 μM simvastatin for 24 hr, 0 – 1.5 M glycerol for 48 hr, or 
0.1 and 10 μM MG132 for 12 and 24 hr, respectively, to evaluate their effects on 
Slco4c1/Oatp4c1 expression in MDCKII-Oatp4c1 cells.  
 
8. Western blot  
MDCKII-Oatp4c1 and MDCK-pcDNA cells were grown in a T-75 flask to 
confluence.  Following a wash with ice-cold PBS, cells were scraped and pelleted 
by centrifugation at 300 g for 5 min. Cell pellets were resuspended in RIPA buffer 
(50 mM Tris, 150 mM NaCl, 1% Nonidet P-40, 0.5% deoxycholate, 1 mM EDTA, 
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0.1% SDS, pH 8.0) with protease inhibitor cocktail (Complete Mini tablets) and 
shaken at 4°C for 30 minutes. Cell lysates were stored at -80°C until use. 
Cell lysates were mixed with NuPAGE LDS sample buffer and 0.1 M 
dithiothreitol (DTT) before heating to 70°C for 10 min. Proteins were separated 
on a 10% SDS-polyacrylamide gel with 5% stacking gel and Tris-Glycine SDS 
running buffers (25 mM Tris, 192 mM glycine, 0.1% SDS) and transferred to a 
polyvinylidene difluoride membrane with transfer buffer (25 mM Tris, 192 mM 
glycine) at 200 mA for 2 hr at 4°C. Following blocking with 5% skimmed milk in 
PBST (10 mM phosphate buffer pH 7.6, 150 mM NaCl, 0.05% Tween-20) for 3 hr 
at room temperature, the membranes were incubated with 55 µg/ml anti-Oatp4c1 
polyclonal antibody (PA1343) or 14.5 µg/ml anti-β-actin in 5% skimmed milk in 
PBST at 4°C. After three 10 min washes with PBST, the membranes were 
incubated with 0.04 µg/ml HRP conjugated goat anti-rabbit (for Oatp4c1) or anti-
mouse IgG (for β-actin) in 5% skimmed milk in PBST for 1 hr at room 
temperature. Following three 10 min PBST washes, the membranes were 
visualized by Supersignal® West Pico chemiluminescent kit and imaged on an 
Image Station 2000 MM (Eastman Kodak).  
 
9. Immunohistochemistry  
MDCKII-Oatp4c1 and MDCKII-pcDNA cells were grown in two T-75 flasks 
to confluence.  Following a wash with PBS, cells were scraped and centrifuged at 
300 g for 5 min. Cell pellets were encapsulated with HistoGelTM and then fixed in 
4% paraformaldehyde for 6 hr at room temperature. The cell pellets were 
embedded in paraffin at UK Histology Laboratory of the Imaging Facility, and cut 
as 6 µm-thick sections using Microm HM325 microtome (Thermo Scientific).  
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Sections were heated at 60°C on Barnstead Lab-Line slide warmer (Dubuque, 
IA) to affix the tissues on the slides. Sections were deparaffinized with 3 changes 
of xylene for 5 min each, and rehydrated with 3 changes of 100% ethanol, 1 
change of 95% ethanol, and 1 change of 70% ethanol for 2 min each. Then, the 
antigen was retrieved by pressure-cooking in 10 mM citrate buffer, pH 6.0. 
Sections were blocked with 3% H2O2 in PBS for 5 min, avidin and biotin blocking 
reagent for 15 min each, 2% normal goat serum in PBST for 30 min, and 
subsequently incubated with PA1343 (for Oatp4c1, 220 µg/ml) for 24 hr at room 
temperature. Following three 5 min washes with PBST, sections were incubated 
with 5 µg/ml biotinylated goat anti-rabbit IgG for 30 min at room temperature. 
Sections were washed with PBST for 5 min four times, and incubated with 
streptavidin-HRP reagent for 20 min. After five more 5 min PBST washes, 
sections were incubated with NovaRED chromogen substrate for 5 min for 
visualization. Sections were then washed with H2O for 5 min three times, and 
counterstained with hematoxylin to visualize nuclei. After washing with running 
tap water for 5 min, sections were dehydrated with 1 change of 70% ethanol, 1 
change of 95% ethanol, 3 changes of 100% ethanol for 2 min each. Glass 
coverslips were then mounted onto the glass slides with Vecta Mount. 
 
10. Immunofluorescence microscopy 
Oatp4c1-expressing and vector-transfected MDCKII and LLC-PK1 cells (5 x 
105 cells/well) were seeded on polycarbonate #3407 snapwell (0.4 µm pore size, 
1.12 cm2 growth area) and grown for 4 days to allow for polarization. 
Transepithelial electrical resistance (TEER) was measured every day with a 
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Millicell ohmmeter and a Millicell-ERS probe (Millipore, Bedford, MA) until > 200 
Ω•cm2 was achieved.  
Cell containing inserts were washed with ice-cold PBS. Filter membranes 
were then cut and transferred to 24 well plates for staining. Cells were fixed with -
20°C methanol for 10 min, rehydrated with room temperature PBS for 5 min, 
permeabilized with 0.2% Triton X-100/PBS for 15 min, blocked with 10% goat 
serum for 1 hr, and then incubated with PA1343 (for Oatp4c1, 110 µg/ml) and 
anti-Zo-1 (5 µg/ml) for 2 hr at room temperature.  Following three 5 min washes 
with 0.2% Triton X-100/PBS, cells were incubated with 4 µg/ml Alexa Fluor 568 
anti-rabbit IgG and Alexa Fluor 488 anti-mouse IgG in blocking solution for 1 hr at 
room temperature. Cells were washed with 0.2% Triton X-100/PBS three times 
and mounted on glass slides with Prolong Gold containing DAPI solution to 
visualize nuclei. The fluorescence emission was visualized using Axiovert 200M 
confocal microscope (Carl Zeiss, Thornwood, NY).   
 
11. Surface protein biotinylation assay 
MDCKII-Oatp4c1 and MDCKII-pcDNA cells (1 x 106 cells/well) were grown 
on polycarbonate #3414 transwell (3 µm pore size, 4.67 cm2 growth area) for 4 
days to achieve TEER > 200 Ω•cm2. Cells were washed with ice-cold PBS-
Mg/Ca buffer (PBS buffer containing 0.1 mM CaCl2 and 1.0 mM MgCl2). Freshly 
prepared Sulfo-NHS-SS-Biotin (1 mg/ml in PBS-Mg/Ca) was added to either the 
apical or basolateral chamber and incubated with slow rocking at 4°C for 20 min. 
Cells were then washed and incubated with quenching buffer (5 mM glycine in 
PBS-Mg/Ca) with slow rocking at 4°C for 20 min to remove unreacted biotin. 
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Following washing with PBS-Mg/Ca, the cells were lysed with 700 µl lysis buffer 
(10 mM Tris, 150 mM NaCl, 1 mM EDTA, 0.1% SDS, 1% Triton X-100, pH 7.4) 
with the protease inhibitor cocktail for 30 min at 4°C with shaking. Cell lysates 
were centrifuged at 10,000 g for 2 min at 4°C, and the supernatants were 
incubated with streptavidin agarose beads with end-over-end rotation for 1 hr at 
4°C. Samples were washed three times with lysis buffer, and incubated with 50 µl 
2X Laemmli Buffer (125 mM Tris, 10% glycerol, 2% SDS, 5% 2-β-
mercaptoethanol, pH 6.8) for 30 min at room temperature. 2-β-mercaptoethanol 
was used to break the disulfide (SS) bond between the biotin and the protein 
reactive group, releasing the biotinylated membrane proteins from the beads. 
The samples were centrifuged at 10,000 g for 2 min, and the supernatants were 
subjected to Western blot analysis as described in Section B-8 Western blot. 
 
C.  Determination of Oatp4c1 expression and subcellular localization in rat tissues 
1. Quantitative real time polymerase chain reaction (qRT-PCR) 
RNA isolation from rat tissues and reverse-transcription were performed as 
described in Section B-2 Construction of plasmid vector. Quantification of the 
expression level of Slco4c1 and the house-keeping gene 18s rRNA was 
performed using the qRT-PCR on the iCycler Multicolor Real-Time PCR 
Detection System (Bio-Rad, Hercules, CA).  Slco4c1 primer sequences were 
obtained from published literature (79), and 18s rRNA primers were designed 
using reference sequences deposited in NCBI’s Entrez Gene with the software 
assistance of PrimerQuest (Integrated DNA Technologies, Coralville, IA). 
Reference accession numbers, primer sequences, and product sizes are 
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provided in Table 3-1.  PCR reaction master mixes (50 µL) were made using the 
SYBR® Green PCR Core Reagents kit and contained 200 nM of each primer, 
1.25 mM dNTPs, 1x SYBR Green buffer, 0.025 U/μl Taq polymerase, and 4 mM 
MgCl2, 20 nM fluorescein.  Amplification conditions were as follows: 95°C (5 min), 
[95°C (45 sec), 61.6°C (1 min), 72°C (1 min)] × 50 cycles. No-template (water) 
reaction mixtures were prepared as negative control. To confirm the generation 
of a single product of appropriate size, all amplification products were separated 
by 3% agarose gel electrophoresis in 1 x TBE running buffer for 50 min at 150 V. 
The gel was visualized by staining with ethidium bromide, and imaged on an 
Image Station 2000 MM (Eastman Kodak).  Relative copy number of each gene 
in the samples was determined in triplicate and normalized to relative copy 
number of the housekeeping gene 18s rRNA within each sample. The fold 
change in Slco4c1 expression relative to reference tissue (FC) was calculated 
with 2-∆∆Ct method using the following equation:   
ܨܥ ൌ 2ିሾሺ஼௧ೄ೗೎೚ర೎భି஼௧భఴೞሻ೟ೌೝ೒೐೟ିሺ஼௧ೄ೗೎೚ర೎భି஼௧భఴೞሻೝ೐೑೐ೝ೐೙೎೐ሿ   Equation 3-1 
The error propagation was as follows: 
ܵௗ஼் ൌ ܵ஼௧ೄ೗೎೚ర೎భି஼௧భఴೞ ൌ ටܵ஼௧ೄ೗೎೚ర೎భଶ ൅ ܵ஼௧భఴೞଶ     Equation 3-2 
ܵௗௗ஼் ൌ ටܵ݀ܥܶ,ݐܽݎ݃݁ݐ2 ൅ ܵ݀ܥܶ,ݎ݂݁݁ݎ݁݊ܿ݁2      Equation 3-3 
ܵி஼ ൌ ݈݊2 ൈ ܵௗௗ஼் ൈ ܨܥ        Equation 3-4 
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Table 3-1: Slco4c1 and 18s rRNA primers information. 
Gene Reference sequence 
Forward primer (5’  3’) 
Product 
size (bp) Ref. 
Reverse primer (5’  3’) 
Slco4c1 NM_001002024 
GCAAGGTATTGTAGTAAATGGCCTAG 
127 (79) 
AGACAACACGCAAAAGGAGATGT 
18s 
rRNA X03205.1 
CGCCGCTAGAGGTGAAATTCTT 
101  
CGAACCTCCGACTTTCGTTCTT 
 
 
2. Western blot 
Crude membrane fractions were prepared from Sprague-Dawley female rat 
tissues (kidney, liver, lactating and non-lactating MG). The tissues were disrupted 
in Dounce Buffer (10 mM Tris, pH 7.6, 0.5 mM MgCl2 with protease inhibitor 
cocktail) with brief pulses of sonication using a probe ultrasonic processor 
(Thermo Fisher Scientific) at 4°C and the tonicity was restored to 150 mM with 
sodium chloride. Following 300 g centrifugation for 5 min, EDTA was added to 
the supernatant to a final concentration of 5 mM. The samples were centrifuged 
at 100,000 g for 1 hr at 4°C. Pellets were resuspended in Resuspension Buffer 
(0.2 M mannitol, 0.07 M sucrose, 50 μM Tris HCl, 1 μM EDTA). Protein 
concentrations were measured using the BCA Protein Assay Kit. Crude 
membrane fractions were stored at -80°C until use. Procedures for Western blot 
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analysis of Oatp4c1 expression in rat tissues were the same as those described 
in Section B-8 Western blot. 
 
3. Immunohistochemistry  
Female Sprague-Dawley rat liver, kidney and MG were isolated and fixed in 
4% paraformaldehyde for 6 hr at room temperature. The tissues were embedded 
in paraffin at UK Histology Laboratory of the Imaging Facility, and cut as 6 µm-
thick sections. Procedures for immunohistochemical analysis of Oatp4c1 
localization in rat tissues were as described in Section B-9 
Immunohistochemistry. 
To further study the localization of Oatp4c1, rat tissue sections were double 
stained with anti-Oatp4c1 antibody (PA1343, 110 µg/ml) and the following 
antibodies: anti-E-cadherin (2 µg/ml), anti-AQP1 (10 µg/ml), and anti-calbindin-
D28k (40 µg/ml), anti-Abcg2 (BXP-53, 12.5 µg/ml), anti-Mrp4 (3 µg/ml), anti-P-gp 
(2.5 µg/ml). For visualization, the sections were incubated with fluorescence 
conjugated secondary antibodies for 30 min at room temperature and mounted 
with glass coverslips using Prolong Gold containing DAPI solution. Fluorescence 
was visualized using Axiovert 200M confocal microscope (Carl Zeiss). 
 
4. BBM (brush-border membrane) and BLM (basolateral membrane) isolation 
The BBM and BLM were isolated by Percoll density gradient centrifugation 
according to procedures described by Goldinger et al. with some modifications 
(113). Briefly, two male Sprague-Dawley rats were anesthetized with isoflurane 
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and euthanized by cervical dislocation. The kidneys were excised and frozen 
immediately. Kidney cortex tissues were excised and homogenized in sucrose 
buffer (250 mM sucrose, 10 mM triethanolamine, pH 7.4, protease inhibitor 
cocktail) with a motorized homogenizer. Samples were centrifuged at 2,500 g for 
15 min at 4°C. The resultant supernatant was centrifuged at 20,000 g for 20 min 
at 4°C. The less dense top layer of the pellet was collected and the lower dark 
segment of the pellet was discarded. The pellet was resuspended in 26.5 ml 
sucrose buffer with 10 strokes of a tight plunger in a Dounce homogenizer. 
Following addition of 3.5 ml Percoll, the suspension was mixed by inversion and 
centrifuged at 48,000 g for 30 min at 4°C. Two distinct bands were formed and 
carefully isolated. The upper band was BLM and the lower one was BBM (113).  
An equal volume of sucrose buffer was added to each fraction, and the Percoll 
was removed by centrifuging at 93,000 g for 1 hr at 4°C. The single band of 
membrane proteins was collected and the glassy Percoll pellet was discarded.  
The BLM was resuspended in mannitol buffer (150 mM mannitol, 2.5 mM EGTA, 
6 mM HEPES, pH 7.4). The BBM pellet was further purified by magnesium  
precipitation (114). Briefly, following resuspension of the BBM pellet in a buffer 
(100 mM mannitol, 1.6 mM EGTA, 0.3 mM PMSF, 0.3 mM sodium 
orthovanadate, 4 mM HEPES, pH 7.4), MgCl2 was added to yield a final 
concentration of 12 mM. The mixture was incubated on ice for 15 min with 
intermittent and gentle mixing. Remaining cellular debris were removed by 
centrifuging at 3,000 g for 10 min at 4°C, and the resultant supernatant was 
centrifuged at 30,000 g for 40 min at 4°C to isolate membrane proteins. The BBM 
pellet was resuspended in mannitol buffer and again precipitated by addition of 
12 mM MgCl2 as described above. The final pellet was resuspended in mannitol 
buffer. The BBM and BLM were stored at -80°C until use. 
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Separation efficiency was evaluated by Western blot analysis following 
procedures described in Section B-8 Western blot. Procedures were the same 
but with different antibodies. Na+/K+-ATPase was used as a basolateral marker 
and was labeled with anti-Na+/K+-ATPase (1:1000). Mrp4 and Abcg2 served as 
apical markers and were labeled with anti-Mrp4 (3 µg/ml) and rabbit polyclonal 
anti-Abcg2 (150 µg/ml), respectively. The rabbit polyclonal anti-Abcg2 antibodies 
were generated (Open Biosystems) against Walker A peptide 
(GKSSLLDVLAARKD) of rat Abcg2 (115). 
 
5. Protein trypsin digestion and LC-MS/MS analysis 
Approximately 100 µg of proteins from the BBM and BLM were subjected to 
10% SDS-PAGE separation. The protein gel bands at 65-100 and 100-150 kDa 
were excised and underwent DTT reduction, iodoacetamide (IAA) alkylation, and 
in-gel trypsin digestion using a standard protocol as previously reported (116, 
117). The resulting tryptic peptides were extracted, and concentrated to 15 µl 
each using a SpeedVac, and 5 µl was injected for nano-LC-MS/MS analysis. LC-
MS/MS data were acquired on an LTQ Velos Orbitrap mass spectrometer 
(Thermo Fisher Scientific) coupled with a Nano-LC Ultra/cHiPLC-nanoflex HPLC 
system (Eksigent) through a nano-electrospray ionization source. The tryptic 
peptides sample was injected by an autosampler, desalted on a trap column, and 
subsequently separated by reverse phase C18 column (75 µm i.d. x 150 mm) at 
a flow rate of 250 nl/min. The HPLC gradient was linear from 5% to 60% mobile 
phase B for 30 min using mobile phase A (H2O, 0.1% formic acid) and mobile B 
(90% acetonitrile, 0.1% formic acid). Eluted peptides were analyzed using data-
dependent acquisition: peptide mass spectrometry was obtained by Orbitrap with 
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a resolution of 100,000. The seven most abundant peptides were subjected to 
collision induced dissociation (CID) and MS/MS analysis in LTQ linear trap. The 
LC-MS/MS data were submitted to a local MASCOT server for MS/MS protein 
identification search via the ProteomeDiscoverer software. The mass error 
tolerance was 5 ppm for peptide MS and 0.8 Da for MS/MS. All peptides were 
required to have an ion score greater than 30 (P < 0.05). The false discovery rate 
(FDR) in each LC-MS/MS analysis was set to be less than 1%. 
 
D.  Functional characterization of Oatp4c1 in MDCKII-Oatp4c1 cells 
1. [3H]-E3S uptake and inhibition studies 
MDCKII-Oatp4c1 and MDCKII-pcDNA cells (5 x 105 cells/well) were grown 
in 6-well plates. The cell culture medium was replaced with that containing 5 mM 
sodium butyrate to induce transporter expression 24 hr prior to uptake. The 
uptake buffer used in all transport experiments contained 118 mM NaCl, 23.8 
mM NaHCO3, 4.83 mM KCl, 0.96 mM KH2PO4, 1.20 mM MgSO4, 5.0 mM glucose 
and 1.53 mM CaCl2. Buffer pH was adjusted to 7.4 by supplementation with 12.5 
mM HEPES and pH adjustment with 1M Tris-base. Alternatively, the buffer was 
supplemented with 12.5 mM 2-(N-morpholino)ethanesulfonic acid (MES) and pH 
was adjusted to 4.5 or 5.5 with 1M Tris-base. Before the study, cells were 
washed once and pre-incubated with uptake buffer for 15 min at 37°C. Uptake 
was initiated by replacing the uptake buffer with that containing [3H]-E3S. After 
incubation for designated time at 37°C, cells were washed three times with ice-
cold PBS, lysed with 0.5 ml of 0.5 N NaOH and neutralized with 0.1 ml of 2.5 N 
HCl. The intracellular radioactivity was determined by transferring 0.5 ml of lysate 
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into scintillation cocktail for liquid scintillation counting with a Packard 2200CA 
Tri-Carb (PerkinElmer, Waltham, MA) liquid scintillation counter. Protein 
concentrations were measured using the BCA Protein Assay Kit. Net uptake was 
calculated as the difference between [3H]-E3S uptake into MDCKII-Oatp4c1 cells 
and uptake into MDCKII-pcDNA cells. For [3H]-E3S uptake under ATP-depletion 
conditions, cells were pre-incubated for 20 min prior to the experiment and during 
the experiment (1 min) with uptake buffer containing 20 mM 2-deoxy-D-glucose 
and 10 mM NaN3 without D-glucose (69). For the inhibition study, cells were pre-
incubated for 15 min prior to and during the experiment with 100 µM of various 
compounds (T3, T4, digoxin, ouabain, MTX, kynurenic acid, indoxyl sulfate, 
hippuric acid and trans-aconitic acid, uric acid, citric acid, and riboflavin) 
compounds at pH 5.5 or 7.4. Based on model fitting criteria, transport parameters 
were estimated using a sigmoid-Emax equation: 
ݒ ൌ ௠ܶ௔௫ ൈ ܵ௡/ሺܵହ଴௡ ൅ ܵ௡)         Equation 3-5 
Where, V, S, Tmax, S50, and n represent the initial uptake velocity, substrate 
concentration, maximum uptake velocity, Michaelis-Menten constant equivalent, 
and Hill slope, respectively. The model was fitted to the data (obtained in 
triplicate) by nonlinear regression using GraphPad Prism (GraphPad Software, 
San Diego, CA). 
Values are presented as means ± S.D. Statistical analysis was performed 
by an unpaired Student’s t-test or two-way ANOVA and Bonferroni post-hoc test 
for multiple comparisons as indicated with p < 0.05 as the criterion of 
significance. The software program GraphPad Prism was used for statistical 
analysis (GraphPad Software, San Diego, CA)  
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2. [3H]-MTX uptake and inhibition studies 
Time dependent 1 μM [3H]-MTX uptake studies as well as the inhibition 
studies at pH 5.5 or pH 7.4 were performed. Procedures were the same as 
described above in [3H]-E3S uptake and inhibition studies. 
 
E.  Creation and validation of human OATP4C1-expressing cell lines 
1. MDCKII cells 
i.  Plasmid vector construction and transfection 
Human SLCO4C1 DNA purchased from OriGene (Rockville, MD) was 
amplified by PCR using Phusion High-Fidelity PCR kit with forward (5’-
CACCATGAAGAGCGCCAAAGGTATTG- 3’) and reverse (5’-
CTACCCTTCTTTTACTATTTTGTTGAG-3’) primers. Amplification conditions 
were as follows: 98°C (1 min), [98°C (10 sec), 63°C (30 sec), 72°C (40 sec)] × 
25 cycles, 72°C (10 min).  The amplified fragment of appropriate size was 
examined on 1% agarose gel, and further purified. The subsequent sequence 
was cloned into pENTR vector and transformed into competent One Shot 
TOP10 E. coli. The competent cells were grown in an agar plate with 50 µg/ml 
kanamycin.  The plasmid DNA (pENTR/SLCO4C1) from positive 
transformants was validated by EcoRI restriction enzyme digestion and by 
PCR with M13 forward (5’-GTTTTCCCAGTCACGAC-3’) and M13 reverse (5’-
CAGGAAACAGCTATGAC-3’) primers with following amplification conditions: 
98°C (1 min), [98°C (10 sec), 52°C (30 sec), 72°C (45 sec)] × 25 cycles, 72°C 
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(5 min). The restriction enzyme product and PCR product were examined on 
0.8% agarose gel. The plasmid DNA sequence was also confirmed (Davis 
sequencing) to share 100% identity with human SLCO4C1 sequence 
(GeneBank accession number NM_180991). The plasmid DNA was 
subcloned into pcDNA6.2/EmGFP-Bsd/V5-DEST vector. The construct was 
transformed into XL1-Blue Supercompetent cells and the competent cells 
were grown in an agar plate with 100 µg/ml carbenicillin. The plasmid 
construct (pcDNA6.2/EmGFP-Bsd/V5-DEST/SLCO4C1, Figure 3-4) was 
validated by PCR with T7 forward (5’- TAATACGACTCACTATAGGG-3’) and 
SLCO4C1 reverse (5’-CTACCCTTCTTTTACTATTTTGTTGAG-3’) primers 
with following amplification conditions: 98°C (1 min), [98°C (10 sec), 53°C (30 
sec), 72°C (30 sec)] × 25 cycles, 72°C (10 min). The PCR product was 
examined on 0.8% agarose gel. The detailed procedures are described in 
Section Chapter 3B2 Construction of plasmid vector. The plasmid construct 
(pcDNA6.2/EmGFP-Bsd/V5-DEST/SLCO4C1) and vector (pcDNA6.2/EmGFP-
Bsd/V5-DEST) were transfected into MDCKII cells as described in Section 
Chapter 3B3 Cell culture and transfection.  
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Figure 3-4: pcDNA6.2/EmGFP-Bsd/V5-DEST/SLCO4C1 plasmid 
construct. 
 
ii.  Validation of OATP4C1 expression and subcellular localization  
Transfection efficiency was evaluated by Western blot analysis and 
immunohistochemistry following procedures described in Section Chapter 3B8 
Western blot and Section B9 Immunohistochemistry, respectively. Subcellular 
localization of OATP4C1 in MDCKII-OATP4C1 cells was assessed by 
immunofluorescence microscopy and surface protein biotinylation assay as 
described in Section B10 Immunofluorescence microscopy and Section B11 
Surface protein biotinylation assay, respectively. Procedures were the same 
but with different antibodies: rabbit polyclonal antibodies against human 
OATP4C1 generated against amino-terminus [DPQRENSQPQELQKPQEPQK 
(PA1243)] and carboxyl-terminus [VLAEQDLNKIVKEG (PA1245)] sequence 
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peptides (Figure 3-5). Antibodies development was as described in Section B1 
Development of rat Oatp4c1 antibody. 
 
 
Figure 3-5: Human OATP4C1 antibody antigen peptide sequence and 
location.  
 
iii.  Validation of OATP4C1 function in MDCKII-OATP4C1 cells 
OATP4C1 function was evaluated with [3H]-ouabain or [3H]-E3S uptake 
studies. Procedures were the same as described in Section D1 [3H]-E3S 
uptake and inhibition studies. 
 
2. Spodoptera frugiperda (Sf9) insect cells 
i.  Plasmid vector construction 
The construction of pENTR/SLCO4C1 was described in Section .  
Plasmid vector construction and transfection. The plasmid construct was 
cloned into pDEST8 vector and transformed into XL1-Blue Supercompetent 
cells. The competent cells were grown in an agar plate with 100 µg/ml 
carbenicillin. The plasmid construct (pDEST8/SLCO4C1, Figure 3-6) was 
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validated by Bsu361 restriction enzyme digestion and 0.8% agarose gel 
electrophoresis. The plasmid DNA was then recombined in MAX Efficiency® 
DH10BacTM competent E. Coli containing baculovirus genome. The competent 
cells were grown in an agar plate with 100 µg/ml carbenicillin. For background 
control, the empty vector (pDEST8) was also recombined as above. The 
plasmid DNA from positive transformants was verified by PCR with M13 
forward (5’-GTTTTCCCAGTCACGAC-3’) and M13 reverse (5’-
CAGGAAACAGCTATGAC-3’) primers with the following amplification 
conditions: 94°C (1 min), [94°C (30 sec), 54°C (30 sec), 68°C (1 min)] × 30 
cycles, 68°C (10 min). The PCR product was examined on 0.8% agarose gel. 
 
 
Figure 3-6: pDEST8/SLCO4C1 plasmid construct. 
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ii.  Cell culture, transfection and infection 
Sf9 cell suspensions were grown in Sf-900 II SFM medium 
supplemented with 100 U/ml penicillin and 100 µg/ml streptomycin at 27°C 
with constant shaking in Barnstead® MaxQTM 4000 incubated shaker 
(Dubuque, IA). Sf9 cells (9 × 105 cells/well) were seeded in a 6-well plate and 
incubated at 27°C for 1 hr for cells to be attached. The recombinant bacmids 
(pDEST8/SLCO4C1 and pDEST8) were transfected into Sf9 cells with 
Cellfectin reagent as directed by manufacturer’s protocol. After 48 hr, cells 
were scraped and centrifuged at 500 g for 5 min. The supernatant containing 
the recombinant baculovirus (P1 viral stock) was harvested.  
To minimize experimental variability from protein expression and inside-
out ratio of membrane vesicles, a large batch of membranes was prepared 
for all subsequent transport studies. The recombinant baculovirus stock was 
amplified by infecting Sf9 cell suspensions (1 × 106 cells/ml, log phase) with 
P1 viral stock at a 1:4 (v/v ; viral stock: Sf9 cell suspensions) at 27°C for 48 hr 
with constant shaking. The supernatant (P2 viral stock) was harvested by 
centrifugation at 500 g for 5 min. Sf9 cells were infected with P2 viral stock at 
27°C for 48 hr and again with P3 viral stock as described above. After 
incubation at 27°C for 48 hr, cells were centrifuged at 500 g for 5 min. The 
supernatant (P4 viral stock) was dispensed in aliquots and stored at −80°C 
until use. Cell pellets for membrane vesicle preparation were stored at –80°C 
until use. 
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iii.  Membrane vesicle preparation 
The cell pellets were thawed on ice and resuspended in ice-cold 
hypotonic buffer (0.5 mM Na2HPO4, 0.1 mM EDTA, pH 7.4) supplemented 
with protease inhibitor cocktails and incubated for 90 min at 4°C. The 
suspension was centrifuged at 100,000 g for 40 min at 4°C, and the pellet 
was homogenized in ice-cold TS buffer (50 mM Tris-HCl, 250 mM sucrose, 
0.25 mM CaCl2, pH 7.4) using a tight-fitting Dounce homogenizer. After 
centrifugation at 500 g at 4°C for 10 min, the supernatant was centrifuged at 
100,000 g for 40 min at 4°C. The pellet was resuspended in TS buffer and 
passed through a 27-gauge needle 25 times. The vesicles were dispensed in 
aliquots and stored at −80°C until use. The membrane protein concentrations 
were determined by BCA Protein Assay Kit. OATP4C1 expression was 
determined by Western blotting as described in Section Chapter 3E1.ii.  
Validation of OATP4C1 expression and subcellular localization. 
 
iv.  Vesicular transport assay 
Sf9 membrane vesicles (40 μg) containing OATP4C1 or vector were 
incubated with the indicated concentrations of [3H]-ouabain in 50 μl of TS 
buffer supplemented with 10 mM creatine phosphate, 0.1 mg/ml of creatine 
phosphokinase, 10 mM MgCl2 and 4 mM ATP at 37°C. At the designated 
time, the reaction was stopped by adding 1.5 ml of ice-cold stop buffer (10 
mM Tris-HCl, 250 mM sucrose, 100 mM NaCl, pH7.4) and immediately 
vacuum filtered onto a cellulose acetate filter (0.45-μm pore size, OE67). The 
filter was washed twice with 1.5 ml of ice-cold stop buffer, and the 
radioactivity retained on the filter was measured by liquid scintillation 
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counting. Procedures for [3H]-E3S were the same as described above but 
with regenerated cellulose filters (0.45-μm pore size, RC55). The filters were 
selected due to their minimal binding of ouabain or E3S. OATP4C1-mediated 
uptake was calculated after subtraction of nonspecific uptake by vector 
membrane vesicle.  
 
F.  Validation of OATP4C1 expression in human kidney and cancer cells 
1. Immunohistochemical analysis in human kidney sections 
De-identified human kidney sections were obtained from Markey Cancer 
Center Biospecimen Core (IRB#05-0155-X1G). Subcellular localization of 
OATP4C1 was assessed by immunohistochemical analysis as described in 
Section Chapter 3B9 Immunohistochemistry. Procedures were the same but with 
a different antibody. MRP4 was served as a positive control and was labeled with 
3 µg/ml of M4I10. OATP4C1 was detected with 550 µg/ml of PA1243 or PA1245. 
 
2. qRT-PCR analysis for SLCO4C1 expression in cancer cells 
Prostate cancer cell lines (LnCap, DU145, PC3) and lung cancer cell line 
H1299  were cultured in RPMI 1640 medium supplemented with 10% fetal bovine 
serum, 100 U/ml penicillin, and 100 µg/ml streptomycin. Lung cancer cell lines 
(A549, H460), breast cancer cell line MCF7 and glioblastoma cell line U118 were 
cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 
10% fetal bovine serum, 100 U/ml penicillin, and 100 µg/ml streptomycin. Breast 
cancer cell line MDA-MB-231 and melanoma cell line MDA-MB-435 were 
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cultured in Improved Minimum Essential Medium (IMEM) with 10% fetal bovine 
serum, 100 U/ml penicillin, and 100 µg/ml streptomycin. 
Cancer cell lines were grown in a T-25 flask to confluence. Cells were 
trypsinized and pelleted by centrifugation at 300 g for 5 min. RNA isolation from 
cell pellets and reverse-transcription were performed as described in Section 
Chapter 3B2 Construction of plasmid vector. Procedures for qRT-PCR were the 
same as described in Section Chapter 3C1 Quantitative real time polymerase 
chain reaction (qRT-PCR) with different primers (Table 3-2). 
 
Table 3-2: SLCO4C1 and 18s rRNA primers information. 
Gene Reference sequence 
Forward primer (5’  3’) 
Product 
size (bp) 
Reverse primer (5’  3’) 
SLCO4C1 NM_180991 
GAGAAGCTCCGGTCACTGTC  
149 
ACTACAATACCTTGCGTGAC 
18s rRNA X03205.1 
CGCCGCTAGAGGTGAAATTCTT 
101 
CGAACCTCCGACTTTCGTTCTT 
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3. OATP4C1/SLCO4C1 expression in lung tumor and adjacent normal lung tissue 
sections 
i.  qRT-PCR 
Human lung tumor and adjacent normal lung tissue sections were 
obtained from the Markey Cancer Center Biospecimen Core (IRB#05-0155-
X1G). The tissues were rinsed with 20 µl of xylene, scraped from the slides 
with blades and transferred to microcentrifuge tubes for RNA isolation. RNA 
isolation was performed with RecoverALLTM total nucleic acid isolation kit as 
directed by manufacture’s protocol. Total RNA quality was verified by an 
OD260/OD280 absorption ratio within a range of 1.8-2.1. Reverse-
transcription of 100 ng RNA to cDNA was performed with reverse 
ThermoScriptTM RT-PCR kit with oligo (dT)20 primers using Peltier Thermal 
Cycler. PCR was conducted using TaqMan® Gene Expression Assay (Table 
3-3) and TaqMan® Universal PCR Master mix in a total volume of 20 µl using 
ABI PRISM® 7000 sequence detection system (Applied Biosystems, Foster 
city, CA). Amplification conditions were as follows: 50°C (2 min), 95°C (10 
min), [95°C (15 sec), 60°C (1 min)] × 40 cycles. No-template (water) reaction 
mixtures were prepared as negative control. 
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Table 3-3: TaqMan® Gene Expression Assay for SLCO4C1 and 18s rRNA. 
Gene Reference sequence Assay ID 
Exon 
Boundary 
Amplicon 
length (bp) 
SLCO4C1 NM_180991 
Hs00698884_m1 4-5 77 
Hs01030668_m1 7-8 58 
Hs01030660_m1 10-11 64 
18s rRNA X03205.1 Hs03003631_g1 - 69 
 
ii.  Immunohistochemistry 
Procedures were as described in Section Chapter 3B9 
Immunohistochemistry. OATP4C1 was detected with 110 µg/ml of PA1243 or 
PA1245. 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Kuei-Ling Kuo 2012 
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CHAPTER 4 : RESULTS 
A.  Creation and validation of a rat Oatp4c1-expressing cell line  
1. Specific Aim 1a: To develop and validate rat Oatp4c1 antibodies amenable for 
immunoblotting, immunohistochemistry and immunofluorescence.  
To investigate the expression and subcellular localization of rat Oatp4c1 in 
the in vitro cell models or rat tissues, four rabbit polyclonal antibodies were 
generated against either amino-terminus or carboxyl-terminus of rat Oatp4c1. 
The antibody specificities were determined by Western blotting, 
immunohistochemical analysis, and immunofluorescence staining in the in vitro 
cell models developed in Specific Aim 1b. Among the four antibodies, PA1343 
was affinity-purified and used for subsequent experiments. 
 
2. Specific Aim 1b: To create and validate a stably transfected rat Oatp4c1-
expressing cell line with appropriate characteristics for uptake studies. 
To study the role of rat Oatp4c1 in drug disposition, we generated rat 
Oatp4c1-expressing MDCKII cells. Rat Slco4c1 mRNA was isolated from rat 
kidney and amplified by PCR. The amplified fragment of appropriate size was 
examined by agarose gel electrophoresis. As shown in Figure 4-1 A, rat Slco4c1 
mRNA was successfully isolated from rat kidney. The amplification product was 
further purified and cloned into pENTR vector. The plasmid construct was 
validated by KpnI, SalI and EcoRV restriction enzyme digestion (Figure 4-1 B) 
and DNA sequencing which had 100% identity with the published rat Slco4c1 
sequence (GeneBank accession number NM_001002024). The plasmid DNA 
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was then subcloned into pcDNA6.2/GFP-DEST vector and was validated by 
EcoRV, SspI and KpnI restriction enzyme digestion (Figure 4-1 C).  
The plasmid DNA (pcDNA6.2/GFP-DEST/Slco4c1) and vector 
(pcDNA6.2/GFP-DEST) were transfected into MDCKII and LLC-PK1 cells. 
Transfection efficiency was examined by Western blotting using the antibody 
generated in Specific Aim 1a (PA1343) (Figure 4-2 A). Oatp4c1 expression was 
detectable as a band at ~80 kDa in MDCKII-Oatp4c1 cells, but not in MDCKII-
pcDNA (empty vector) cells. Expression was also confirmed in 
paraformaldehyde-fixed paraffin-embedded cell pellet sections by 
immunohistochemical analysis (Figure 4-2 B). Oatp4c1 was observed on the cell 
membrane (Figure 4-2 B, inset) in the MDCKII-Oatp4c1 cells, and no staining 
was observed in the negative control (rabbit IgG) or in the MDCKII-pcDNA cells. 
This demonstrated that the transfection was successful and that the antibody 
was specific. 
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Figure 4-1: Validation of Slco4c1 plasmid constructs.  
PCR products of Slco4c1 isolated from rat kidney and the restriction enzyme digestion 
products of the plasmid construct were examined by agarose gel electrophoresis. 
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Figure 4-2: Validation of Oatp4c1 expression and subcellular localization in 
MDCKII-Oatp4c1 cells.  
(A) Western blot of Oatp4c1 (~ 80 kDa) and β-actin (~42 kDa) in 50 µg cell lysates. (B) 
Immunohistochemical analysis of Oatp4c1 expression in paraformaldehyde-fixed 
paraffin-embedded cell sections. (C) Confocal microscopy of Oatp4c1 (red) expression 
and localization in polarized MDCKII cells. Center image in the Oatp4c1 panel is a single 
optical section of the x-y plane while top and right images represent x-z and y-z planes, 
respectively, reconstructed from image stacks. The apical and basal sides can be 
demarcated by Zo-1 (green) and the nuclei (DAPI, blue), respectively, in both x-z and y-z 
sections. (D) Western blot of Oatp4c1 in proteins isolated from either the apical (AP) or 
basolateral (BL) membranes of polarized MDCKII cells. Na+/K+-ATPase served as a BL 
marker to demonstrate the relative efficiency of AP and BL membrane separation. 
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Subsequently, we sought to determine the subcellular localization of 
Oatp4c1 in polarized cell monolayers by confocal immunofluorescence laser 
scanning microscopy (Figure 4-2 C). A tight-junction protein, Zo-1, was used as 
an apical marker. As shown in Figure 4-2 C, Oatp4c1 localized at the apical 
membrane, along with Zo-1, in MDCKII-Oatp4c1 cells. This result was also 
confirmed by the surface membrane protein biotinylation method. The surface 
proteins on either apical or basolateral membranes of polarized MDCKII-Oatp4c1 
cells were labeled with biotin and isolated from streptavidin agarose beads. 
Western blot analysis of a basolateral marker Na+/K+-ATPase demonstrated the 
efficient separation of the apical and basolateral membranes. Western blot 
analysis of Oatp4c1 demonstrated that the transporter was enriched in the apical 
membrane fraction, but not in the basolateral membrane (Figure 4-2 D). 
Collectively, these data verified the apical expression of the transporter in 
Oatp4c1-expressing MDCKII cells. However, there is precedent showing that a 
transporter can mislocalize in MDCKII cells. Expression studies in MRP4-
transfected MDCKII cells show that MRP4 traffics to the basolateral membrane 
due to low expression of an adaptor protein, Na+/H+ exchanger regulatory factor 
1 (NHERF1), in these cells (118, 119). However, MRP4 polarized correctly in 
NHERF1 expressing LLC-PK1 cells. While the adaptor proteins facilitating 
Oatp4c1 trafficking are not known, we transfected LLC-PK1 with pcDNA6.2-
Oatp4c1 and determined its polarity. As observed in MDCKII cells, Oatp4c1 also 
localized to the apical membrane in LLC-PK1 cells (Figure 4-3)  
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Figure 4-3: Confocal microscopy of Oatp4c1 expression and subcellular 
localization in LLC-PK1-Oatp4c1 cells.  
Center image in the Oatp4c1 (red) panel is a single optical section of the x-y plane while 
top and right images represent x-z and y-z planes, respectively, reconstructed from 
image stacks. The apical and basal sides can be demarcated by Zo-1 (green) and the 
nuclei (DAPI, blue), respectively, in both x-z and y-z sections. 
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Despite successful transfection, our immunofluorescence studies showed 
that expression was not detectable in at least 97% of the cells (Figure 4-4). 
Therefore, we attempted to generate a single clone with homogenous high 
Oatp4c1 expression. Our initial attempt was to sort individual live cells into a 96-
well plate by FACS analysis with transient C-terminal-tagged GFP. MDCKII-
Oatp4c1 cells were treated with Tag-On-DemandTM Suppressor Supernatant, 
which decodes the stop codon as serine, allows translation to continue through 
the downstream reading frame and produces transient C-terminal tagged GFP 
fusion protein. In this initial attempt, 70 clones were obtained. However, 
immunofluorescence staining showed none of them exhibited Oatp4c1 
expression. 
The second attempt was to sort the cells by immunofluorescence labeling. 
Oatp4c1-expressing cells were labeled with PA1343 (rabbit polyclonal anti-
Oatp4c1) and Alexa Fluor 488 goat anti-rabbit IgG, and then sorted with Alexa 
Fluor 488 fluorescence by FACS analysis. However, none of 110 clones showed 
Oatp4c1 expression by immunofluorescence staining. The third attempt was to 
randomly seed individual live cells in 96-well plates. Unfortunately, none of 220 
clones showed Oatp4c1 expression by immunofluorescence staining. It has 
previously been demonstrated that the expression of foreign protein in 
recombinant cells decreases the cell proliferation rate (120, 121). Expressing 
foreign protein utilizes host cell’s resources and imposes a metabolic burden 
(metabolic load) on the host cells, which may change the physiology and 
biochemistry of the cells.  This led us to hypothesize that the expression of 
Oatp4c1 decreases the cell proliferation rate and this effect is magnified when 
expanding from a single cell. In this case, single cells expressing the protein 
were perhaps not dividing during the time we were expanding the single clones. 
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Therefore, the fourth attempt was to generate the clones starting from more than 
one cell using the serial dilution method. Finally, out of 100 clones, 15 showed 
Oatp4c1 expression by immunofluorescence staining. Among them, clone 94 
(c94) had more cells exhibiting Oatp4c1 expression as compared to the pooled 
cells (Figure 4-4). This clone was selected to use for uptake studies in Specific 
Aim 3a and Specific Aim 3b.  
Despite multiple efforts and approaches to generate this single clone of 
Oatp4c1-expressing MDCKII cells (c94), immunofluorescence staining showed 
that expression was detectable in only ~11% of the cells determined by manual 
counting. To increase Oatp4c1 expression, we sought to treat the cells with 
sodium butyrate, simvastatin, glycerol, MG132 or increase the concentration of 
the selection antibiotic, blasticidin. Oatp4c1 expression was determined by PCR, 
Western blotting and immunofluorescence staining.  
Sodium butyrate is commonly used to induce protein expression (122, 123). 
In this study, MDCKII-pcDNA and MDCKII-Oatp4c1 pooled cells were treated 
with 0.1 - 5 mM sodium butyrate for 24 hr. Oatp4c1 expression was increased by 
sodium butyrate in a concentration-dependent manner at mRNA (Figure 4-5 A) 
and protein (Figure 4-5 B) levels. However, the number of cells exhibiting 
Oatp4c1 expression was not remarkably increased with sodium butyrate 
treatment (Figure 4-5 C). In addition, since sodium butyrate was reported to 
disrupt basolateral localization of overexpressed Na+/K+-ATPase β1- and β2 
subunits in MDCK I cells (124), we wanted to ensure that induced expression did 
not interfere with the subcellular localization of Oatp4c1. Immunofluorescence 
staining was performed and demonstrated that the apical polarity was maintained 
(Figure 4-5 D). 
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Figure 4-4: Immunofluorescence staining for Oatp4c1 expression in MDCKII-
Oatp4c1 pooled cells and c94.  
Oatp4c1 and nuclei were stained with PA1343 (red) and DAPI (blue), respectively. 
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Figure 4-5: Effect of 24 hr sodium butyrate (NaB) treatment on Oatp4c1 expression 
and subcellular localization in MDCKII-Oatp4c1 pooled cells.  
(A) PCR and agarose gel electrophoresis of Slco4c1 and 18s rRNA (loading control). (B) 
Western blot of Oatp4c1 (~80 kDa) and β-actin (~42 kDa) in cell lysates (40 µg protein).  
(C) Immunofluorescence staining for Oatp4c1 expression (red). (D) Confocal microscopy 
of Oatp4c1 (red) expression and localization in polarized cells. Center image in the 
Oatp4c1 panel is a single optical section of the x-y plane while top and right images 
represent x-z and y-z planes, respectively, reconstructed from image stacks. The apical 
and basal sides can be demarcated by Zo-1 (green) and the nuclei (DAPI, blue), 
respectively, in both x-z and y-z sections. 
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The second approach to enhance Oatp4c1 expression was to increase the 
selection antibiotic, blasticidin, concentration from 5 μg/ml to 10 or 30 μg/ml. 
MDCKII-pcDNA and MDCKII-Oatp4c1 cells were grown in designated 
concentration of blasticidin for 2 passages. Oatp4c1 expression was higher in the 
cells grown in 10 or 30 μg/ml blasticidin than those in 5 μg/ml blasticidin at 
mRNA (Figure 4-6 A) and protein (Figure 4-6 B) levels, and achieved a maximum 
at 10 μg/ml. The number of cells exhibiting Oatp4c1 expression was slightly 
enhanced with increasing blasticidin concentration (Figure 4-6 C). 
A promoter analysis showed SLCO4C1 promoter region has xenobiotic-
responsive element (XRE) motifs (106), which are generally recognized by aryl 
hydrocarbon receptors (AhR) and AhR nuclear translocator heterodimer (108). 
Simvastatin, an inducer of nuclear AhR, can enhance promoter activity and 
upregulate SLCO4C1 expression (106). MDCKII-pcDNA and MDCKII-Oatp4c1 
cells were treated with 10 or 20 μM of simvastatin for 24 hr. Slco4c1 mRNA 
expression was increased by simvastatin in a concentration-dependent manner 
(Figure 4-7 A), but this did not lead to changes in protein expression (Figure 4-7 
B). Additionally, the number of cells exhibiting Oatp4c1 expression was not 
changed with simvastatin treatment (Figure 4-7 C). 
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Figure 4-6: Effect of increasing blasticidin (Bsd) concentration for two passages 
on Oatp4c1 expression in MDCKII-Oatp4c1 pooled cells.  
(A) PCR and agarose gel electrophoresis of Slco4c1 and 18s rRNA (loading control). (B) 
Western blot of Oatp4c1 (~80 kDa) and β-actin (~42 kDa) in cell lysates (40 µg protein).  
(C) Immunofluorescence staining for Oatp4c1 expression (red).  
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Figure 4-7: Effect of 24 hr simvastatin (Sim) treatment on Oatp4c1 expression in 
MDCKII-Oatp4c1 pooled cells.  
(A) PCR and agarose gel electrophoresis of Slco4c1 and 18s rRNA (loading control). (B) 
Western blot of Oatp4c1 (~80 kDa) and β-actin (~42 kDa) in cell lysates (40 µg protein).  
(C) Immunofluorescence staining for Oatp4c1 expression (red). 
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Primary amino acid sequence of rat Oatp4c1 showed a considerably higher 
number of cysteine residues (27 cysteine/724 amino acids) as compared with 
other transporters, such as ABCG2 (12 cysteine/655 amino acids), p-glycoprotein 
(7 cysteine/1279 amino acids) or MRP4 (11 cysteine/859 amino acids). Disulfide 
bonds between cysteine residues in proteins play a key role in protein folding. 
More cysteine residues may cause more turns or folding, and the protein may be 
more difficult to be properly folded. Therefore, we hypothesized that most of 
Oatp4c1 in the transfected MDCKII cells is misfolded so that scarce number of 
cells exhibit Oatp4c1 expression. Misfolded proteins fail to traffic from 
endoplasmic reticulum (ER) via the Golgi apparatus to plasma membrane, and 
are targeted for degradation via the ubiquitin/proteasome-dependent pathway. In 
an attempt to rescue misfolded proteins, we treated the cells with the chemical 
chaperone, glycerol or the proteasome inhibitor, MG132. 
Glycerol is a chemical chaperone, and stabilizes misfolded proteins into 
conformations that are not targeted for degradation and can escape the ER (125, 
126). In this study, MDCKII-pcDNA and MDCKII-Oatp4c1 cells were treated with 
0.5 - 1.5 M glycerol for 48 hr. However, glycerol decreased Oatp4c1 expression, 
and did not change the number of cells exhibiting Oatp4c1 expression (Figure 
4-8).  
N-benzoyloxycarbonyl (Z)-Leu-Leu-leucinal (MG132) is a proteasome 
inhibitor, and can prevent misfolded proteins, which are retained in the ER from 
being targeted for premature proteolysis. In this study, MDCKII-pcDNA and 
MDCKII-Oatp4c1 cells were treated with MG132 (0.1 μM for 24 hr or 10 μM for 
12 hr). However, MG132 decreased Oatp4c1 expression, and did not change the 
number of cells exhibiting Oatp4c1 expression (Figure 4-9). 
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Figure 4-8: Effect of 48 hr glycerol treatment on Oatp4c1 expression in MDCKII-
Oatp4c1 pooled cells.  
(A) Western blot of Oatp4c1 (~80 kDa) and β-actin (~42 kDa) in cell lysates (40 µg 
protein).  (B) Immunofluorescence staining for Oatp4c1 expression (red). 
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Figure 4-9: Effect of MG132 treatment on Oatp4c1 expression in MDCKII-Oatp4c1 
pooled cells.  
(A) Western blot of Oatp4c1 (~80 kDa) and β-actin (~42 kDa) in cell lysates (40 µg 
protein).  (B) Immunofluorescence staining for Oatp4c1 expression (red). 
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In summary, Oatp4c1 expression was enhanced by sodium butyrate 
treatment or increasing blasticidin concentration, but not by simvastatin, glycerol 
or MG132 treatment. To optimize growth conditions to obtain the highest 
Oatp4c1 expression, MDCKII-Oatp4c1 pooled cells and c94 were treated with 5 
mM sodium butyrate or 30 μg/ml blasticidin or both. As shown in Figure 4-10, the 
impact of sodium butyrate on inducing Oatp4c1 expression was substantial, so 
that the effect of blasticidin was negligible. The substantially higher Oatp4c1 
expression in c94 than in pooled cells was also demonstrated. Finally, after 
multiple efforts and approaches, as compared with the pooled cells, the number 
of cells exhibiting Oatp4c1 expression in c94 with sodium butyrate treatment was 
substantially higher (Figure 4-11). Therefore, to achieve the highest Oatp4c1 
expression, c94 prior treated with sodium butyrate were applied for the following 
uptake studies described in Specific Aim 3a and Specific Aim 3b.  
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Figure 4-10: Effect of sodium butyrate (NaB, 5 mM) and blasticidin (Bsd, 30 μg/ml) 
on Oatp4c1 expression in MDCKII-Oatp4c1 pooled cells and c94.  
Western blot of Oatp4c1 (~80 kDa) and β-actin (~42 kDa) in cell lysates (40 µg protein). 
 
 
Figure 4-11: Immunofluorescence staining for Oatp4c1 expression in MDCKII-
Oatp4c1 pooled cells and sodium butyrate (NaB) treated c94.  
Oatp4c1 and nuclei were stained with PA1343 (red) and DAPI (blue), respectively. 
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B.  Determination of Oatp4c1 expression and subcellular localization in rat tissues 
1. Specific Aim 1c: To determine the expression and subcellular localization of 
Oatp4c1 in the rat tissues (liver, kidney, lactating and non-lactating mammary 
gland). 
Microarray analysis of various transporters expressed in lactating MEC 
isolated from breast milk and non-lactating MEC isolated from surgical reduction 
mammoplasty specimen showed that human SLCO4C1 is increased 70-fold in 
lactating MEC relative to non-lactating MEC. The upregulation of SLCO4C1 
expression during lactation has been confirmed by qRT-PCR (30). This 
phenomenon was also confirmed in rats by qRT-PCR (Figure 4-12 A) and 
Western blotting (Figure 4-12 B). Liver and kidney served as a negative and 
positive control, respectively, and has been demonstrated by Northern analysis 
(79). Oatp4c1 was expressed in the rat kidney and lactating MG, but not in the 
rat liver and non-lactating MG. This result was confirmed by Western blotting 
(Figure 4-12 B). A single band was detected at ~80 kDa in the rat kidney, and at 
a slightly lower molecular weight in the rat MG, and both of the bands were 
reduced to ~65 kDa after deglycosylation. In accord with the mRNA expression, 
no protein band was detected in the rat liver and non-lactating MG. The specific 
band reactivity was confirmed by pre-absorbing the antibody with antigen peptide 
(STITVEEDLNKIENEG) prior to use. The bands were abolished after antigen 
peptide blocking (Figure 4-12 C).  
In addition, the ontogeny of Oatp4c1 in rat kidney (Figure 4-13) and liver 
(Figure 4-14) was investigated. In rat kidney, Slco4c1 mRNA expression was 
minimal at birth and then gradually increases to adult levels (Figure 4-13 A), and 
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this was confirmed by Western blotting (Figure 4-13 B). This phenomenon was 
consistent with the ontogenic expression of Slco4c1 in mouse kidney (52). In 
addition, higher Oatp4c1 expression was observed in non-lactating female rat 
kidney as compared with males at both mRNA and protein levels, but it was 
inconsistent with the previous finding showing no gender differences of Slco4c1 
mRNA expression in the rat kidney (79). Neither Slco4c1 mRNA (Figure 4-14 A) 
nor Oatp4c1 protein (Figure 4-14 B) were detected in rat livers of pups or adults 
across the ages. 
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Figure 4-12: Oatp4c1 expression in female adult rat liver, kidney, lactating and 
non-lactating MG.  
(A) i. qRT-PCR and agarose gel electrophoresis analysis for Slco4c1 mRNA and 18s 
rRNA (loading control) expression in rat tissues. ii. Relative Slco4c1 mRNA expression 
normalized with 18s rRNA. Each bar represents the mean ± S.D (n=2 (liver) or 3). (B) 
Western blot of native (~80 kDa), deglycosylated (~60 kDa) Oatp4c1 and β-actin (~42 
kDa) in rat tissue crude membrane fractions (40 µg protein). PNGaseF was used for 
deglycosylation. (C) Western blot of Oatp4c1 and β-actin in rat tissue crude membrane 
fractions (40 µg protein) with and without antigen peptide blocking. Lac: lactating, Non-
lac: non-lactating 
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Figure 4-13: Ontogeny of Oatp4c1 in rat kidney.  
(A) Relative Slco4c1 mRNA expression calculated with 2-∆∆Ct method. Relative copy 
number of SLCO4C1 in the samples was normalized to 18s rRNA within each sample 
and values were then normalized with those in lac-d16 kidney. Each dot represents the 
mean of three determinations from one rat. (B) Western blot of Oatp4c1 (~80 kDa) and 
β-actin (~42 kDa) in rat tissue crude membrane fractions (40 µg protein). Lac-d16: rats 
had been lactating for 16 days, Lac-d21: rats had been lactating for 21 days, Non-lac: 
non-lactating, F: female, M; male 
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Figure 4-14: Ontogeny of Oatp4c1 in rat liver.  
(A) Relative Slco4c1 mRNA expression calculated with 2-∆∆Ct method. Relative copy 
number of SLCO4C1 in the samples was normalized to 18s rRNA within each sample 
and values were then normalized with those in lac-d16 kidney. Each dot represents the 
mean of three determinations from one rat. (B) Western blot of Oatp4c1 (~80 kDa) and 
β-actin (~42 kDa) in rat tissue crude membrane fractions (40 µg protein). Lac-d16: rats 
had been lactating for 16 days, Lac-d21: rats had been lactating for 21 days, Non-lac: 
non-lactating, F: female, M; male. 
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The subcellular localization of Oatp4c1 was then assessed by 
immunohistochemical analysis in paraformaldehyde-fixed paraffin-embedded 
liver, kidney and MG tissue sections. To assure the quality of the tissue 
specimens, the rat liver and MG sections were stained with anti-Abcg2 antibody, 
and the rat kidney sections were stained with anti-Mrp4 antibody. All tissues 
showed specific staining. Consistent with the PCR and Western blot results 
(Figure 4-12 A, B), Oatp4c1 was not detected in the rat liver, but Oatp4c1 stained 
strongly in apical membranes of kidney tubules and MG (Figure 4-15). No 
staining was observed in tissue sections exposed to rabbit IgG, instead of 
primary antibody, and Oatp4c1 staining was abolished when probing with 
antibody that was pre-adsorbed with antigen peptide (Figure 4-16). The distinct 
apical expression of Oatp4c1 in rat kidney was also demonstrated using dual 
staining for a basolateral marker E-cadherin (127) and Oatp4c1 (Figure 4-17). 
Because these results were in contrast to the reported expression pattern 
of Oatp4c1 in the rat kidney, we developed additional antibodies, including the 
polyclonal antibody reported previously (79). As shown in Figure 4-16, apical 
expression was confirmed using three different antibodies (PA1254, F3608 and 
PA1562), however, we were not able to observe any staining, above background 
levels, with the antibody reported previously (79).   
In rat MG, the apical expression of Oatp4c1 was demonstrated by 
colocalization of Oatp4c1 and an apical marker Abcg2 (10) and distinct 
localization of Oatp4c1 and a basolateral marker E-cadherin (128) (Figure 4-18). 
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Figure 4-15: Oatp4c1 localization in rat liver, kidney and lactating MG.   
Immunohistochemical analysis for Oatp4c1 subcellular localization in paraformaldehyde-
fixed paraffin-embedded rat tissue sections. Oatp4c1 was detected with PA1343. Rabbit 
IgG was used as a negative control. Magnification: 40x. 
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Figure 4-16: Verification of apical Oatp4c1 localization in rat renal tubules by four 
different antibodies.  
Immunohistochemical analysis for Oatp4c1 subcellular localization in paraformaldehyde-
fixed paraffin-embedded rat kidney sections with rabbit polyclonal anti-Oatp4c1 
antibodies as indicated. A. Antibody specificity (PA1343) was demonstrated by pre-
absorbing PA1343 with antigen peptide (STITVEEDLNKIENEG) overnight at 4°C prior to 
use. Magnification: 40x. 
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Figure 4-17: Double immunofluorescence staining for Oatp4c1 (green) and E-
cadherin (red) in rat kidney.  
E-cadherin served as a basolateral marker. Magnification: 40x. 
 
 
Figure 4-18: A. Double immunofluorescence staining for Oatp4c1 (green) and 
Abcg2 (A, red) or E-cadherin (B, red) in rat lactating MG.  
Abcg2 and E-cadherin served as apical and basolateral marker, respectively. 
Magnification: 40x.  
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2. Specific Aim 2a: To verify the apical localization of Oatp4c1 in the rat kidney 
cortex by proteomic analysis in the isolated brush-border membrane (BBM) and 
basolateral membrane (BLM). 
Concurrently with the studies outlined in Figure 4-16, we wanted to 
definitively demonstrate the specificity of our PA1343 antibody used for Western 
blot and immunolocalization of Oatp4c1. Proteomic analysis was performed on 
proteins collected from BBM and BLM, which were isolated from rat kidney cortex 
by Percoll density gradient. Western blotting (Figure 4-19 A) and proteomic 
analysis (Figure 4-19 B) were applied to analyze the proteins in these two 
fractions.  Abcg2 and Mrp4 were used as apical markers, which were enriched in 
BBM. Na+/K+-ATPase, a basolateral marker (127), was detectable in both 
membrane fractions, but more so in BLM than BBM. Oatp4c1 was detected in 
BBM but not in BLM (Figure 4-19 A), which was consistent with 
immunohistochemistry results (Figure 4-15). 
To validate the specificities of our antibodies, the proteome in BBM and 
BLM were each analyzed by LC-MS/MS following separation by SDS-PAGE. The 
gel bands of proteins eluting at 65-100 and 100-150 kDa were excised, and 
underwent reduction, alkylation, and in-gel trypsin digestion (116, 117). The 
abundance of the identified proteins was determined by the total number of 
spectra identified from a protein (spectral counts, SC) (129, 130), and SC > 2 
was used as the cutoff. The proteins with molecular weight less than 65 kDa or 
more than 150 kDa were excluded. The LC-MS/MS analysis identified 6 proteins 
unique to the BBM, 19 proteins unique to the BLM, and 56 proteins were either 
enriched in one membrane or equally distributed in both membrane preparations. 
Among them, the spectral counts of the SLC and ABC family with reported 
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localization, along with the apical marker (meprin) and basolateral marker 
(Na+/K+-ATPase) are shown in Figure 4-19 B. Eleven apical proteins were 
predominantly in the BBM, four basolateral proteins were enriched in the BLM, 
and three proteins with previously reported apical localization were found in both 
fractions (ambiguous). Four unique peptides of Oatp4c1 
(GVENPAFVPSSPDTPRR; RASASPSQVEVSAVASR; 
TSQTHQNNSTSFQHMDENFGK; KVDITSTAXSPDFEAR) were found only in the 
BBM and not in the BLM. These qualitative data provide additional and 
conclusive evidence that Oatp4c1 localizes at the apical membrane in the rat 
kidney cortex.   
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Figure 4-19: Expression of Oatp4c1 in isolated kidney brush border membrane 
(BBM) and basolateral membrane (BLM) fractions.  
(A) Western blot of Oatp4c1 in BBM and BLM fractions (20 µg protein) isolated from rat 
kidney cortex. Na+/K+-ATPase α 1 was used as a basolateral marker. Abcg2 and Mrp4 
served as apical markers. Oatp4c1 was detected with PA1343. (B) Spectral counts 
detected in protein digests obtained from ~65-150 kDa sections excised from the SDS-
PAGE gel.  Proteins with 3 or more spectral counts in one fraction are presented as 
“Apical” or “Basolateral” based on previously published literature. Spectral counts 
indicate the number of unique peptides detected in each fraction. 
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3. Specific Aim 2b: To determine the precise expression pattern of Oatp4c1 at the 
organ and nephron level. 
To further gain insight on the potential physiological role of Oatp4c1, we 
assessed its precise expression pattern at the organ and nephron level. 
Immunohistochemical analysis (Figure 4-20) showed that Oatp4c1 is expressed 
densely in the renal tubules located in the juxtamedullary cortex. To ascertain its 
location within the tubule, we used double immunofluorescence to stain for 
Oatp4c1 and the proximal tubule marker, aquaporin 1 (AQP1) (131), or a distal 
tubule marker, calbindin-D28K (132). As shown in Figure 4-21, Oatp4c1 
colocalized with AQP1, but not with calbindin-D28K. Therefore, Oatp4c1 is 
expressed in the proximal tubule within the juxtamedullary cortex, which 
suggests that it localizes in the proximal straight tubules (S3). Double 
immunofluorescence staining was also used to access the location of Oatp4c1 
relative to major apical efflux transporters in the rat kidney. As shown in Figure 
4-22, Mrp4 was expressed in the superficial cortex (S1, S2) and did not 
colocalize with Oatp4c1. P-gp was expressed in the juxtamedullary cortex (S3) 
and colocalized with Oatp4c1. Abcg2 was expressed in the whole cortex (S1, S2, 
S3) and partially colocalized with Oatp4c1. 
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Figure 4-20: Oatp4c1 location in rat kidney.  
Immunohistochemical analysis for Oatp4c1 (red) location in paraformaldehyde-fixed 
paraffin-embedded rat kidney sections with PA1343. Magnification: 4x.  
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Figure 4-21: Double immunofluorescence staining for Oatp4c1 (red) and the 
proximal tubule marker AQP1 (A, green) or the distal tubule marker calbindin-D28K 
(B, green).  
Yellow color in merged panels indicates colocalization. Nuclei (blue) were stained with 
DAPI. Magnification: 10x. 
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Figure 4-22 (part 1 of 2): Oatp4c1 colocalization with major efflux transporters in 
the kidney cortex.  
(A) Paraformaldehyde-fixed paraffin-embedded rat kidney sections were stained for 
Oatp4c1 (red), Mrp4 (red), P-gp (green), and Abcg2 (red). The images were stitched 
from six individual images using Image J with Fiji plug-in (National Institute Health, 
Bethesda, MD). Magnification: 4x. 
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Figure 4-22 (part 2 of 2) Oatp4c1 colocalization with major efflux transporters in 
the kidney cortex.  
(B-D) Sections were double stained for Mrp4 (red) and Oatp4c1 (green) (B); P-gp 
(green) and Oatp4c1 (red) (C); Abcg2 (red) and Oatp4c1 (green) (D). Yellow/orange 
color in merged panels indicates colocalization. Nuclei (blue) were stained with DAPI. 
Magnification: 10x (B-D). 
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C.  Functional characterization of Oatp4c1 in MDCKII-Oatp4c1 cells 
1. Specific Aim 3a: To investigate Oatp4c1 transport characteristics and driving 
force. 
To validate the functional activity of rat Oatp4c1 in MDCKII cells generated 
in Specific Aim 1b and to gain further insight on its role in the transport of 
physiological substrates, we performed uptake and inhibition studies using E3S, 
which was previously shown to be a human OATP4C1 substrate (110, 111). In 
preliminary studies, MDCKII-pcDNA and MDCKII-Oatp4c1 c94 cells were 
incubated with 0.5 µM [3H]-E3S in the absence (control) and presence of 100 µM 
unlabeled E3S for 1 min at pH 5.5 and pH 7.4. As shown in Figure 4-23, the 
uptake of [3H]-E3S in MDCKII-Oapt4c1 c94 cells was susceptible to inhibition by 
100 µM unlabeled E3S and transport appeared to be more efficient in cells 
exposed to media with pH 5.5 than pH 7.4. These data demonstrated the 
functionality of the in vitro model and provided evidence that E3S is also a 
substrate of rat Oatp4c1.  
The transport kinetics of [3H]-E3S in MDCKII-Oatp4c1 (c94) cells were 
studied further to determine the pH dependent differences in transport. From a 
physiological perspective, relating to the expression of Oatp4c1 in the kidney, 
this could be important as the pH in urine is in the acidic range under normal 
conditions, but can be basic (pH > 7) under pathological conditions.  The time 
dependent uptake of [3H]-E3S (0.5 μM) was more efficient in Oatp4c1 cells as 
compared to vector-transfected cells at pH 4.5, 5.5 and 7.4 (Figure 4-24 A). 
Oatp4c1-mediated uptake, obtained by subtracting transport in vector-transfected 
cells, was more efficient at pH 4.5 and 5.5 than at pH 7.4 (Figure 4-24 B).   
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Figure 4-23: Inhibition of Oatp4c1-mediated 0.5 μM [3H]-E3S uptake by 100 μM E3S 
at 1 min at pH 5.5 and pH 7.4.  
Oatp4c1-mediated uptake was calculated after subtraction of nonspecific uptake by 
pcDNA cells. Each column represents the mean ± S.D. of triplicate determinations from 
one representative experiment. Statistical analysis was performed by unpaired student’s 
t-test. * p<0.05, significant differences from control. 
 
  
 97 
 
 
Figure 4-24: Time-dependent Oatp4c1-mediated [3H]-E3S (0.5 μM) transport in 
MDCKII-Oatp4c1 c94 cells at pH 4.5, pH 5.5 and pH 7.4.  
(A) [3H]-E3S intracellular concentration in MDCKII-pcDNA and MDCKII-Oatp4c1 c94 
cells. (B) Oatp4c1-mediated uptake was calculated after subtraction of nonspecific 
uptake by pcDNA cells. Each point represents the mean ± S.D. of triplicate 
determinations from one representative experiment. 
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To obtain quantitative estimates of the pH dependent differences in 
transport, we examined the concentration dependent uptake of 1 - 150 µM [3H]-
E3S, and estimated transport kinetic parameters under conditions of linearity with 
respect to time (1 min). [3H]-E3S uptake in MDCKII-Oatp4c1 c94 and MDCKII-
pcDNA cells at pH 4.5, pH 5.5 and pH 7.4 is shown in Figure 4-25 A, and the net 
uptake is shown in Figure 4-25 B. A Michaelis-Menten or a modified Michaelis-
Menten model, incorporating Hill slope, (Sigmoid-Emax) was fitted to the net 
Oatp4c1 transport data, and Sigmoid-Emax model was selected because of lower 
AIC (Table 4-1). Transport kinetic parameters were estimated by nonlinear 
regression (Table 4-2). The Michaelis-Menten Km-equivalent parameter, S50, at 
pH 7.4 (21.5 ± 3.6 µM) was comparable to the reported Km (26.6 ± 4.9 µM) for 
human OATP4C1 at pH 7.4 (110). There was a trend toward increasing S50 with 
a decrease in pH. Similarly, the estimated Tmax was 5- and 4-fold higher at pH 4.5 
and pH 5.5, respectively, than the Tmax estimate at pH 7.4. Accordingly, increased 
E3S transport activity at acidic extracellular pH could be ascribed to the 
increased maximum transport rate. In addition, the estimated Hill slope value of 
2.6 at pH 7.4 suggests positive cooperativity. 
Using the estimated transport parameters we then determined the uptake 
transport clearance as a function of [3H]-E3S concentration. As shown in Figure 
4-26, the uptake transport clearance (ݒ/ܵ) was constant at concentrations below 
the S50 value, but decreased rapidly as the substrate concentration saturated the 
transporter. This analysis also demonstrated that the transporter uptake 
clearance was 10-20 fold higher at acidic pH conditions. 
The relationship between proton concentration and E3S uptake velocity 
was also examined. E3S uptake velocity was estimated from the parameter 
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estimates in Table 4-2. In a log-log scale, the function of y = axb appears as a 
straight line, in which b is the slope. At 0.3 µM E3S, the slope was 1, indicating 
E3S uptake velocity was linear with proton concentration (Figure 4-27). At higher 
concentrations of E3S, the slope was less than 1, indicating that E3S uptake 
velocity reached a plateau faster with increasing proton concentration, 
suggesting that proton concentration plays a role in Oatp4c1-mediated E3S 
uptake. 
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Figure 4-25: Concentration-dependent Oatp4c1-mediated [3H]-E3S transport in 
MDCKII-Oatp4c1 c94 cells at pH 4.5, pH 5.5 and pH 7.4.  
(A) [3H]-E3S intracellular concentration in MDCKII-pcDNA and MDCKII-Oatp4c1 c94 
cells at 1 min. (B) Oatp4c1-mediated uptake was calculated after subtraction of 
nonspecific uptake by pcDNA cells. Each point represents the mean ± S.D. of triplicate 
determinations from one representative experiment. 
 
Table 4-1: Akaike Information Criterion (AIC) of model selection for transport 
kinetic parameter estimation of Oatp4c1-mediated E3S transport at pH 4.5, 5.5 and 
7.4.  
Model selection was performed using WinNonlin. 
pH 4.5 pH 5.5 pH 7.4 
Michaelis-Menten 62.3 57.3 53.2 
Sigmoid-Emax 60.5 49.8 37.4 
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Table 4-2: Transport kinetic parameters of Oatp4c1-mediated E3S transport at pH 
4.5, 5.5 and 7.4 (mean ± S.E.).  
The parameters were estimated by fitting a Sigmoid-Emax to the data by GraphPad. 
Statistical analysis was performed by two-way ANOVA with Bonferroni post-hoc test for 
all pairwise comparisons. *, **, *** p<0.05 indicate significant differences between pH 4.5 
and 5.5, pH 4.5 and 7.4, and pH 5.5 and 7.4, respectively. 
pH 4.5 pH 5.5 pH 7.4 
Tmax 
(pmol/mg protein/min) 
612.6 ± 109.7* 484.0 ± 50.4*** 129.3 ± 11.0** 
S50 (µM) 60.5 ± 22.7 49.3 ± 8.8 21.5 ± 3.6 
Hill Slope 1.1 ± 0.2 1.5 ± 0.2 2.6 ± 1.0 
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Figure 4-26: The effect of pH on uptake transport clearance.  
The uptake clearance v/S was simulated using the parameter estimates in Table 4-2. 
The solid lines show the best fit to the data using v/S=Vmax×Sn-1/(S50n+Sn)  obtained from 
[3H]-E3S uptake. 
 
 
Figure 4-27: The relationship between proton concentration and E3S uptake.  
E3S uptake velocity 	was simulated at 0.3, 1, 3 and 10 µM using the parameter 
estimates in Table 4-2. The solid lines show the best fit to the data using V=aHs, where 
V, H and s represent E3S uptake velocity, proton concentration, and slope, respectively.  
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Examination of the reported Oatp4c1 and OATP4C1 primary amino acid 
sequences had revealed the presence of a potential ATP binding site (Walker A 
motif) (79). However, an ATP-depletion assay revealed that OATP4C1 mediated 
transport of T3 was not ATP-dependent at pH 7.4 (79). To examine whether 
Oatp4c1-mediated [3H]-E3S transport was ATP-dependent, the effect of ATP 
depletion on its accumulation was assessed. Twenty minutes prior to the 
transport experiment, and for the duration (1 min) of transport, cells were 
incubated with either uptake buffer or buffer lacking glucose, but supplemented 
with 20 mM 2-deoxy-D-glucose and 10 mM NaN3 at pH 5.5 and pH 7.4. Oatp4c1-
mediated [3H]-E3S (0.5 µM) uptake did not change under ATP-depleted condition 
at both pH 5.5 and pH 7.4 (Figure 4-28 B). In addition, [3H]-E3S intracellular 
concentrations in Oatp4c1-expressing and vector-transfected MDCKII cells were 
higher under ATP-depleted condition at pH 5.5 (Figure 4-28 A), suggesting the 
presence of an endogenous ATP-dependent efflux transporter in the MDCKII 
cells.    
 
  
 104 
 
 
Figure 4-28: Effect of ATP depletion on [3H]-E3S uptake (0.5 μM) via Oatp4c1.  
(A) [3H]-E3S intracellular concentration in MDCKII-pcDNA and MDCKII-Oatp4c1 c94 
cells. ATP-depletion was achieved by incubating the cells in uptake buffer containing 20 
mM 2-deoxy-D-glucose and 10 mM NaN3 without D-glucose at pH 5.5 and pH 7.4. (B) 
Oatp4c1-mediated uptake was calculated after subtraction of nonspecific uptake by 
pcDNA cells. Each column represents the mean ± S.D. of triplicate determinations from 
one representative experiment. 
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2. Specific Aim 3b: To identify potential Oatp4c1 substrates.  
Having validated E3S as an Oatp4c1 substrate, we next attempted to 
determine the interaction of Oatp4c1 with potential physiological substrates by 
studying their capacity to inhibit transport of this prototypical substrate. OATP4C1 
was reported to transport T3, T4, ouabain, digoxin and MTX (79). In addition, in 
vivo studies suggested that OATP4C1/Oatp4c1 is involved in the elimination of 
uremic toxins (106). [3H]-E3S (0.5 µM) uptake was determined in the absence 
and presence of 100 µM of putative substrates for 1 min at pH 5.5 (Figure 4-29 
A, B) or pH 7.4 (Figure 4-29 C, D). Oatp4c1-mediated [3H]-E3S uptake was 
significantly inhibited by T4 at pH 5.5, and significantly stimulated in the presence 
of T3 at both pH 5.5 and pH 7.4 (Figure 4-29 B, D). In addition, [3H]-E3S 
accumulation was significantly higher in the presence of T3 in both Oatp4c1-
expressing and vector-transfected cells (Figure 4-29 A, C). Neither reported 
OATP4C1 substrates (digoxin, ouabain, MTX), nor putative substrates (kynurenic 
acid, indoxyl sulfate, hippuric acid and trans-aconitic acid, uric acid, citric acid, 
riboflavin) affected Oatp4c1-mediated E3S uptake at either pH 5.5 or pH 7.4.  
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Figure 4-29: Effect of putative substrates on [3H]-E3S uptake at pH 5.5 and 7.4. 
MDCKII-pcDNA and MDCKII-Oatp4c1 c94 cells were incubated with 0.5 µM [3H]-E3S in 
the absence (control) and presence of various compounds (100 µM) for 1 min at pH5.5 
(A, B) and 7.4 (C, D). Oatp4c1-mediated uptake was estimated after subtracting the 
nonspecific uptake measured in pcDNA cells (B, D). Each bar represents the mean ± 
S.D. of triplicate determinations from one representative experiment. Statistical analysis 
was performed by two-way ANOVA with Bonferroni post-hoc test compared with 
control.* p<0.05, significant differences from control. 
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Human OATP4C1 has been proposed to possess multiple substrate 
recognition sites. In accord with a previous report demonstrated in MDCKII-
OATP4C1 cells (110), Oatp4c1-mediated E3S uptake was not inhibited by 
digoxin and ouabain. Therefore, Oatp4c1 may also have multiple substrate 
binding sites. If so, the unchanged Oatp4c1-mediated E3S uptake by putative 
substrates (Figure 4-29) may be because they interact with a different site than 
that of E3S. To verify these putative substrates, we used another reported 
OATP4C1 substrate, MTX (79), as a prototype substrate. As shown in Figure 
4-30 A, time dependent uptake of [3H]-MTX (1 μM) was more efficient in Oatp4c1 
cells as compared to vector-transfected cells at pH 5.5 and pH 7.4, suggesting 
MTX is Oatp4c1 substrate. However, Oatp4c1-mediated MTX uptake was 
comparable at pH 5.5 and pH 7.4 (Figure 4-30 B), which is unlike the pH effect 
observed with E3S uptake. 
The capacity of the putative substrates to inhibit MTX transport was 
examined. [3H]-MTX (1 µM) uptake was determined in the absence and presence 
of 100 µM various compounds for 1 min at pH 5.5 (Figure 4-31 A, B) or pH 7.4 
(Figure 4-31 C, D). Oatp4c1-mediated [3H]-MTX uptake was significantly 
stimulated by the presence of trans-aconitic acid and uric acid at pH 5.5 (Figure 
4-31 B). Oatp4c1-mediated [3H]-MTX uptake was significantly inhibited by T3 at 
pH 7.4. (Figure 4-31 D). Additionally, as observed in [3H]-E3S inhibition studies, 
[3H]-MTX accumulation was significantly higher in the presence of T3 in both 
Oatp4c1-expressing and vector-transfected cells (Figure 4-31 A, C). Neither 
reported OATP4C1 substrates (T4, digoxin, ouabain, and E3S), nor putative 
substrates (kynurenic acid, indoxyl sulfate, riboflavin) changed Oatp4c1-
mediated MTX uptake at either pH 5.5 or pH 7.4.  
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Figure 4-30: Time-dependent Oatp4c1-mediated [3H]-MTX (1 μM) transport in 
MDCKII-Oatp4c1 c94 cells at pH 5.5 and pH 7.4.  
(A) [3H]-MTX intracellular concentration in MDCKII-pcDNA and MDCKII-Oatp4c1 c94 
cells. (B) Oatp4c1-mediated uptake was calculated after subtraction of nonspecific 
uptake by pcDNA cells. Each point represents the mean ± S.D. of triplicate 
determinations from one representative experiment. 
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Figure 4-31: Effect of putative substrates on [3H]-MTX uptake at pH 5.5 and 7.4.  
MDCKII-pcDNA and MDCKII-Oatp4c1 c94 cells were incubated with 1 µM [3H]-MTX in 
the absence (control) and presence of various compounds (100 µM) for 1 min at pH5.5 
(A, B) and 7.4 (C, D). Oatp4c1-mediated uptake was estimated after subtracting the 
nonspecific uptake measured in pcDNA cells (B, D). Statistical analysis was performed 
by two-way ANOVA with Bonferroni post-hoc test compared with control. Each bar 
represents the mean ± S.D. of triplicate determinations from one representative 
experiment. * p<0.05, significant differences from control. 
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D.  Creation and validation of human OATP4C1-expressing cell lines 
1. Specific Aim 4a: To develop and validate human OATP4C1 antibodies amenable 
for immunoblotting, immunohistochemistry and immunofluorescence. 
To investigate the expression and subcellular localization of human 
OATP4C1 in the in vitro cell models and human tissues, two rabbit polyclonal 
antibodies were generated against either amino-terminus (PA1243) or carboxyl-
terminus (PA1245) of human OATP4C1. The antibodies specificities were 
validated by Western blotting, immunohistochemical analysis, and 
immunofluorescence staining in the in vitro cell models developed in Specific Aim 
4b.  
 
2. Specific Aim 4b: To create and validate human OATP4C1-expressing cells with 
appropriate characteristics for functional studies. 
To study the role of human OATP4C1 in drug disposition, we generated 
OATP4C1-expressing MDCKII cells and OATP4C1-expressing Sf9 cells. Human 
SLCO4C1 DNA purchased from OriGene was amplified by PCR reaction. The 
amplified fragment of appropriate size was confirmed by agarose gel 
electrophoresis (Figure 4-32 A). The amplification product was purified and 
cloned into pENTR vector. The plasmid construct was verified by EcoRI 
restriction enzyme digestion and by PCR with M13 forward and M13 reverse 
primers, which bound to ~110 bp upstream and ~150 bp downstream of the gene 
insertion site, respectively, in the pENTR vector (Figure 4-32 B). This sequence 
was confirmed with 100% identity as compared to the published human 
SLCO4C1 sequence (GeneBank accession number NM_180991). The plasmid 
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DNA was then subcloned into pcDNA6.2/EmGFP-Bsd/V5-DEST vector and was 
verified by PCR with T7 forward primer, which bound to 50 bp upstream of gene 
insertion site in the vector, and SLCO4C1 reverse primers (Figure 4-32 C). 
The SLCO4C1 plasmid DNA (pcDNA6.2/EmGFP-Bsd/V5-DEST/SLCO4C1) 
and empty plasmid DNA (pcDNA6.2/EmGFP-Bsd/V5-DEST) were transfected 
into MDCKII cells. Transfection efficiency was examined by Western blotting 
using the antibody generated in Specific Aim 4a (PA1245) (Figure 4-33 A). 
OATP4C1 expression was detectable as a band at ~60 kDa in MDCKII-
OATP4C1 cells, but not in MDCKII-pcDNA (empty vector) cells. Human kidney 
served as a positive control with a band detected at ~70 kDa. OATP4C1 was 
also detectable as a broad band at 60-70 kDa in OATP4C1-expressing Sf9 cells, 
which will be described later. In addition, validation of antibody PA1243 for 
Western blotting is shown in Figure 4-33 B. OATP4C1 was detected at ~60 and 
80 kDa in human kidney and at ~60 kDa in Sf9-OATP4C1 cells, but not in Sf9-
vector cells. After antigen peptide blocking, the specific bands in human kidney 
(~80 kDa) and Sf9-OATP4C1 cells (~60 kDa) were abolished, demonstrating the 
antibody specificity. 
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Figure 4-32: Validation of SLCO4C1 plasmid constructs.  
PCR products and the restriction enzyme digestion products of SLCO4C1 and plasmid 
DNA were examined by agarose gel electrophoresis. 
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OATP4C1 expression in MDCKII-OATP4C1 cells was also confirmed in 
paraformaldehyde-fixed paraffin-embedded cell pellet sections by 
immunohistochemical analysis using antibody PA1243 (Figure 4-33 C). 
OATP4C1 was observed on the cell membrane in the MDCKII-OATP4C1 cells, 
and the staining was abolished when probed with antibody that was pre-
adsorbed with antigen peptide. Despite some background staining detected in 
the negative control (rabbit IgG), no staining was observed in the MDCKII-pcDNA 
cells. This demonstrated that the transfection was successful and that the 
antibody was specific. 
The subcellular localization of OATP4C1 in polarized cell monolayers was 
assessed by confocal immunofluorescence laser scanning microscopy (Figure 
4-33 D) and surface protein biotinylation assay (Figure 4-33 E). As observed for 
rat Oatp4c1, OATP4C1 localized at the apical membrane in MDCKII-OATP4C1 
cells (Figure 4-33 D). As shown in Figure 4-33 E, surface biotinylation assay 
demonstrated that OATP4C1 was enriched in the apical membrane fraction as 
compared to the basolateral membrane. Collectively, these data verified the 
apical localization of the transporter in OATP4C1-expressing MDCKII cells.  
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Figure 4-33: Validation of OATP4C1 expression and subcellular localization in 
MDCKII-OATP4C1 cells.  
(A) Western blot of OATP4C1 and β-actin. OATP4C1 was detected with PA1245. (B) 
Western blot of OATP4C1 and β-actin with and without antigen peptide blocking. 
OATP4C1 was detected with PA1243. (C) Immunohistochemical analysis of OATP4C1 
expression in paraformaldehyde-fixed paraffin-embedded cell sections. OATP4C1 was 
detected with PA1243. (D) Confocal microscopy of OATP4C1 (red) expression and 
localization in polarized MDCKII cells. Center image is a single optical section of the x-y 
plane while top and right images represent x-z and y-z planes, respectively, 
reconstructed from image stacks. The apical and basal sides can be demarcated by Zo-
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1 (green) and the nuclei (DAPI, blue), respectively, in both x-z and y-z sections. 
OATP4C1 was detected with PA1245. (E) Western blot of OATP4C1 in proteins isolated 
from either the apical (AP) or basolateral (BL) membranes of polarized MDCKII cells. 
Na+/K+-ATPase served as a BL marker to demonstrate the relative efficiency of AP and 
BL membrane separation. OATP4C1 was detected with PA1245. 
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To validate the functional activity of OATP4C1 in MDCKII cells, the uptake 
studies of reported OATP4C1 substrates, ouabain and E3S (79, 110, 111), was 
performed. Ouabain transport kinetics were determined by [3H]-ouabain uptake 
for concentrations ranging from 1 to 150 µM at 5 min. OATP4C1-mediated 
uptake (net) was calculated after subtraction of nonspecific uptake by pcDNA 
cells. As shown in Figure 4-34, [3H]-ouabain uptake was higher in MDCKII-
OATP4C1 as compared to MDCKII-pcDNA cells, and a saturable concentration-
dependent OATP4C1-mediated ouabain uptake was observed. It confirmed 
ouabain as an OATP4C1 substrate and showed the functional activity of 
OATP4C1 in the transfected cells. Michaelis-Menten and sigmoid-Emax were fitted 
to the net OATP4C1 transport data. The transport kinetic parameters were 
estimated by nonlinear regression ( 
Table 4-3). The AIC for the two models were comparable. Therefore, the 
simpler Michaelis-Menten model was selected. The estimated S50 (0.19 ± 0.09 
µM) was in the similar range of the reported Km (0.38 ± 0.1 µM) (79).  
The functional activity of OATP4C1 in MDCKII cells was also validated with 
E3S. [3H]-E3S uptake was determined at 0.5 and 1 µM for 5 min. As shown in 
Figure 4-35, [3H]-E3S uptake was higher in MDCKII-OATP4C1 than that in 
MDCKII-pcDNA cells, and the net uptake was increased with concentration. 
Despite that the concentrations were not high enough to reach saturation, the 
data suggest that E3S is an OATP4C1 substrate. 
 
 117 
 
 
Figure 4-34: Concentration-dependent OATP4C1-mediated [3H]-ouabain transport 
in MDCKII-OATP4C1 cells at pH 7.4.  
[3H]-ouabain intracellular concentration (5 min) in MDCKII-pcDNA and MDCKII-
OATP4C1 cells. OATP4C1-mediated uptake (net) was calculated after subtraction of 
nonspecific uptake by pcDNA cells. Each point represents the mean ± S.D. of triplicate 
determinations from one representative experiment. 
 
Table 4-3: Transport kinetic parameters of OATP4C1-mediated [3H]-ouabain 
transport at pH 7.4 (mean ± S.E.).  
The transport parameters were estimated by GraphPad, and AIC for model selection 
was estimated by WinNonlin. 
Michaelis-Menten Sigmoid-Emax 
Tmax 
(pmol/min/mg protein) 
0.17 ± 0.03 0.26 ± 0.24 
S50 (µM) 0.19 ± 0.09 0.70 ± 2.02 
Hill Slope - 0.67 ± 0.36 
AIC -34.00 -34.23 
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Figure 4-35: Concentration-dependent OATP4C1-mediated [3H]-E3S 
transport in MDCKII-OATP4C1 cells at pH 7.4.  
[3H]-E3S intracellular concentration (5 min) in MDCKII-pcDNA and MDCKII-
OATP4C1 cells. OATP4C1-mediated uptake (net) was calculated after 
subtraction of nonspecific uptake by pcDNA cells. Each point represents the 
mean ± S.D. of triplicate determinations from one representative experiment. 
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In addition to MDCKII cells, we also overexpressed OATP4C1 in Sf9 cells. 
Sf9 can express higher level of recombinant protein and is easily scaled up for 
substrate screening to study the role of human OATP4C1 in drug disposition. 
pENTR/SLCO4C1 construct was generated as previously described in 
developing OATP4C1-expressing MDCKII cells, and was subcloned into pDEST8 
vector. The size of the plasmid construct was confirmed by Bsu361 restriction 
enzyme digestion (Figure 4-36 A). The plasmid DNA was then recombined in 
DH10BacTM competent E. Coli. containing baculovirus genome. For background 
control, the empty vector (pDEST8) was also recombined as above. 
Recombinant bacmid DNA was verified by PCR with M13 forward and M13 
reverse primers (Figure 4-36 B).  
The recombinant bacmids (pDEST8/SLCO4C1 and pDEST8) were 
transfected into Sf9 cells, and the supernatant containing recombinant 
baculovirus stock was harvested after 48 hr. The viral stock was amplified by 
infecting a large volume of Sf9 cell suspensions. The infected Sf9 cells were 
centrifuged to collect cell pellets for membrane vesicle preparation. Successful 
infection was confirmed by Western blotting for OATP4C1 expression in the 
membrane vesicles. As shown in Figure 4-37, OATP4C1 was detected in Sf9-
OATP4C1 membrane vesicles but not in Sf9-vector.  
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Figure 4-36: Validation of pDEST8-SLCO4C1 plasmid construct.  
Restriction enzyme digestion products and PCR products of pDEST8-SLCO4C1 were 
examined by agarose gel electrophoresis. 
 
 
Figure 4-37: Validation of OATP4C1 expression in Sf9-OATP4C1 membrane 
vesicles. 
Western blot analysis for OATP4C1 expression in Sf9-pDEST8 and Sf9-OATP4C1 
membrane vesicles (0.2 μg protein). OATP4C1 was detected with PA1245. 
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To validate the functional activity of OATP4C1 in Sf9 cells, vesicular 
transport studies of [3H]-ouabain and [3H]-E3S were performed. As shown in 
Figure 4-38, the time dependent uptake of [3H]-ouabain (0.5 μM) was higher in 
Sf9-OATP4C1 as compared to Sf9-pDEST8 membrane vesicles at pH 7.4. 
Based on this result, the 3 min time point was chosen to determine the initial rate. 
To evaluate [3H]-ouabain transport kinetics, the initial rate of [3H]-ouabain uptake 
were determined for concentrations ranging from 0.01 to 1 µM (Figure 4-39 A 
and B). However, the nonspecific adsorption determined by incubation in cold 
uptake buffer was substantial. At 1 µM, the nonspecific adsorption was 55% of 
the total radioactivity remaining on the filter. After subtracting the nonspecific 
adsorption, [3H]-ouabain uptake in Sf9-pDEST8 showed saturation transport 
kinetics, indicating the presence of an endogenous uptake transporter (Figure 
4-39 B). OATP4C1-mediated ouabain uptake was calculated after subtraction of 
nonspecific uptake in Sf9-pDEST8. Michaelis-Menten and sigmoid-Emax models 
were fitted to the net OATP4C1 transport data. The transport kinetic parameters 
were estimated by nonlinear regression (Table 4-4). The simpler Michaelis-
Menten model was selected because the AIC of the two models were 
comparable. The estimated S50 (0.18 ± 0.09 µM) was comparable with the S50 
estimated from MDCKII-OATP4C1 cells (0.19 ± 0.09 µM) and was in the similar 
range of the reported Km (0.38 ± 0.1 µM) (79). However, the high nonspecific 
adsorption decreased the sensitivity, therefore another substrate with low 
adsorption was needed to study OATP4C1 function. 
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Figure 4-38: Time-dependent OATP4C1-mediated [3H]-ouabain (0.5 μM) transport 
in Sf9-OATP4C1 membrane vesicles at pH 7.4.  
[3H]-ouabain accumulation in Sf9-pDEST8 and Sf9-OATP4C1 membrane vesicles. 
OATP4C1-mediated uptake was calculated after subtraction of nonspecific uptake by 
Sf9-pDEST8. Each point represents the mean ± S.D. of triplicate determinations from 
one representative experiment. 
 
Figure 4-39: Concentration-dependent OATP4C1-mediated [3H]-ouabain transport 
in Sf9-OATP4C1 membrane vesicles at pH 7.4.  
(A) [3H]-ouabain accumulation (3 min) in Sf9-pDEST8 and Sf9-OATP4C1 membrane 
vesicles. Nonspecific adsorption on the filter was measured by incubation in cold buffer. 
(B) Data from panel A with nonspecific adsorption subtraction. OATP4C1-mediated 
uptake was calculated after subtraction of nonspecific uptake by Sf9-pDEST8. Each 
point represents the mean ± S.D. of triplicate determinations from one representative 
experiment. 
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Table 4-4: Transport kinetic parameters of OATP4C1-mediated [3H]-ouabain 
transport in Sf9-OATP4C1 membrane vesicles at pH 7.4 (mean ± S.E.).  
The transport parameters were estimated by GraphPad, and AIC for model selection 
was estimated by WinNonlin. 
Michaelis-Menten Sigmoid-Emax 
Tmax 
(pmol/min/mg protein) 
0.15 ± 0.02 0.37 ± 0.90 
S50 (µM) 0.18 ± 0.09 2.76 ± 20.80 
Hill Slope - 0.55 ± 0.39 
AIC -30.83 -30.70 
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Because of the high nonspecific adsorption on the filter membrane of 
ouabain, which interfered with data interpretation, another substrate, E3S, was 
used to investigate OATP4C1 transport characteristics. Preliminary studies 
showed that nonspecific adsorption of E3S was only 0.3% of the total 
radioactivity. The time dependent uptake of [3H]-E3S (30 μM) was higher in Sf9-
OATP4C1 as compared to Sf9-pDEST8 membrane vesicles at pH 7.4, and the 5 
min time point was chosen to determine the initial rate (Figure 4-40 A). To 
evaluate [3H]-E3S transport kinetics, the initial rate of [3H]-E3S uptake was 
determined for concentrations ranging from 1 to 30 µM (Figure 4-40 B). The net 
uptake was increased with concentration, but did not reach a plateau, implying 
that the transporter was not saturated at these concentrations. In addition, the pH 
effect on OATP4C1-mediated E3S transport was examined. [3H]-E3S (20 μM) 
accumulation in Sf9-pDEST8 and Sf9-OATP4C1 for 5 min at pH 6.5 and pH 7.4 
was determined (Figure 4-41 A). As shown in Figure 4-41 B, there was a trend 
toward increasing net uptake with a decrease in pH.  
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Figure 4-40: Time-dependent and concentration-dependent OATP4C1-mediated 
[3H]-E3S transport in Sf9-OATP4C1 membrane vesicles at pH 7.4.  
(A) Time-dependent 30 μM [3H]-E3S accumulation in Sf9-pDEST8 and Sf9-OATP4C1 
membrane vesicles. (B) Concentration-dependent [3H]-E3S accumulation in Sf9-
pDEST8 and Sf9-OATP4C1 membrane vesicles at 5 min. Nonspecific adsorption on the 
filter was measured by incubation in cold buffer and was subtracted as background. 
OATP4C1-mediated (net) uptake was calculated after subtraction of nonspecific uptake 
by Sf9-pDEST8. Each point represents the mean ± S.D. of triplicate determinations from 
one representative experiment. 
 
  
 126 
 
 
Figure 4-41: Effect of pH on OATP4C1-mediated [3H]-E3S transport in Sf9-
OATP4C1 membrane vesicles.  
(A) [3H]-E3S (20 μM) accumulation in Sf9-pDEST8 and Sf9-OATP4C1 membrane 
vesicles for 5 min at pH 6.5 and pH 7.4. (B) OATP4C1-mediated uptake was calculated 
after subtraction of nonspecific uptake by Sf9-pDEST8. Each point represents the mean 
± S.D. of triplicate from one representative experiment. 
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E.  Validation of OATP4C1 expression in human kidney and cancer cells 
1. Specific Aim 4c: To determine the expression and subcellular localization of 
OATP4C1 in the human kidney. 
OATP4C1 expression in human kidney by Western blotting was shown in 
Figure 4-33 A and B. The subcellular localization of OATP4C1 was then 
assessed by immunohistochemical analysis in paraformaldehyde-fixed paraffin-
embedded human kidney tissue sections. To assure the quality of the kidney 
specimens, sections were stained with anti-MRP4 antibody (clone M4I10), which 
showed specific staining (Figure 4-42). However, no staining was observed using 
the PA1243 and PA1245 anti-OATP4C1 antibodies, despite several attempts to 
improve antigen recovery and to maximize reaction time (prolonged incubations). 
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Figure 4-42: Immunohistochemical analysis for OATP4C1 subcellular 
localization in human kidney sections.  
OATP4C1 was detected with rabbit polyclonal anti-OATP4C1 antibodies as 
indicated. Rabbit IgG was used as a negative control. MRP4, a positive control, 
was detected with M4I10. Magnification: 40x. 
  
 129 
 
2. Specific Aim 4d: To determine the expression of OATP4C1 in cancer cells. 
Microarray analysis showed a 18-fold increase of SLCO4C1 expression in 
lung tumor relative to normal lung (104). In addition, SLCO4C1 expression in 
lung tumor was 2-fold higher than that in human kidney. To screen SLCO4C1 
expression in different type of cancer cells, qRT-PCR was performed in 10 
cancer cell lines, including prostate cancer, glioblastoma, breast cancer and 
melanoma cells. As shown in Figure 4-43, SLCO4C1 expression in H1299 (non-
small cell lung cancer cells) was 20-fold higher than that in human kidney, 
whereas SLCO4C1 expression in other cell lines was not significantly different 
from that in human kidney.   
SLCO4C1 was also observed in human formalin fixed paraffin embedded 
lung cancer specimens. SLCO4C1/OATP4C1 expression in these tissues was 
determined by qRT-PCR and immunohistochemical analysis. Because tissue 
fixation and storage typically cause nucleic acid fragmentation and chemical 
modification, three primers were used in qRT-PCR to prevent false negative 
interpretation from unsuccessful amplification. 18s rRNA was used as an internal 
control, and relative SLCO4C1 expression was normalized with normal lung 
tissue from the same patient calculated by the 2-∆∆Ct method. Compared with 
adjacent normal lung tissue, SLCO4C1 expression was higher in the tumor for 
five patients (2451, 2492, 2506, 2508 and 2509), but lower for four patients 
(2493, 2497, 2507 and 2534) (Figure 4-44). Two patients from each group were 
chosen for immunohistochemical analysis to confirm OATP4C1 expression in 
tumor and normal lung tissue. Unlike the qRT-PCR results, OATP4C1 staining 
was stronger in the tumor than in the normal lung in all of four patients (Figure 
4-45). Despite this discrepancy between immunohistochemistry and qRT-PCR 
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results, these data collectively suggested that OATP4C1 is highly expressed in 
lung tumors.  
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Figure 4-43: Relative SLCO4C1 expression in cancer cells calculated with the 2-∆∆Ct 
method.  
Relative copy number of SLCO4C1 in the samples was normalized to 18s rRNA within 
each sample and values were then normalized with those in human kidney. Each bar 
represents mean of triplicate determinations. Statistical analysis was performed by one-
way ANOVA with Dunnett’s test. * p<0.05, significant difference from control (human 
kidney). 
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Figure 4-44: Relative SLCO4C1 expression in lung tumor and adjacent normal 
lung tissue of 9 patients calculated with the 2-∆∆Ct method.  
Relative copy number of SLCO4C1 in the samples was normalized to 18s rRNA within 
each sample and values were then normalized with those in adjacent normal lung tissue 
of each patient. Each bar represents mean of triplicate determinations. The amplicon 
length of the primer is denoted in the parentheses. Four patients selected for 
immunohistochemical analysis are indicated by the blue underline.  
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Figure 4-45: OATP4C1 expression in the lung tumor and adjacent normal lung 
tissue of 4 patients.  
Immunohistochemical analysis of OATP4C1 expression in paraformaldehyde-fixed 
paraffin-embedded lung tumor and adjacent normal lung tissue slides. OATP4C1 was 
detected with PA1243. Magnification: 10x (inset 40x). 
 
Copyright © Kuei-Ling Kuo 2012 
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CHAPTER 5 : DISCUSSION 
A.  Creation and validation of a rat Oatp4c1-expressing cell line  
Despite the well documented benefits of breastfeeding, limited data regarding the 
risk of drug transfer into breast milk and the possibility of exposing infants to drugs 
poses a dilemma for lactating mothers and their physicians. To identify the transporters 
involved in drug transfer into the milk, a comprehensive microarray analysis examining 
xenobiotic transporter genes regulation during lactation was performed and 
demonstrated that SLCO4C1 expression was upregulated 70-fold in LMEC as compared 
to MEC. This suggests its potential role in drug transfer into the milk. In accord with the 
published literature, ABCG2 expression was upregulated during lactation 164-fold (10). 
OATP4C1/Oatp4c1 had been demonstrated to localize at the basolateral membrane in 
the kidney (79, 106). Therefore, we hypothesized that OATP4C1/Oatp4c1 localized at 
the basolateral membrane in the mammary gland and coupled with ABCG2/Abcg2, an 
apical efflux transporter, to facilitate the transfer of their common substrates into breast 
milk.  
To examine the expression and subcellular localization of rat Oatp4c1 in the cells 
and tissues, antibodies amenable to immunohistochemistry, immunofluorescence, and 
immunoblotting were generated and validated. Rat Oatp4c1-expressing MDCKII cell 
lines were generated to study the role of Oatp4c1 in drug disposition. The MDCKII cell 
line was selected because of its extensive use in the published literature, ease of 
transfection and subsequent selection, ability to form a polarized monolayer and tight 
junctions. The successful transfection was demonstrated by a distinct band at 
appropriate molecular weight by Western blotting and specific membrane localization by 
immunohistochemical analysis. Unexpected results from immunofluorescence confocal 
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microscopy and surface protein biotinylation assay both showed that the transporter 
localized at the apical rather than the basolateral membranes (Figure 4-2). Although this 
result was unexpected, it is not without precedent, as others demonstrated that 
apical/basolateral sorting depends on the host cell (35). Previous results by Lai and Tan 
showed that MRP4 localized in the basolateral membrane of MDCKII cells (118). 
However, MRP4 localizes at the apical membrane of human and rodent renal proximal 
tubules (133). This discrepancy was later attributed to species differences in NHERF1 
expression, an adaptor protein that determines the trafficking of MRP4 (119). Therefore, 
Oatp4c1-expressing LLC-PK1 cells were generated to confirm the subcellular 
localization of Oatp4c1. As observed in MDCKII cells, Oatp4c1 also localized at the 
apical membrane in LLC-PK1 cells (Figure 4-3).  
Apical/basolateral sorting of newly synthesized proteins typically occurs in the 
trans-Golgi network, where apical and basolateral components are selectively packaged 
into specific transport vesicles mediated by sorting signals (134, 135). Apical sorting 
signals localized to all the portions of apical proteins (extracellular, transmembrane and 
cytoplasmic domain) include the glycosylphosphatidylinositol (GPI) anchor or N- and O-
linked protein glycosylation. Basolateral sorting signals usually located in the 
cytoplasmic tail of basolateral proteins include tyrosine-based YXXØ, NPXY motifs 
(where X can be any amino acid and Ø is a bulky hydrophobic residue) and dileucine-
based motifs. The trafficking of basolateral proteins containing the tyrosine-based or 
dileucine-based sorting signals is via adaptor proteins. AP1-µ1B is a well-characterized 
adaptor protein associated with basolateral sorting. It is expressed in various polarized 
epithelial cell lines, including MDCKII, Caco-2, but not in LLC-PK1 cells.  Lack of AP1-
µ1B in LLC-PK1 cells results in missorting of many basolateral proteins to the apical 
membrane, but stable expression of AP1-µ1B restores the basolateral trafficking (136). 
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Although Oatp4c1 localized at the apical membrane in both of MDCKII and LLC-PK1 
cells, we can not rule out the possibility that the adaptor protein for Oatp4c1 trafficking is 
lacking in both cells. Therefore, it was necessary to determine the subcellular 
localization of Oatp4c1 in the kidney to confirm this result.     
Although transfection led to detectable protein by Western blot, 
immunofluorescence studies showed that the transfection efficiency was very low (~ 3%) 
in MDCKII cells (Figure 4-4). Therefore, we attempted to obtain a single clone with 
homogenous high Oatp4c1 expression. Our initial attempt was to sort individual live cells 
into a 96-well plate by FACS analysis with transient C-terminal-tagged GFP, which was 
produced by adding Tag-On-DemandTM Suppressor Supernatant. However, none of the 
subsequent clones showed Oatp4c1 expression. Tag-On-DemandTM Suppressor 
Supernatant is a replication-incompetent adenovirus containing human tRNAser 
suppressor, which has been mutated to recognize the TAG stop codon and decode it as 
serine. Translation is thereby continued through the downstream reading frame and 
produces a transient C- terminal tagged GFP fusion protein. The sorting gate 
(fluorescence channel boundaries) was set based on the fluorescence intensity, which 
was determined by the efficiency of Tag-On-DemandTM Suppressor Supernatant. 
Observed low GFP intensity was probably due to low efficiency of Tag-On-DemandTM 
Suppressor Supernatant, and resulted in a wide sorting gate which may have 
compromised the purity of sorted cells. Therefore, some of the sorted cells may not have 
contained the Slco4c1 gene. 
The second attempt was to sort the cells by immunofluorescence labeling. Oatp4c1 
was labeled with rabbit polyclonal antibody PA1343 and Alexa 488 anti-rabbit IgG. 
Individual live cells were then sorted into a 96-well plate by FACS analysis with Alexa 
488 fluorescence. However, none of the subsequent clones exhibited Oatp4c1 
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expression. The labeling of Oatp4c1 needs the C-terminal primary antibody and the 
secondary antibody to penetrate into the cells, and that may be difficult to achieve 
without permeabilization agent, Triton-X 100. Therefore, low fluorescence intensity was 
observed and resulted in a wide sorting gate, which compromised the purity of sorted 
cells.  
The third attempt was to randomly seed individual live cells in 96-well plates. 
Unfortunately, none of the subsequent clones showed Oatp4c1 expression. These 
failures lead us to hypothesize that the expression of Oatp4c1 decreases the cell 
proliferation rate and this effect is magnified when expanding from a single cell. The 
decreased cell proliferation rate is probably because of the metabolic burden created 
from expressing a foreign protein in recombinant host cells (121). Therefore, the fourth 
attempt was to generate the clones starting from more than one cell using the serial 
dilution method. Although the homogeneity of Oatp4c1 expression was compromised, 
but we finally obtained one clone (c94) that showed higher Oatp4c1 expression by 
Western blotting (Figure 4-10) and more cells exhibiting Oatp4c1 expression as 
compared to the pooled cells (11% vs. 3%) by immunofluorescence staining (Figure 
4-4). 
To increase Oatp4c1 expression, we sought to treat the cells with sodium butyrate, 
simvastatin, glycerol, MG132, or to increase the selection antibiotic, blasticidin, 
concentration. Sodium butyrate is commonly used to induce protein expression (122, 
123). It is a short-chain fatty acid that has been recognized to function as a transcription 
activator due to its ability to influence chromatin structure via inhibition of histone 
deacetylase activity (137). However, sodium butyrate was reported to disrupt the protein 
trafficking in Na+/K+-ATPase β1- and β2 subunits-overexpressed MDCK-I cells (124). A 
concentration-dependent upregulation of Oatp4c1 expression was observed at mRNA 
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and protein levels, while apical polarity was maintained (Figure 4-5). The upregulation of 
Oatp4c1 expression, as well as increased number of cells exhibiting Oatp4c1 
expression, were also observed in high concentrations of selection antibiotic, blasticidin 
(Figure 4-6). However, the effect of blasticidin was negligible when co-treating Oatp4c1-
expressing MDCKII c94 cells with sodium butyrate and blasticidin (Figure 4-10).   
Several HMG-CoA reductase inhibitors (statins) have been shown to enhance 
SLCO4C1 promoter activity by inducing nuclear AhR, which binds to the XRE motifs on 
SLCO4C1 promoter region. However, our data showed that simvastatin induced Slco4c1 
mRNA expression, but this did not result in increased protein expression in the MDCKII-
Oatp4c1 cells (Figure 4-7). This is inconsistent with a previous report, which showed that 
pravastatin/fluvastatin increased SLCO4C1 expression as well as protein function, T3 
uptake, in ACHN cells (renal carcinoma cells) (106). However, other transporters 
expressed in ACHN cells (107), which transport T3, may also be regulated by 
pravastatin/fluvastatin and thereby increase T3 uptake.  Although a direct relationship 
between mRNA and protein levels is often expected, several reports have demonstrated 
weak correlation between mRNA and protein levels (138, 139). This may be the result of 
differences in regulatory controls, translation rates, posttranslational modification and 
protein degradation. In fact, simvastatin was shown to decrease androgen receptor 
protein expression, while its mRNA expression was not changed (140). Whether the 
discrepancies in Oatp4c1 mRNA and protein expression by simvastatin treatment are 
due to protein degradation will have to be investigated further.  
The primary amino acid sequence of rat Oatp4c1 contains a high number of 
cysteine residues as compared to other transporters, such as ABCG2, P-gp, and MRP4. 
Disulfide bonds between cysteine residues play a key role in protein folding, which is 
important for protein trafficking and function. The high number of cysteine residues in 
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Oatp4c1 may lead to a higher degree of folding, which may not be possible in the 
MDCKII cells. In turn, misfolded proteins fail to traffic out of the endoplasmic reticulum 
(ER) via the Golgi apparatus to the plasma membrane, and are targeted for degradation 
via the ubiquitin/proteasome-dependent pathway. Glycerol is a chemical chaperone, and 
has protein-stabilizing properties in vitro, due to its ability to increase protein hydration 
(126). Glycerol has been shown to stabilize misfolded ∆F508 cystic fibrosis 
transmembrane conductance regulator protein (CFTR) mutant protein into conformations 
that are not targeted for degradation and can escape ER and degradation (125). 
Treatment of ∆F508 CFTR-expressing cells with high concentrations (1 - 1.25 M) of 
glycerol for 2 or 3 days increased the stability of fully glycosylated matured form of CFTR 
on Western blotting and restored the ability of forskolin-dependent (cAMP-activated) 
chloride transport (141). MG132 is a proteasome inhibitor that can prevent misfolded 
proteins, which are retained in ER, from being targeted for premature proteolysis. Its 
effect on misfolded protein rescue has been demonstrated in ABCG2 mutant C592G- or 
C608G-expressing Flp-In-293 cells. MG132 increased the expression of the fully 
glycosylated mature form of ABCG2 mutant by Western blotting, membrane localization 
by immunofluorescence staining, and also protein function as cellular resistance to 
ABCG2 substrate, SN-38 (142). However, treatment with glycerol or MG132 did not 
increase Oatp4c1 expression (Figure 4-8, Figure 4-9). This suggests that Oatp4c1 was 
properly folded in MDCKII cells and the low number of cells exhibiting Oatp4c1 
expression (~11%) was not due to misfolded proteins. The potential cause for low 
Oatp4c1-expressing cells is that Oatp4c1 expression decreases the cell proliferation 
rate, and therefore the majority of the cell population doesn’t express Oatp4c1. The slow 
growth rate of Oatp4c1-expressing cells is possibly due to the metabolic burden created 
from expressing foreign protein or protein toxicity caused from overexpressing proteins 
at levels higher than the physiological level (121). Recombinant protein expression 
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introducing a foreign protein in host cells utilizes host cell’s resources, such as ATP or 
amino acids, imposes a metabolic burden on the host cells, and may decrease the 
growth rate of the host cells. The recombinant protein expression is usually significantly 
higher than that in physiological environment, which may not need for the host cells and 
cause toxicity in the host cells. In addition, Oatp4c1 functions as an uptake transporter, 
which may increase intracellular concentrations of substances that slow the growth rate 
or cause cell death.  
Overall, although the number of cells exhibiting Oatp4c1 expression is low, we 
believe that Oatp4c1 expression with sodium butyrate induction is adequate to study 
Oatp4c1 function.  
 
B.  Determination of Oatp4c1 expression and subcellular localization in rat tissues 
The upregulation of human SLCO4C1 expression in MG during lactation was also 
observed in rats by RT-PCR analysis, and protein upregulation was confirmed by 
Western blotting (Figure 4-12). In accord with the published literature, Slco4c1/Oatp4c1 
was expressed in the kidney, but not in the liver (79). The expression of Slco4c1 in rat 
kidney was lower than that in rat MG at the mRNA level, but was higher at the protein 
level. The discrepancies in Slco4c1 mRNA and protein expression in kidney and MG 
may be due to tissue-dependent regulatory controls and/or posttranslational 
modification. An ontogenic study showed that Slco4c1 mRNA expression in rat kidney 
increases with age, whereas liver expression was absent in rats of all ages (Figure 4-13, 
Figure 4-14). However, our observation is inconsistent with the previous findings that 
showed no gender differences of Slco4c1 mRNA expression in the rat kidney (79). In 
terms of gender differences, higher Oatp4c1 expression was observed in non-lactating 
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female rat kidney as compared with males at both mRNA and protein levels (Figure 
4-13). The expression of Slco4c1 in non-lactating female rat kidney was higher than that 
in lactating female rat kidney at the mRNA level, but was the same at the protein level. 
The discrepancies may be due to differences in regulatory controls and/or 
posttranslational modification during lactation. However, these results were not 
conclusive because of the small sample size (one).   
The subcellular localization of Oatp4c1 in rat tissues was determined by 
immunohistochemical analysis and showed apical localization in both rat kidney and MG 
(Figure 4-15), which was inconsistent with a previous report showing that Oatp4c1 
localized at the basolateral membrane in the rat proximal tubule (79). The 
immunohistochemistry result was verified with four different antibodies, which were 
raised against unique C- and N-terminal peptides (Figure 4-16). The apical localization 
was also demonstrated by distinct localization of Oatp4c1 and a basolateral marker E-
cadherin (Figure 4-17), and colocalization of Oatp4c1 and an apical marker p-
glycoprotein (Figure 4-22 C). In addition, biochemical separation of BBM and BLM from 
proximal rat kidney tubules confirmed the location of Oatp4c1 at the apical/brush border 
membranes by Western blot and proteomic analyses (Figure 4-19). Furthermore, the 
proteomic analyses provide additional validation for the Oatp4c1 antibody specificity.  
This extensive validation of the in vitro and in vivo subcellular localization was 
deemed necessary as our results were not in accordance with  previous reports, which 
showed that Oatp4c1 localizes at the basolateral membrane in the rat proximal tubule 
(79), as did human OATP4C1 in the transgenic rat harboring human SLCO4C1 (106). 
These authors hypothesized that basolateral expression of Oatp4c1 worked in tandem 
with an apical efflux transporter to efficiently transport substrates across the kidney 
epithelium and into the urine (79, 106).  The contradictory finding in the original report by 
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Mikkaichi and colleagues may have been a result of limited validation performed with the 
antibody used in that study. Our attempt to develop this polyclonal antibody (79), using 
the reported 11 amino acid peptide antigen, did not yield a reagent that was amenable to 
immunohistochemistry (Figure 4-16). The results of the transgenic OATP4C1 expression 
pattern reported by Toyohara et al., however, are more difficult to reconcile (106). In 
their publication, they present evidence that OATP4C1 localizes in the basolateral 
membrane of renal tubule epithelium in transgenic rats. Provided that the anti-OATP4C1 
antibody recognized the correct transgenic protein, one potential explanation for the 
observed differences in the subcellular localization could be abnormal trafficking of the 
human OATP4C1 protein in the transgenic rat.  
It is not without precedent that antibodies used to detect transporter proteins result 
in controversial findings. For instance while both BXP-9 and BXP-21 are well-validated 
antibodies, ABCG2 was only recently detected in human kidney using BXP-9 (57), but 
not with BXP-21 (143). Similarly, numerous examples can be found in the literature 
demonstrating the cross-reactivity of several P-glycoprotein antibodies including the 
C219 antibody used in this study (144). In fact, close examination of the P-gp staining 
obtained in Figure 4-22 A showed that both membrane and intracellular expression 
pattern. However, the knowledge that P-gp is expressed on the membrane allows for the 
correct interpretation of its expression across the kidney structures. To avoid potential 
misinterpretation of results due to antibody immunoreactivity, we also applied two-
dimensional LC/MS-MS analysis to identify the proteome in BBM and BLM isolated from 
the rat kidney cortex and indirectly validate our Western blot results. Methods for 
separation of the BBM from the BLM have been developed based on the fact that these 
membranes have distinct lipid and carbohydrate compositions, so that their density and 
net charge are different (145). Density gradient centrifugation (146), phase partitioning, 
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differential centrifugation (147), and free flow electrophoresis (148) have all been 
described to separate BBM from BLM. In this study, differential and density gradient 
centrifugation were applied for the separation, and BBM were further purified by 
magnesium precipitation. Some of the most abundant proteins, such as Na+/K+-ATPase 
or rBat, SGLT2, TSC or NKCC2, were detectable in both membrane fractions, showing 
lack of absolute efficiency in the separation of the two membrane fractions. Cross-
contamination between the two fractions was also observed in previous reports using the 
same method (145, 149, 150). However, these proteins were sufficiently enriched in the 
appropriate fraction, suggesting adequate separation of basolateral and apical 
membranes.  In all, the LC-MS/MS analyses detected 81 proteins in both the apical and 
basolateral membranes. Among those, eighteen were either in the SLC or ABC 
transporter families (Figure 4-19 B). Based on the literature, fourteen of these proteins, 
not including Oatp4c1, were enriched or uniquely identified in the appropriate fraction 
(apical or basolateral) and three proteins (ambiguous) were equally present in both 
preparations. Four unique Oatp4c1 sequence peptides were found only in BBM but not 
in BLM. These results are in agreement with the findings from Western blotting and 
immunohistochemical analyses and definitively demonstrate that Oatp4c1 localized at 
the apical membrane in the rat proximal tubule.  
The expression of Oatp4c1 at the apical membrane in the kidney suggests its 
potential role in renal reabsorption of its substrates as other apically expressed organic 
anion transporters (OATs or OATPs) do.  As examples, Oatp1a1 expressed at the apical 
membrane of rat proximal straight tubule in the outer medulla is responsible for renal 
reabsorption of perfluorocarboxylates (PFO) (63, 64). Oatp2a1 localized at the apical 
surface of rat collecting ducts is responsible for renal reabsorption of prostanoids (78). 
OAT4 expressed at the apical membrane in the proximal tubule is involved in E3S and 
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urate reabsorption (97, 98). URAT1 expressed at the apical membrane in the proximal 
tubule plays a key role in urate homeostasis via a renal reabsorption mechanism (99). 
OATP1A2 expressed at the apical membrane in the distal tubule  may participate in the 
saturable reabsorption of MTX (67).  
The upregulation of Oatp4c1 in MG during lactation indicates that Oatp4c1 may 
play a role in determining the final concentrations of endogenous and exogenous 
substances into milk. The apical localization of Oatp4c1 in rat MG was demonstrated by 
immunohistochemical analysis (Figure 4-15) and confirmed further by the distinct 
localization of Oatp4c1 and the basolateral marker E-cadherin, and colocalization of 
Oatp4c1 with the apical marker Abcg2 (Figure 4-18). The apical localization of Oatp4c1 
suggests that it is involved in xenobiotic reuptake from the milk to reduce exposure to 
the suckling infants, or that it functions as a scavenger system, as Pept2 does. Pept2 is 
expressed at the apical membrane in MG and has been suggested to transport the 
hydrolyzed milk protein product, as well as some peptide-like drugs, such as 
cephalosporins, back into the mammary epithelium (23).  
 
C.  Functional characterization of Oatp4c1 in MDCKII-Oatp4c1 cells 
The apical localization of Oatp4c1 in the proximal straight tubule suggests its 
potential role in renal reabsorption of its substrates. Several human OATP4C1 
substrates have been reported, including cardiac glycosides (digoxin, ouabain), thyroid 
hormones (T3, T4), cAMP, MTX, sitagliptin and E3S (79, 109, 110). To explore the 
physiological role of Oatp4c1, several uptake studies and inhibition studies were 
performed in MDCKII-Oatp4c1 cells. In agreement with previous studies with OATP4C1 
(110, 111), we showed that E3S is an Oatp4c1 substrate (Figure 4-23, Figure 4-24 and 
Figure 4-25). Oatp4c1-mediated E3S uptake was inhibited by T4 and enhanced by T3 
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(Figure 4-29 B and D), suggesting that T4 is a substrate/inhibitor and T3 is an enhancer. 
However, a previous report showed that OATP4C1-mediated E3S transport was 
decreased by T3 at pH 7.4 (110). The discrepancies may be attributable to differences 
between the rat Oatp4c1 and human OATP4C1, which share 80.4% homology. It is 
interesting to note that E3S accumulation was significantly higher in the presence of T3 
in both Oatp4c1-expressing and vector-transfected cells (Figure 4-29 A and C). This 
suggests the presence of a T3-inhibitable endogenous transporter involved in E3S efflux 
in the MDCKII cells. 
OATP4C1 has been suggested to possess multiple substrate recognition sites. In a 
previous study it was shown that digoxin does not inhibit OATP4C1-mediated T3 (79) or 
E3S (110) uptake and vice versa, while E3S and T3 have mutual inhibition. Consistent 
with that report (110), our results showed that digoxin and ouabain did not change 
Oatp4c1-mediated E3S uptake, nor did MTX (Figure 4-29). These data provide initial 
evidence that Oatp4c1 possess multiple substrate recognition sites. One interacts with 
E3S/T4, and another with digoxin/ouabain, and possibly MTX. Therefore, to verify 
putative substrates, multiple prototypical substrates recognized by different binding sites 
need to be used for future inhibition studies. In addition to E3S, the capacity of putative 
substrates to inhibit MTX transport was examined. MTX was shown to be an Oatp4c1 
substrate (Figure 4-30). However, neither digoxin nor ouabain inhibited Oatp4c1-
mediated MTX uptake (Figure 4-31 B and D), suggesting that they do not share the 
same binding site. In contrast, Oatp4c1-mediated MTX uptake was inhibited by T3, which 
was suggested to be an enhancer for E3S uptake (Figure 4-29). Both MTX and T3 may 
bind to the same site to modulate Oatp4c1 function, but the affinity of MTX was too low 
to change Oatp4c1-medaited E3S uptake. In addition, MTX accumulation was also 
significantly higher in the presence of T3 in both Oatp4c1-expressing and vector-
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transfected cells (Figure 4-31 A and C). This suggests the presence of a T3-inhibitable 
endogenous transporter involved in MTX efflux in the MDCKII cells. However, the low 
value/percentage of the net MTX uptake (0.2-0.5 pmol/min/mg protein corresponding to 
0.0002-0.0005 %) indicated that Oatp4c1 transported MTX at a low efficiency as 
compared to E3S (~0.074 %). Therefore, additional inhibition studies with digoxin as a 
model substrate and by direct measurement of putative substrates, such as uremic 
toxins, are needed to definitively determine if these are substrates and/or inhibitors of 
Oatp4c1. These studies are necessary so that physiological role of Oatp4c1, as well as 
its function in the renal disposition of drugs and/or their metabolites, can be understood. 
Overall, we demonstrated that Oatp4c1 transports E3S and MTX. Both molecules are 
known to be reabsorbed in the tubules (151, 152), and this process is possibly mediated 
by Oatp4c1. The increased uremic toxin plasma concentrations observed in wild-type 
rats in the 5/6 nephrectomy renal failure model were reduced in OATP4C1 transgenic 
rats (106), consistent with a model of basolateral uptake by OATP4C1 and apical efflux 
by another transporter. However, our data demonstrated that Oatp4c1 was expressed at 
the apical membranes and functions as an uptake transporter, thereby implying a 
function in renal reabsorption, not tubular secretion. Therefore, there may be other 
basolateral uptake or apical efflux transporters involved in renal elimination of uremic 
toxins. Oat1 and Oat3, which are expressed at the basolateral membrane in the proximal 
tubule (91), have been shown to be responsible for indoxyl sulfate and hippuric acid 
uptake from blood into tubular cells (153). Moreover, the down-regulation of Oat1 and 
Oat3 expression in a chronic renal failure model may result in the uremic toxin 
accumulation (154). As for apical efflux transporters, hippuric acid, indoxyl sulfate and 
kynurenic acid have been shown to inhibit MRP4-mediated MTX uptake and ABCG2-
mediated E3S uptake in inverted membrane vesicles (155). Furthermore, ABCG2-
mediated transport is more efficient under acidic conditions (156, 157), which are likely 
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to prevail under normal physiological conditions in the proximal tubules. Thus, impaired 
efflux by an ABC transporter may also provide an explanation for increased uremic toxin 
accumulation in the blood of animals in the renal failure models. Clearly, more studies 
are required to elucidate the role of different transporters in human kidney 
pathophysiology and in the animal models of renal failure. 
The driving force responsible for Oatp4c1 mediated transport is not fully 
understood. Mikkaichi et al. showed that pH did not affect OATP4C1-mediated uptake 
(79), while Leuthold et al. showed that E3S and T3 uptake were significantly higher at 
extracellular pH 6.5 than pH 8.0 in Xenopus laevis oocytes expressing OATP4C1 (111). 
The pH-dependent transport has been also demonstrated in rat Oatp1a1, Oatp1a4, 
Oatp1a5, Oatp1b2 and human OATP1A2, OATP1B1, OATP1B3, OATP2B1, 
OATP3A1_v1, OATP3A2_v2, OATP4A1 (111, 158-160). In this study, we demonstrated 
that Oatp4c1-mediated E3S uptake was pH dependent. In our estimates, Vmax and 
transport uptake clearance (ݒ/ܵ) were 4- and 10-fold higher, respectively, at pH 5.5 than 
at pH 7.4 (Figure 4-25 B, Figure 4-26, Table 4-2). The observed pH-dependent Oatp4c1-
mediated uptake may be a consequence of changed intrinsic transport activity at 
different pH and/or altered ionization state of the substrate molecules and thus different 
substrate-transporter protein interaction. With a  pKa of 2 (156), in our experiments (pH 
4.5, 5.5 and 7.5) the ionization state of E3S is essentially constant. Therefore, any 
changes in E3S uptake from pH 7.4 to 4.5 could be a result of pH gradient as the driving 
force or changes in the protein structure. As shown in Figure 4-27, Oatp4c1-mediated 
E3S uptake reached a plateau with increasing H+, suggesting that H+ plays a role in E3S 
transport, either directly by E3S/H+ cotransport mechanism, or indirectly by E3S/HCO3- 
exchange mechanism. The increasing extracellular H+ concentration leads to a 
conversion of HCO3- and H+ into H2O and CO2, causing an outwardly directed HCO3- 
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gradient across cell membranes. The outwardly HCO3- gradient facilitates the substrate 
uptake, which suggests that Oatp4c1 may be a HCO3- exchanger as are other OATPs 
(Oatp1a1, OATP1B3 and OATP2B1 (111)). Further studies examining substrate uptake 
in HCO3- replete and depleted conditions are needed to confirm a potential organic 
anion/HCO3- exchange mechanism. In addition, the pH in renal proximal tubules of rats 
is acidic (6.68-6.87 (161-164)) and may provide the driving force for Oatp4c1 function. 
Furthermore, pH-dependent changes in the protein structure may also be important for 
substrate transport (111, 156). A conserved histidine amino acid in the third TMD has 
been proposed to be critical for pH dependent transport by OATPs/Oatps. However, this 
histidine is only present in rat and mouse Oatp4c1, but not in human OATP4C1, which 
showed pH-dependent E3S and T4 uptake (111). Therefore, this histidine in the rodent 
proteins may not be important for Oatp4c1-mediated transport. 
Interestingly, the primary amino acid sequence of rat Oatp4c1 and human 
OATP4C1 contain one and two potential ATP binding sites, respectively,  characteristic 
of the Walker A motif found in ABC transporters, but not in OATP family proteins (79). 
Upon investigation, Mikkaichi et al. showed that ATP depletion by sodium azide and 2-
deoxyglucose decreases, but does not significantly affect T3 transport in MDCKII-
OATP4C1 cells (79). Similarly, our results showed that ATP depletion did not affect E3S 
transport in MDCKII-Oatp4c1 cells, suggesting that ATP is not involved in Oatp4c1-
mediated transport (Figure 4-28). In addition, E3S accumulation in Oatp4c1-expressing 
and vector-transfected MDCKII cells were higher under ATP-depleted condition at pH 
5.5 but not at pH 7.4 (Figure 4-28 A), suggesting the presence of an endogenous ATP-
dependent efflux transporter, which has increased transport activity at pH 5.5 in MDCKII 
cells. Interestingly, increased E3S accumulation in Abcg2-expressing and vector-
transfected MDCKII cells was also observed after GF120918 treatment at pH 5.5 but not 
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pH 7.4 (Figure A-1), suggesting the existence of a GF120918-inhibitable endogenous 
efflux transporter, which has increased transport activity at pH 5.5 in MDCKII cells. The 
indicated endogenous transporters may be the same. There are three endogenous ABC 
transporters identified in MDCKII cells: p-glycoprotein, Mrp1 and Mrp2 (165). P-
glycoprotein is inhibitable by GF120918, but there is no evidence that it transports E3S 
(166, 167). Mrp1 can transport E3S, but is not inhibitable by GF120918 (168-170). Mrp2 
can transport E3S, but its inhibition by GF120918 is controversial (43, 165, 167, 169, 
171). Therefore, there may be other GF120918-inhibitable ATP-dependent endogenous 
transporter present in MDCKII cells or these two phenomena are governed by different 
transporters. 
Most of the OATPs/Oatps are bidirectional transporters. However, a previous 
report showed that OATP4C1-mediated T3 transport is unidirectional from outside to 
inside (79). To investigate the transport direction of Oatp4c1, further studies examining 
E3S efflux in E3S pre-loaded cells or examining E3S flux from apical to basolateral or 
from basolateral to apical in a polarized monolayer are needed. 
D.  Creation and validation of human OATP4C1-expressing cell lines 
Although the primary sequence homology between human and rat Oatp4c1 is 
80.4%, it is possible that species differences exist in subcellular localization. Human 
OAT2 and rat Oat2 share 79% homology, but human OAT2 localizes at the basolateral 
membrane of proximal tubules (92), whereas rat Oat2 localizes at the apical surface of 
proximal tubule S3 segments, medullary thick ascending limb of Henle’s loop and the 
collecting ducts (91, 93). To examine the expression and subcellular localization of 
human OATP4C1 in cells and tissues, two antibodies amenable to 
immunohistochemistry, immunofluorescence, and immunoblotting were generated and 
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validated. To study the role of OATP4C1 in drug disposition, two human OATP4C1-
expressing cell lines were generated. The MDCKII cell line was selected because of its 
ability to form a polarized monolayer and tight junctions for directional transport study. 
Sf9 cells were selected because of their higher expression level of recombinant proteins 
and ease of scaling up for substrate screening. The successful transfection in MDCKII 
cells was demonstrated as a distinct band at ~60 kDa in MDCKII-OATP4C1 cells but not 
in MDCKII-pcDNA cells by Western blotting (Figure 4-33 A). The apparent molecular 
weight was lower than the calculated molecular weight (79 kDa) which may be 
attributable to absent glycosylation or misfolded truncated protein. The successful 
transfection was also verified by immunohistochemical analysis showing specific 
membrane localization in OATP4C1-expressing cells, but not in vector-transfected cells. 
The specific staining was abolished when probing with antibody that was pre-absorbed 
with antigen peptide, but some background staining was observed in sections exposed 
to rabbit IgG instead of primary antibody (Figure 4-33 C). As observed in rat Oatp4c1, 
OATP4C1 localized at the apical membrane in MDCKII-OATP4C1 cells (Figure 4-33 D). 
Surface biotinylation assay demonstrated that OATP4C1 was enriched in the apical 
membrane fraction as compared with the basolateral membrane (Figure 4-33 E). 
Although efficient separation between apical and basolateral membrane was 
demonstrated by Na+/K+-ATPase, the membrane fractions may be contaminated with 
cytosol, which contains partially processed or misfolded OATP4C1 in the ER/Golgi 
system. Functional activity of OATP4C1 in MDCKII-OATP4C1 cells was probed with 
ouabain and E3S by uptake studies. A saturable concentration-dependent OATP4C1-
mediated ouabain uptake was observed and the transport parameters were estimated 
(Figure 4-34, Table 4-3). The estimated Km (0.19 ± 0.09 µM) was in the similar range of 
the reported Km (0.38 ± 0.1 µM) (79). In addition, a concentration-dependent OATP4C1-
mediated E3S uptake was observed, despite the concentrations we used were not high 
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enough to show saturation kinetics (Figure 4-35). Further studies with higher 
concentrations are needed to show saturation kinetics and obtain transport parameters. 
These data confirmed that ouabain and E3S were OATP4C1 substrates (79, 110) and 
showed the functional activity of OATP4C1 in MDCKII-OATP4C1 cells, although its 
apparent molecular weight was lower than the calculated one. Collectively, OATP4C1 
expression and function were validated in MDCKII-OATP4C1 cells which can be used to 
investigate the driving force and transport direction of OATP4C1-mediated transport and 
explore the potential substrates and the role of OATP4C1 in drug disposition. 
In addition to MDCKII cells, OATP4C1 was overexpressed in Sf9 cells with a 
baculovirus expression system. The successful infection was demonstrated as a broad 
band at ~60 kDa as observed in MDCKII-OATP4C1 cells (Figure 4-37). The recombinant 
protein expressed in Sf9 cells commonly appears as a deglycosylated form, however, no 
reports indicate any functional consequence of different glycosylation patterns (172, 
173). Functional activity of OATP4C1 in Sf9-OATP4C1 cells was probed with ouabain 
and E3S by vesicular transport assay. Selecting membrane filters with minimal drug 
adsorption is important for this assay. High background adsorption may decrease the 
sensitivity and interfere with data interpretation. This was the case with ouabain studies 
using the OE67 filter membrane. Although the estimated Km (0.18 ± 0.09 µM) of  
OATP4C1-mediated ouabain uptake was comparable with the Km estimated from 
MDCKII-OATP4C1 cells (0.19 ± 0.09 µM) and in the similar range of the reported Km 
(0.38 ± 0.1 µM) (79) (Figure 4-39, Table 4-4), the high background adsorption may 
decrease the sensitivity of the capacity to be inhibited for substrate screening during 
inhibition studies.  The nonspecific adsorption of E3S on RC55 filter membrane was 
relatively low (~0.3%). A concentration-dependent OATP4C1-mediated E3S uptake was 
observed, but the concentrations we used were not high enough to saturate the 
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transporter (Figure 4-40 B). Further studies with higher concentrations are needed to 
show saturation kinetics and obtain transport parameters. The pH effect on OATP4C1-
mediated E3S transport was also examined (Figure 4-41). There was a trend toward 
increasing net uptake with a decrease in pH. Additional studies at more than two pH 
conditions are needed to confirm the pH-dependency of OATP4C1-mediated E3S 
transport. Vesicular transport assay is a good tool to study ATP-dependent transport for 
efflux transporters, but not for uptake transporters such as OATP4C1. Extracellular ATP 
is not able to penetrate into cells and bind to the intracellular ATP-binding site of 
OATP4C1 to function. Therefore, to examine if ATP is the driving force for OATP4C1, 
determining E3S uptake in the presence and absence of a cell-permeable ATP-
analogue, formycin A (174, 175), is needed. Collectively, OATP4C1 expression and 
function were validated in Sf9-OATP4C1 cells and the system can be used to further 
investigate the role of OATP4C1 in drug disposition. 
 
E.  Validation of OATP4C1 expression in human kidney and cancer cells 
OATP4C1/Oatp4c1 was isolated from human/rat kidney (79) and its basolateral 
localization in the renal proximal tubules was determined in the transgenic rat harboring 
human SLCO4C1 and in the rat (79, 106). However, we have definitively demonstrated 
that rat Oatp4c1 localized at the apical membrane in the kidney, and thereby its 
physiological function implies a role in renal reabsorption, not tubular secretion. We also 
attempted to determine OATP4C1 subcellular localization in human kidney by 
immunohistochemical analysis. Despite multiple approaches and efforts, no staining was 
observed using our anti-OATP4C1 antibodies, whereas the quality of tissue specimens 
was verified with MRP4 expression (Figure 4-42) and the amenability of our anti-
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OATP4C1 antibodies in immunohistochemistry was validated in MDCKII-OATP4C1 cells 
(Figure 4-33 C) and in lung tumor specimens (Figure 4-45). It is not without precedent 
that well-validated antibodies failed to detect transporter proteins in tissues which were 
later detected by other antibodies. For instance, ABCG2 was not detected in human 
kidney with BXP-21 (143), but was recently detected with BXP-9 (57). In addition, the 
antibodies used in immunohistochemical analysis of OATP4C1 in human kidney may 
have been degraded because it was performed one year later than that in MDCKII-
OATP4C1 cells and in lung tumor specimens. Further studies with different antibodies or 
performing Western blot analysis on isolation BBM and BLM from human kidney are 
needed to verify the subcellular localization in human kidney. 
Microarray analysis has shown that SLCO4C1 was highly expressed in lung tumor, 
and its expression in lung tumor was 18- and 2- fold higher than in normal lung, and 
normal kidney, respectively (104). SLCO4C1 was also detected in several cancer cell 
lines, including renal carcinoma cells (ACHN, SN12C), ovarian cancer cells (OVCAR-8, 
OVCAR-3), leukemia cells (HL-60, RPMI-8226, CCRF-CEM), lung cancer cells (H322M, 
H23, HOP-62, H460), glioblastoma (SF-539) and breast cancer cells (BT-549) (107). 
The high SLCO4C1 expression in lung tumor was confirmed in non-small cell lung 
cancer cells H1299 and in lung tumor specimens. Our data demonstrated a 20-fold 
increase of SLCO4C1 expression in H1299 cells relative to human kidney (Figure 4-43). 
Further studies need to confirm this message with Western blotting.  
RT-PCR and immunohistochemical analysis were performed in the lung tumor and 
adjacent normal lung tissue specimen isolated from patients. Total RNA isolated from 
formaldehyde-fixed paraffin-embedded (FFPE) slides is typically fragmented and 
chemically modified. During tissue fixation process, formaldehyde reacts with the 
nitrogen atoms of lysine, arginine, and histidine, resulting in extensive cross-linking of 
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the proteins within each cell. Nucleic acids are subsequently trapped and modified by 
extensive protein-protein and protein-nucleic acid crosslinks. Even after protease 
treatment, some of the nucleic acid bases are still crosslinked, which cannot be 
recognized as templates and be amplified by polymerases. During storage, atmospheric 
oxygen, water and light cause nucleic acid degradation and fragmentation over time. 
Samples that have been stored over five years typically yield nucleic acids with only 
~100 nt (176-178). Therefore, successful amplification is limited to small fragments and 
less sensitivities in template detection. Our samples were stored for over 2.5 years so 
that the isolated RNA was possibly fragmented. To prevent false negative interpretation 
from unsuccessful amplification due to fragmented and chemically modified RNA, three 
primers were utilized in RT-PCR analysis. Results from only one of three primers 
demonstrated higher SLCO4C1 expression in the tumor than in the adjacent lung tissue 
in five out of nine patients (Figure 4-44). Two patients with either higher or lower 
SLCO4C1 expression in tumor relative to adjacent normal lung were selected to 
examine OATP4C1 expression by immunohistochemical analysis. All of four patients 
showed stronger OATP4C1 staining in the tumor than in the adjacent normal lung tissue 
(Figure 4-45). The discrepancies from RT-PCR and immunohistochemistry results may 
be due to unsuccessful amplification of the fragmented RNA. Collectively, these data 
demonstrated highly OATP4C1 expression in lung tumor and possibly higher than in 
normal lung. The high OATP4C1 expression in the lung tumor may facilitate the uptake 
of physiological substrates that facilitate tumor cell survival but may also uptake 
anticancer drugs, such as MTX, and these functions may have implications in cancer 
therapy.  Clearly, more studies are required to elucidate the role of OATP4C1 in the 
treatment for lung cancer. 
Copyright © Kuei-Ling Kuo 2012 
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CHAPTER 6 : CONCLUSIONS 
This dissertation focused on validation of the subcellular localization of 
OATP4C1/Oatp4c1 in in vitro models and in human/rat tissues and on its transport 
characteristics. Multiple antibodies amenable to immunohistochemistry, 
immunofluorescence, and immunoblotting were developed and validated with 
OATP4C1/Oatp4c1-expressing in vitro models. The expression of Slco4c1/Oatp4c1 in 
Oatp4c1-expressing MDCKII cells was increased with sodium butyrate or blasticidin 
treatment, but was not changed with glycerol or MG132 treatment. Simvastatin 
enhanced Oatp4c1 expression only at the mRNA level, but not at the protein level. A 
single clone with highest Oatp4c1 expression (c94) was obtained by serial dilution 
method. The effect of blasticidin on increasing Oatp4c1 expression was negligible when 
co-treating sodium butyrate and blasticidin in c94 cells. Therefore, for in vitro functional 
studies, c94 cells were first treated with sodium butyrate to induce Oatp4c1 expression.  
Oatp4c1 expression in rat kidney was increased with age, while it was not detected 
in rat liver at any age. Higher Slco4c1/Oatp4c1 expression was observed in female rat 
kidney as compared with males. To determine the subcellular localization of Oatp4c1 in 
the in vitro models and in rat tissues, a comprehensive approach was undertaken, and 
these studies definitively demonstrated that Oatp4c1 is expressed at the apical 
membrane in the rat proximal tubule and mammary epithelium. Our approach included a 
variety of complementary methods to verify this observation. Western blotting 
demonstrated that the antibody used recognized a protein of appropriate molecular 
weight. Immunofluorescence and immunohistochemical analysis revealed that the 
protein localizes at the apical membrane of polarized epithelium in vitro (Oatp4c1-
expressing MDCKII, LLC-PK1 cells) and in vivo (rat kidney, MG). The 
immunohistochemistry results were verified with four different antibodies, which were 
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raised against unique C- and N-terminal peptides, and also confirmed by double 
immunofluorescence staining with apical or basolateral markers. In addition, biochemical 
separation of apical and basolateral membranes from polarized cells in vitro and 
proximal rat kidney tubules confirmed the location of Oatp4c1 at the brush border 
membranes by Western blot and proteomic analyses. Furthermore, the proteomic 
analyses provide additional validation for the Oatp4c1 antibody specificity. In addition, 
double immunofluorescence staining and immunohistochemical analysis showed that 
Oatp4c1 localized in the proximal straight tubule (S3 segment) in the juxtamedullary 
cortex, and colocalized with P-gp and Abcg2, but not with Mrp4.  
The apical localization of rat Oatp4c1 in the kidney suggests its potential role in 
tubular reabsorption of its substrates. Although we did not perform extensive studies to 
identify potential Oatp4c1 substrates, we demonstrated that most human OATP4C1 
substrates were rat Oatp4c1 substrates, including E3S, MTX and possibly T4 (79, 110). 
T3 was an enhancer for Oatp4c1-mediated E3S uptake, but was an inhibitor for Oatp4c1-
mediated MTX uptake. This suggests that T3 and MTX shared the same binding site 
while the affinity of MTX was too low to change Oatp4c1-mediated E3S uptake. In 
accord with the previous finding of OATP4C1 (110), ouabain and digoxin did not inhibit 
Oatp4c1-mediated E3S uptake, which provides corroborating evidence that Oatp4c1 
possesses multiple binding sites. In addition, previously purported uremic toxin 
substrates failed to inhibit Oatp4c1-mediated E3S uptake, suggesting that they were not 
substrates or that they interact with a different binding site. The Oatp4c1-mediated E3S 
uptake was ATP-independent and pH-dependent, suggesting that the pH gradient is the 
driving force for Oatp4c1-mediated transport. The increased E3S transport activity at 
acidic extracellular pH was ascribed to the increased maximum transport rate (Vmax). In 
addition, our data indicated the presence of an ATP-dependent and/or GF120918-
 157 
 
inhibitable endogenous E3S efflux transporter with increased transport activity at acidic 
pH in MDCKII cells. 
In accord with previous microarray data demonstrating that human SLCO4C1 
expression was upregulated during lactation, rat Slco4c1/Oatp4c1 expression was 
increased in lactating MG as compared with non-lactating MG, indicating a potential role 
of Oatp4c1 in endogenous or exogenous substances transport into the milk. The apical 
localization of Oatp4c1 suggests that it is involved in reuptake of xenobiotic from the 
milk, resulting in their reduced exposure to the suckling infants, or that it functions as a 
scavenger system. 
Human OATP4C1 was demonstrated to localize at the apical membrane in the in 
vitro model (MDCKII cells). However, the determination of the subcellular localization of 
OATP4C1 in human kidney was not possible, even though that the antibody we 
developed was amenable for immunohistochemistry and the quality of tissue specimens 
was verified. Further studies with different antibodies or performing Western blot 
analysis on isolation BBM and BLM from human kidney are needed to verify the 
subcellular localization in human kidney. Uptake study in MDCKII-OATP4C1 cells and 
vesicular transport study in Sf9-OATP4C1 cells confirmed that ouabain and E3S were 
OATP4C1 substrates (79, 110). In addition, our data demonstrated that OATP4C1 was 
highly expressed in lung cancer cells (H1299) and lung tumor specimens by RT-PCR 
and immunohistochemical analysis, respectively.  
For future studies, generating OATP4C1-knockout mice will be useful to gain more 
insight of the physiological role of OATP4C1 and its impact on the pharmacokinetics of 
drugs. Metabolomic analysis of urine from OATP4C1-knockout mice will be applied in an 
attempt to identify endogenous substrates without prior knowledge of transport studies. 
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In addition, to determine the role of OATP4C1 in lung cancer cells, cell viability will be 
first examined in the OATP4C1-transfected cells or in the SLCO4C1 siRNA-silencing 
lung cancer cells (H1299) with treatment of anticancer drugs which are also OATP4C1 
substrates, such as MTX. To examine if OATP4C1 confers cell death through apoptotic 
pathways, the apoptotic outcome will be examined by terminal deoxynucleotidyl 
transferase-mediated deoxyuridine triphosphate nick end-labeling (TUNEL) assay or 
Annexin V assay. 
Overall, the apical localization of Oatp4c1 in the rat kidney and MG is a highly 
novel finding of this study, and thereby implies its physiological role in renal 
reabsorption, not tubular secretion. Further studies to identify Oatp4c1 substrates will 
explore the physiological role and significance of Oatp4c1.  
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Kuei-Ling Kuo 2012 
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APPENDICES 
Appendix 1: Lists of abbreviations 
CFTR Cystic fibrosis transmembrane conductance regulator protein  
ER Endoplasmic reticulum 
AB From apical to basolateral 
ABC ATP-binding cassette  
AE Apical efflux  
AhR Aryl hydrocarbon receptors 
AIC Akaike Information Criterion  
ANOVA Analysis of variance 
AP Apical 
AQP1 Aquaporin 1 
ATP Adenosine triphosphate 
AU Apical uptake  
BA  From basolateral to apical 
BBM Brush-border membrane 
BCRP Breast cancer resistance protein 
BL Basolateral 
BLM Basolateral membrane 
Bsd Blasticidin 
C Substrate concentration 
c94 Clone 94 
cAMP Cyclic adenosine monophosphate 
cGMP Cyclic guanosine monophosphate 
D Diffusion 
DMEM Dulbecco's modified Eagle's medium 
dNTP Deoxyribonucleotide triphosphate 
DTT Dithiothreitol 
E3S Estrone-3-sulfate  
FACS Fluorescence-activated cell sorting  
GF GF120918 
GFP Green fluorescent protein  
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HMG-CoA Hydroxymethylglutaryl–CoA  
HRP Horseradish peroxidase 
IgG Immunoglobulin G 
Km Michaelis-Menten constant 
LMEC Lactating mammary epithelial cells 
MDCKII Madin-Darby canine kidney II  
MDR Multidrug resistance protein  
MEC Non-lactating mammary epithelial cells 
MEM Minimum essential medium  
MG Mammary gland 
MG132 N-benzoyloxycarbonyl (Z)-Leu-Leu-leucinal  
MRP Multidrug resistance-associated protein 
MTX Methotrexate 
n Hill slope 
NaB Sodium butyrate 
NBD Nucleotide binding domains  
NHERF1 Na+/H+ exchanger regulatory factor 1 
NSAIDs Non-steroidal anti-inflammatory drugs 
OAT Organic anion transporter 
OATP Organic anion transporting polypeptide  
OCT Organic cation transporter 
OCTN Zwitterion/cation transporters 
PAH Para-aminohippurate 
PC Paracellular transport  
PEPT Peptide transporter 
PFO Perfluorocarboxylates 
P-gp P-glycoprotein  
PS Permeability-surface area product  
RT-PCR Real-time polymerase chain reaction 
S50 Michaelis-Menten constant equivalent 
SC Spectral counts 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
Sim Simvastatin 
SLC Solute carrier 
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SLCO Solute carrier organic anion transporter 
T3 Triiodothyronine 
T4 Thyroxine 
TEER Transepithelial electrical resistance 
Tmax Maximum uptake velocity 
TMD Transmembrane domains 
URAT Urate transporter 
V Initial uptake velocity 
Vmax Maximum transport rate 
XRE Xenobiotic-responsive element 
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Appendix 2: Identification of Abcg2 as a potential transporter of uremic toxins 
Introduction:  
OATP4C1 has been proposed to be involved in the elimination of uremic toxins 
and its expression in a transgenic rat model was shown to decrease the concentration of 
uremic toxins in a 5/6 nephrectomy renal failure model (106). However, we 
demonstrated that Oatp4c1 is expressed at the apical membrane in the kidney, which 
suggests that Oatp4c1 is involved in renal reabsorption but not tubular secretion as 
previously suggested (79, 106, 110). Lack of E3S transport inhibition by uremic toxins 
led us to probe the interaction of uremic toxins with other transporters as a way to 
reconcile previous observations in a renal failure model (106). Recent evidence 
suggests that human ABCG2 and MRP4 may also transport uremic toxins (155). 
Therefore, we hypothesized that impaired uremic toxin clearance could result from 
impaired transport by an efflux pump in the renal tubules. This hypothesis is consistent 
with previous work demonstrating that the function of ABCG2 is less efficient at pH 7.4 
than in acidic pH, while the urine pH ranges in the acidic range under normal conditions, 
but can be basic (> pH 7) under pathological situations. (156, 157). In this study, the 
capacity of uremic toxins to inhibit Abcg2 –mediated Hoechst 33342 efflux was 
determined by at pH 5.5 and pH 7.4. 
 
Methods:  
Rat Abcg2- and pcDNA3.1 (vector)-transfected MDCKII cells generously provided 
by Dr. McNamara’s lab (13) were grown in MEM supplemented with 5% fetal bovine 
serum, 100 U/ml penicillin, 100 µg/ml streptomycin, and 500 µg/ml geneticin. 
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Functional activity of Abcg2 in MDCKII-Abcg2 cells was preliminary assessed by 
[3H]-E3S uptake studies in the presence and absence of 10 µM GF120918 at pH 5.5 and 
pH 7.4. The procedures were the same as described in Chapter 3 -D -1 [3H]-E3S uptake 
and inhibition studies.  
Functional activity of Abcg2 in MDCKII-Abcg2 cells was also assessed by Hoechst 
33342 efflux. MDCKII-pcDNA and MDCKII-Abcg2 cells were grown in 6-well plates (1 x 
106 cells/well) and allowed to become confluent overnight. Cells were washed once and 
pre-incubated in OptiMEM in the presence and absence of 10 µM GF120918, 2 mM 
MTX, and 1 mM uremic toxins (kynurenic acid, indoxyl sulfate, hippuric acid and trans-
aconitic acid) for 15 min and during the duration of the Hoechst 33342 incubation.  The 
experiment was initiated by incubating cells with 2 µM Hoechst 33342 for 45 min at 
37°C. Cells were washed twice with ice-cold PBS and lysed with 500 µl of 10 mM 
HEPES (pH 7.4) containing 0.2% SDS for 30 min. Lysates (200 µl) were transferred to a 
96-well plate and the fluorescence of Hoechst 33342 was determined in a microplate 
reader (SpectraMax M5, Molecular Devices, Sunnyvale, CA) at excitation and emission 
wavelengths of 360 and 460 nm, respectively. Protein concentration in cell lysates was 
measured by BCA Protein Assay Kit, and used to normalize the fluorescence readings.  
 
Results and Discussion: 
To evaluate functional activity of Abcg2 in MDCKII-Abcg2 cells, the uptake studies 
of ABCG2 substrate, E3S (179), was performed in the presence and absence of Abcg2 
inhibitor GF120918 (13) at pH 5.5 and pH 7.4 . As shown in Figure A-1, there was no 
significant difference between [3H]-E3S accumulation in MDCKII-Abcg2 and MDCKII-
pcDNA cells at both pH values, suggesting that E3S was not a rat Abcg2 substrate or 
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E3S intracellular concentration was not high enough to show a significant Abcg2-
mediated transport. In addition, [3H]-E3S accumulation in both MDCKII-Abcg2 and 
MDCKII-pcDNA cells were substantially higher in the presence of GF120918 at pH 5.5 
but not at pH 7.4, suggesting the presence of a GF120918-inhibitable endogenous efflux 
transporter in MDCKII cells. This endogenous efflux transporter may interfere Abcg2-
mediated E3S transport. 
Therefore, another ABCG2 substrate, Hoechst 33342 (180), was then used to 
access Abcg2 function. Intracellular fluorescence after 45 min incubation with Hoechst 
33342 was determined in the absence and presence of GF120918 at pH 5.5 and 7.4 
(Figure A-2 A). Abcg2-mediated Hoechst 33342 efflux was calculated by subtracting the 
accumulation in Abcg2-expressing cells from that in vector-transfected cells. Transport 
specificity was demonstrated by GF120918 inhibition. As shown in Figure A-2 B, Abcg2-
mediated Hoechst 33342 effluxes were both reduced with GF120918 addition at both pH 
values. At pH 7.4, the decreased net accumulation was resulted from the increased 
accumulation in MDCKII-Abcg2 cells as GF120918 inhibiting Abcg2-mediated efflux, 
However, at pH 5.5, the decreased net accumulation was resulted from the decreased 
accumulation in MDCKII-pcDNA cells while the accumulation in MDCKII-Abcg2 cells was 
not changed (Figure A-2 A). The decreased accumulation in MDCKII-pcDNA cells in the 
presence of GF120918 was probably because of the presence of a GF120918-
inhibitable endogenous uptake transporter functioned at pH 5.5. In addition, inconsistent 
with previous reports showing ABCG2 function was less efficient at pH 7.4 than in acidic 
pH (156, 157). Abcg2-mediated Hoechst 33342 efflux was higher at pH 7.4 than at pH 
5.5. The discrepancy was probably because of different assay system. Inverted 
membrane vesicles were used in previous reports, whereas intact cells were used in this 
study which required the substrates penetrated into the cells before being efflux. In 
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addition, the endogenous uptake transporter functioned at pH 5.5 may also interfere 
Abcg2-mediated Hoechst 33342 transport.  
The capacity of uremic toxins to inhibit Hoechst 33342 efflux was also examined. 
Among the uremic toxins tested, indoxyl sulfate and trans-aconitic acid inhibited Abcg2-
mediated Hoechst 33342 efflux at pH 5.5, but not at pH 7.4.  This suggests that Abcg2 
may transport these uremic toxins only at normal condition (acidic pH) but not at 
pathological conditions (pH >7), and therefore, the uremic toxin plasma concentrations is 
increased in renal failure model (106). With a predicted pKa of 17.0, the ionization states 
of indoxyl sulfate at pH 5.5 and 7.4 are constant. Therefore, the pH-dependent inhibitory 
effect was resulted from the drug-protein interactions. However, the predicted pKa for 
trans-aconitic acid is 2.8 and 4.46. The unionization ratio is 8.4% and 0.1% at pH 5.5 
and pH 7.4, respectively, indicating that the unionized form of 1 mM trans-aconitic acid is 
84 μM and 1 μM at pH 5.5 and pH 7.4, respectively. Therefore, the pH-dependent 
inhibitory effect was probably resulted from different amount of unionized drug diffused 
into the cells. More studies using inverted membrane vesicles or different model 
substrates were required to elucidate the role of Abcg2 or other renal transporters in 
uremic toxins disposition. 
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Figure A-1: The effect of GF120918 on [3H]-E3S uptake in MDCKII-Abcg2 cells at 
pH 5.5 and 7.4.  
MDCKII-pcDNA and MDCKII-Abcg2 cells were incubated with 5 µM [3H]-E3S in the 
absence and presence of 10 µM GF120918 for 15 min at pH 5.5 and 7.4. Each bar 
represents the mean ± S.D. of triplicate determinations from one representative 
experiment. 
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Figure A-2: Inhibition of Hoechst 33342 efflux by various compounds in MDCKII-
Abcg2 cells at pH 5.5 and 7.4.  
MDCKII-pcDNA and MDCKII-Abcg2 cells were incubated with 2 µM Hoechst 33342 in 
the absence (control) and presence of 10 µM GF120918 (GF), 2 mM MTX, and 1 mM 
uremic toxins (kynurenic acid, indoxyl sulfate, hippuric acid and trans-aconitic acid) for 
45 min at pH5.5 and 7.4. Abcg2-mediated efflux was calculated by subtracting the 
accumulation in Abcg2-expressing cells from that in vector-transfected cells (B, D). Each 
bar represents the mean ± S.D. of triplicate determinations from one representative 
experiment. Statistical analysis was performed by two-way ANOVA with Bonferroni post-
hoc test comparing with control.* p<0.05, significant differences from control.  
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Appendix 3: Creation and validation of human ABCG2-expressing Sf9 cells 
Introduction: 
ABCG2 also known as breast cancer resistance protein (BCRP) is a half-
transporter containing only 6 TMD, and forms a homodimer to acquire transport activity. 
ABCG2 is expressed at the apical membrane in multiple tissues, including liver, 
intestine, placenta, blood-brain-barrier, lung, mammary gland and kidney proximal tubule 
(57, 58). It limits the entry of its substrates into the tissues and facilitates the elimination 
of its substrates to the bile and urine. In addition, it is important in nutrients as well as 
xenobiotic accumulation in the milk (10). ABCG2 transports a wide range of substrates 
including uncharged or amphiphilic compounds, such as MTX, mitoxantrone and 
cimetidine (12). To study the role of ABCG2 in drug disposition, ABCG2-expressing Sf9 
cells were developed for substrate screening. 
 
Methods: 
pFastBac1-ABCG2 plasmid vector construct (Figure A-3) was generated previously 
in our lab. Detail procedures for pFastBac1-ABCG2 plasmid vector construct were as 
described in Chapter 3-E-2-i.  Plasmid vector construction. Briefly, ABCG2 was cloned 
into pFastBac1 and recombined in MAX Efficiency® DH10BacTM competent E. Coli. 
containing baculovirus genome. The bacmid DNA from positive transformants was 
verified by PCR with M13 forward (5’-GTTTTCCCAGTCACGAC-3’) and M13 reverse (5’-
CAGGAAACAGCTATGAC-3’) primers and agarose gel electrophoresis. 
 
  
 169 
 
 
Figure A-3: pFastBac1-ABCG2 plasmid construct. 
 
Procedures for Sf9 cell culture, transfection, infection, membrane vesicle 
preparation and vesicular transport assay were the same as described in Chapter 3-E-2 
Spodoptera frugiperda (Sf9) insect cells. The successful infection of AGCG2 was 
detected with 0.25 µg/ml BXP-21. 
MDCKII-ABCG2 c40 cells generously provided by Dr. McNamara’s lab (30) were 
grown in MEM supplemented with 5% fetal bovine serum, 100 U/ml penicillin, 100 µg/ml 
streptomycin, and 500 µg/ml geneticin. 
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Results and Discussion: 
pFastBac1-ABCG2 plasmid vector construct and recombinant bacmid DNA were 
generated previously in our lab.  Recombinant bacmids were verified by PCR with M13 
forward and M13 reverse primers (Figure A-4). 
The recombinant bacmids (pFastBac1-ABCG2 and pFastBac1) were transfected 
into Sf9 cells, and the supernatant containing recombinant baculovirus stock was 
harvested after 48 hr. The viral stock was amplified by infecting a large volume of Sf9 
cell suspensions. The infected Sf9 cells were centrifuged to collect cell pellets for 
membrane vesicle preparation. Successful infection was validated by Western blotting 
for ABCG2 expression in the membrane vesicles. As shown in Figure A-5, ABCG2 was 
detected in Sf9-ABCG2 membrane vesicles but not in Sf9-vector. In addition, in accord 
with previous reports (172), as compared with the protein band in MDCKII-ABCG2 c40 
cells with PNGase F deglycosylation, the overexpressed ABCG2 in Sf9 cells was 
unglycosylated. 
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Figure A-4: Validation of the pFastBac1-ABCG2 plasmid construct.  
PCR product of pFastBac1-ABCG2 with M13 forward and M13 reverse primers by 
agarose gel electrophoresis. 
 
 
Figure A-5: Validation of ABCG2 expression in ABCG2-expressing Sf9 membrane 
vesicles.  
Western blot analysis for ABCG2 expression in 1 μg MDCKII-ABCG2 c40 cell membrane 
fractions, Sf9-vector and Sf9-ABCG2 membrane vesicles. ABCG2 was detected with 
BXP-21. PNGase F was used for deglycosylation. 
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Functional activity of ABCG2 in Sf9-ABCG2 membrane vesicles was validated with 
MTX by vesicular transport assay. MTX transport kinetics were determined by [3H]-MTX 
uptake for concentrations ranging from 500 to 3000 µM at 5 min. ATP-dependent uptake 
was calculated by subtracting values obtained in the presence of AMP from those in the 
presence of ATP. The difference between ATP-dependent uptake in Sf9-vector and in 
Sf9-ABCG2 membrane vesicles was ABCG2-mediated uptake. As shown in Figure A-6, 
ATP-dependent MTX uptake in Sf9-ABCG2 membrane vesicles was saturable, while 
that in Sf9-vector membrane vesicle was a flat line. It confirmed that MTX is an ABCG2 
substrate (181). A sigmoid-Emax was fitted to the net ABCG2 transport data. The 
transport kinetic parameters were estimated by nonlinear regression (Table A-1). The 
estimated Km (1191 ± 380.7) was comparable with the reported Km (~1000 µM) (181). In 
addition, the estimated Hill coefficient value of 1.8 suggests positive transport 
cooperativity. The transport specificity was demonstrated by ABCG2 inhibitor, 
GF120918, inhibition (182). As shown in Figure A-7, ATP-dependent MTX uptake in Sf9-
ABCG2 membrane vesicles was substantially reduced in the presence of GF120918, 
while that in Sf9-vector membrane vesicles was unaltered. Collectively, the expression 
and functional activity of ABCG2 in Sf9-ABCG2 membrane vesicles were validated, and 
the membrane vesicles can be used for substrate screening to study the role of ABCG2 
in drug disposition.  
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Figure A-6: Concentration-dependent ABCG2-mediated [3H]-MTX transport in Sf9-
ABCG2 membrane vesicles at pH 7.4.  
[3H]-MTX accumulation (5 min) in Sf9-vector and Sf9-ABCG2 membrane vesicles. ATP-
dependent uptake was calculated by subtracting values obtained in the presence of 
AMP from those in the presence of ATP. ABCG2-mediated uptake was the difference 
between ATP-dependent uptake in Sf9-vector and in Sf9-ABCG2 membrane vesicles. 
Each point represents the mean ± S.D. of triplicate determinations from one 
representative experiment. 
 
Table A-1: Transport kinetic parameters of ABCG2-mediated MTX uptake at pH 7.4 
(mean ± S.E.).  
The transport parameters were estimated by GraphPad. 
Tmax (pmol/min/mg protein) 994.8 ± 220.7 
S50 (µM) 1191 ± 380.7 
Hill Slope 1.8 ± 0.7 
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Figure A-7: Inhibition of GF120918 on ATP-dependent [3H]-MTX uptake in Sf9-
ABCG2 membrane vesicles at pH 7.4.  
ATP-dependent 500 μM [3H]-MTX uptake (5 min) were determined in the absence and 
presence of 100 µM GF120918 (GF) in Sf9-ABCG2 and Sf9-vector membrane vesicles 
at pH 7.4. ATP-dependent uptake was calculated by subtracting values obtained in the 
presence of AMP from those in the presence of ATP. Each bar represents the mean ± 
S.D. of triplicate determinations from one representative experiment. 
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Appendix 4: Development of a mathematical model to simulate the transport of 
common substrate of apical uptake and apical efflux transporters across the renal 
proximal tubular cells 
Introduction 
Double immunofluorescence staining showed that Oatp4c1, as an uptake 
transporter, were colocalized with efflux transporters, Abcg2 and p-glycoprotein, at the 
apical membrane in rat proximal straight tubule (Figure 4-22 D). For their common 
substrates, such as digoxin (Oatp4c1 and p-glycoprotein substrate (183)) and E3S 
(Oatp4c1 and Abcg2 substrate (179)), a three compartment mathematical model was 
developed to simulate their transport in the renal proximal tubular cells.  
Methods 
This three compartment system incorporates four transport processes including 
apical uptake (AU), apical efflux (AE), paracellular transport between the cells (PC), 
passive diffusion across the apical and basolateral membranes in proximal tubule 
epithelial cell (D) (Figure A-8). AU and AE were calculated saturable Michaelis-Menten 
type transport kinetics. 
 
Figure A-8: A schematic representation of the transport model for flux across 
renal proximal tubule monolayer. 
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Passive diffusion is assumed to be equal for the apical and basolateral 
membranes, and the drug transfer across basolateral membrane is only by passive 
diffusion. The kinetic model was simulated using STELLA (Isee systems, Lebanon, NH) 
(Figure A-9).  
 
Figure A-9: Schematic representation of the mathematical model for flux across 
renal proximal tubule monolayer built by STELLA.  
Squares, circles and “pipes” represent compartments, parameters, and transport 
processes, respectively.  Blue arrows demonstrate the transport direction. Red arrows 
signify the determinants of each compartment and transport processes.  
 
The equations and parameter settings were as follows: 
ܣሺݐሻ ൌ ܣሺݐ െ ݀ݐሻ ൅ ሺܦ஺஼ ൅ ܣܧ ൅ ܲܥ െ ܣܷሻ݀ݐ       Equation A-1   
ܥሺݐሻ ൌ ܥሺݐ െ ݀ݐሻ ൅ ሺܦ஻஼ ൅ ܣܷ െ ܦ஺஼ െ ܣܧሻ݀ݐ          Equation A-2   
ܤሺݐሻ ൌ ܤሺݐ െ ݀ݐሻ ൅ ሺെܦ஻஼ െ ܲܥሻ݀ݐ         Equation A-3           
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ܣܷ ൌ ܲܵܣܷ ൈ ܥ஺ ൌ ௏೘ೌೣ௎ൈ஼ಲ௄೘௎ା஼ಲ ; ܣܧ ൌ ܲܵܣܧ ൈ ܥ஼ ൌ
௏೘ೌೣாൈ஼಴
௄೘ாା஼಴ ;  
VmaxU = VmaxE = 15000 pmol/hr, KmU = KmE = 30 μM           Equation A-4    
ܦ஺஼ ൌ ܲܵܦሺܥ஼ െ ܥ஺ሻ;	ܦ஻஼ ൌ ܲܵܦሺܥ஻ െ ܥ஼ሻ; PSD = 100 ml/hr    Equation A-5  
ܲܥ ൌ ܲܵܲܥሺܥ஻ െ ܥ஺ሻ; PSPC = 1 ml/hr       Equation A-6   
ܥ஺ ൌ ܣ ஺ܸ;⁄ 	ܥ஻ ൌ ܤ ஻ܸ; 	ܥ஼ ൌ ܥ ஼ܸ;⁄⁄  VA = VB = 2000 μl; VC = 20 μl    Equation A-7 
where A, B, and C represent apical (urine), basolateral (blood), and cellular (proximal 
tubule epithelial cells) compartments, respectively; CA, CB, and CC, represent the 
substrate concentrations in each compartment; and VA, VB, and VC, represent the 
volume of each compartment. AU, AE DAC, DBC, PC represent apical uptake, apical 
efflux, passive diffusion across apical membrane, passive diffusion across basolateral 
membrane, and paracellular transport between the cells, respectively. PSAU, PSE, PSD, 
PSPC represent permeability-surface area product (PS) of apical uptake, apical efflux, 
passive diffusion, paracellular transport, respectively. KmU, VmaxU, KmE, VmaxE represent 
the Km and Vmax of uptake and efflux transporters, respectively. 
The flux from BA and AB at 10 min (initial rate) were simulated for the 
concentrations ranging from 0.1 to 100000 μM. PS were calculated by the following 
equation: 
 ܲܵ ൌ ஺்ൈ஼బൈௌ஺             Equation A-8 
where A, T, C0, and SA represents amount of substrate in recipient compartment (pmol), 
time (hr), initial concentration (μM) and surface area (cm2), respectively. The Km and 
Vmax of uptake transporter and efflux transporter were changed one at a time to evaluate 
the effect of each parameter on transport direction. 
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Results and Discussion 
In this model, four transport processes were included: apical uptake (AU), apical 
efflux (AE), passive diffusion across the apical and basolateral membrane (DAC, DBC), 
and paracellular transport between the cells (PC). The substrate flux in each 
compartment and the initial rate of BA and AB are derived as follows:  
ௗ௑ಲ
ௗ௧ ൌ ܲܵ஽ሺܥ௖ െ ܥ஺ሻ െ ܲ ஺ܵ௎ܥ஺ ൅ ܲ ஺ܵாܥ஼ ൅ ܲܵ௉஼ሺܥ஻ െ ܥ஺ሻ      Equation A-9 
ௗ௑ಳ
ௗ௧ ൌ ܲܵ஽ሺܥ௖ െ ܥ஻ሻ ൅ ܲܵ௉஼ሺܥ஺ െ ܥ஻ሻ      Equation A-10 
ௗ௑಴
ௗ௧ ൌ ܲܵ஽ሺܥ஺ െ ܥ஼ሻ ൅ ܲܵ஽ሺܥ஻ െ ܥ஼ሻ ൅ ܲܵ஺௎ܥ஺ െ ܲ ஺ܵாܥ஼   Equation A-11  
Initial rate BA (represents tubular secretion): assuming initial substrate concentration 
in apical compartment is zero (CA = 0), Equation 5-1 becomes: 
ௗ௑ಲ,ಳ→ಲ
ௗ௧ ൌ ܲܵ஽ܥ௖ ൅ ܲ ஺ܵாܥ஼ ൅ ܲܵ௉஼ܥ஻      Equation A-12 
and rapid equilibration between the B and C compartments such that dXC/dt = 0, 
Equation A-11 can be rearranged as: 
ܥ஼ ൌ ௉ௌವ஼ಳଶ௉ௌವା௉ௌಲಶ            Equation A-13 
Substitution of Equation A-13 into Equation A-12 yields: 
ௗ௑ಲ,ಳ→ಲ
ௗ௧ ൌ ܥ஻ ቂ
௉ௌವሺ௉ௌವା௉ௌಲಶሻ
ଶ௉ௌವା௉ௌಲಶ ൅ ܲܵ௉஼ቃ        Equation A-14  
The permeability surface area product (PS) becomes: 
ܲܵ஻→஺ ൌ
೏೉ಲ,ಳ→ಲ
೏೟
஼ಳ஺௥௘௔ ൌ
௉ௌವሺ௉ௌವା௉ௌಲಶሻ
ଶ௉ௌವା௉ௌಲಶ ൅ ܲܵ௉஼ ൌ
௉ௌವା௉ௌಲಶ
ଶାುೄಲಶುೄವ
൅ ௉ௌು಴௉ௌವ    Equation A-15  
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while ܲ ஺ܵா ൌ ௏೘ೌೣா௄೘ாା஼೎  
 
Initial rate AB (represents renal reabsorption): assuming initial substrate concentration 
in basolateral compartment is zero (CB = 0), Equation A-10 becomes: 
ௗ௑ಳ,ಲ→ಳ
ௗ௧ ൌ ܲܵ஽ܥ௖ ൅ ܲܵ௉஼ܥ஺       Equation A-16  
and rapid equilibration between the A and C compartments such that dXC/dt = 0, 
Equation A-11 can be rearranged as: 
ܥ஼ ൌ ஼ಲሺ௉ௌವା௉ௌಲೆሻଶ௉ௌವା௉ௌಲಶ         Equation A-17  
Substitution of Equation A-13 into Equation A-12 yields: 
ௗ௑ಳ,ಲ→ಳ
ௗ௧ ൌ ܥ஺ ቂ
௉ௌವሺ௉ௌವା௉ௌಲೆሻ
ଶ௉ௌವା௉ௌಲಶ ൅ ܲܵ௉஼ቃ      Equation A-18  
The PS becomes: 
ܲ ஺ܵ→஻ ൌ
೏೉ಳ,ಲ→ಳ
೏೟
஼ಲ஺௥௘௔ ൌ
௉ௌವሺ௉ௌವା௉ௌಲೆሻ
ଶ௉ௌವା௉ௌಲಶ ൅ ܲܵ௉஼ ൌ
௉ௌವା௉ௌಲೆ
ଶାುೄಲಶುೄವ
൅ ௉ௌು಴௉ௌವ    Equation A-19   
while ܲ ஺ܵா ൌ ௏೘ೌೣா௄೘ாା஼೎ , ܲ ஺ܵ௎ ൌ
௏೘ೌೣ௎
௄೘௎ା஼ಲ 
As shown in Equation A-15, apical uptake (AU) transporter played no role in 
PSBA. This was demonstrated in Figure A-10 D and Figure A-11 D showing that the 
changes of Km or Vmax of AU transporter did not alter PSBA. Equation 1-11 showed 
PSAB was influenced by both PSAU and PSAE (panels E in Figure A-10, Figure A-11, 
Figure A-12 and Figure A-13), and PSmax,AB was more sensitive to PSAU than PSAE, 
because the effect of PSAE is attenuated by of its scaling by PSD (Equation A-19).  
Intuitively, transporter mediated flux of a substrate is determined by the 
predominant intrinsic clearance (Vmax/Km) of the AU or AE transporters. Flux from AB 
 180 
 
and BA is neutralized if the intrinsic transporter clearances of AU and AE transporters 
are the same. Flux from AB is predominant if the intrinsic transporter clearance of the 
AU transporter is higher than that of AE transporter and vice versa. However, that is only 
true at low concentrations (panels A, B and C in Figure A-10, Figure A-11, Figure A-12 
and Figure A-13). As shown in Equation A-15 and Equation A-19, the only difference 
between PSBA and PSAB is the numerator, PSD+PSAE and PSD+PSAU, respectively. At 
low concentrations (CC << KmE or CA << KmU), PSAE and PSAU approximately equals to 
intrinsic clearance (Vmax/Km). Therefore, the predominance of PSBA or PSAB is 
determined by the intrinsic clearance (Vmax/Km) of the AU or AE transporters. At 
concentration near the Km, CC and CA is unignorable. For PSBA, substrates cross 
basolateral membrane into the cells by passive diffusion down the concentration 
gradient. Therefore, CC is lower than the donor concentration, and, supposedly, lower 
than CA which is the donor concentration for PSAB. When the Km or Vmax of AU and AE 
transporters are equal, PSAE is thereby higher than PSAU, and PSBA is higher than 
PSAB (panels B in Figure A-10, Figure A-11, Figure A-12 and Figure A-13). At high 
concentrations, transporters become saturated, and PSBA and PSAB gradually 
decrease to the same value as passive diffusion (panels A, B and C in Figure A-10, 
Figure A-11, Figure A-12 and Figure A-13).  
In conclusion, at low concentrations (C << Km), transporter mediated flux of a 
substrate is determined by the predominant intrinsic clearance (Vmax/Km) of the AU or AE 
transporters. At concentrations near the Km, flux from BA, indicating tubular secretion, 
is predominant, despite the intrinsic clearance of AU transporter is higher than that of AE 
transporter. 
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Figure A-10: The influence of KmU on flux of BA and AB.  
VmaxU = VmaxE = 15000 pmol/hr, KmE = 30μM, KmU = 15 (A), 30 (B), 60 (C) μM 
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Figure A-11: The influence of VmaxU on flux of BA and AB.  
KmU = KmE = 30 μM, VmaxE = 15000 pmol/hr, VmaxU = 7500 (A), 15000 (B), 30000 (C) 
pmol/hr 
 
Figure A-12: The influence of KmE on flux of BA and AB.  
VmaxU = VmaxE = 15000 pmol/hr, KmU = 30μM, KmE = 15 (A), 30 (B), 60 (C) μM 
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Figure A-13: The influence of VmaxE on flux of BA and AB.  
KmU = KmE = 30 μM, VmaxU = 15000 pmol/hr, VmaxE = 7500 (A), 15000 (B), 30000 (C) 
pmol/hr 
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